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Abstract  
Alzheimer’s disease, the commonest neurodegenerative condition, is characterised by 
accumulation of amyloid plaques and neurofibrillary tangles, neuronal loss, brain atrophy 
and cognitive impairment. Sporadic young onset Alzheimer’s disease shows marked 
clinical heterogeneity, with non-memory presentations including the syndromes of 
posterior cortical atrophy, logopenic aphasia and frontal Alzheimer’s disease, seen in 
around a third of individuals.  This variability presents challenges for diagnosis and may 
confound clinical trial outcomes, but provides an opportunity to explore factors 
influencing differential selective vulnerability within neural networks which in turn may 
provide important clues to Alzheimer’s disease pathogenesis. 
This thesis describes the recruitment of a cohort of a deeply phenotyped patients with 
sporadic young onset Alzheimer’s disease (n=45) and healthy controls (n=24), and a 
series of genetic, clinical, neuropsychological, and structural, diffusion and functional 
magnetic resonance imaging experiments to explore disease heterogeneity and its 
associations.  
There are a number of key findings.  APOE ε4 genotype contributes to, but does not fully 
explain clinical heterogeneity, with the youngest ages of onset and most atypical 
presentations seen in ε4-ve individuals.  Heterozygosity of the rare TREM2 genetic 
variant for late-onset Alzheimer’s disease, p.R47H, is shown to confer risk for young 
onset Alzheimer’s disease, driving younger age of onset rather than clinical phenotype. 
Regional brain atrophy profiles in APOE ε4 genotypes are shown to broadly align with 
the associated neuropsychological deficits.  Microstructural damage studied using 
diffusion tensor imaging, and – applied for the first time to Alzheimer’s disease – Neurite 
Orientation Dispersion and Density Imaging – provides a fine-grained profile of white 
matter network breakdown, revealing regional differences based on APOE ε4 genotype, 
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and correlations with focal neuropsychological deficits.  Finally, activation fMRI using a 
music paradigm to probe relationships between cognitive performance and brain 
function is shown to delineate different patterns of brain activation during memory tasks 
in different Alzheimer’s disease phenotypes.   
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Impact Statement  
The analyses presented in this thesis have advanced our knowledge of the clinical and 
imaging characteristics of young onset Alzheimer’s disease and how associated genetic 
risk factors relate to phenotype.  The mechanisms underlying these observations pose 
questions to be explored in future work.  This thesis also applies new techniques to 
Alzheimer’s disease research.  Music is used as a tool to investigate aspects of memory 
processing and network dysfunction, and the NODDI analyses act as proof of concept 
that the technique can detect microstructural differences in Alzheimer’s disease.  Both 
NODDI and fMRI have potential to further inform our understanding of heterogeneity 
between, as well as within, other neurodegenerative diseases. 
Academic impact has been achieved though the scientific papers I have published in 
peer reviewed journals.  I have also given platform presentations at national and 
international conferences and produced a podcast with the British Neuropsychiatry 
Association on my work in TREM2.  I have lectured UCL undergraduate students on 
atypical forms of Alzheimer’s disease, thereby contributing to the education of future 
clinicians and academics.  
Beyond academia, increased knowledge of heterogeneity in Alzheimer’s disease is likely 
to affect participant recruitment and outcome measure selection for clinical trials.  Study 
of newly identified genetic risk factors, such as TREM2 variants, may lead to new insights 
into disease pathogenesis and potentially new therapeutic targets, or help select 
individuals most likely to benefit from certain disease modifying drugs based on their 
mechanism of action.  Imaging techniques such as NODDI may be useful in clinical trials 
if metrics are shown to be robust, reproducible and capable of tracking disease over 
time.   
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The impact may also extend into clinical practice.  Much as DTI and fMRI are now used 
on an individual patient basis in epilepsy surgery to delineate speech areas and visual 
pathways, NODDI and activation fMRI may be adopted into hospital dementia scanning 
protocols in conjunction with molecular imaging, to offer people with cognitive symptoms 
an earlier and more accurate diagnoses.  Furthermore, should a disease modifying 
treatment for early or pre-symptomatic disease be developed, a national NHS screening 
programme for Alzheimer’s would be required to identify those who would most benefit.  
This may include clinical testing for genetic risk factors, such as APOE and TREM2 to 
risk stratify individuals, and imaging techniques that can show early structural and/or 
functional changes will also be important.    
Greater public and political awareness of atypical and young onset dementia is important 
for the design and delivery of dementia healthcare and services.  I have worked with 
Alzheimer’s Research UK at their Supporters days and contributed to their blog about 
Alzheimer’s disease being more than just a ‘memory problem’, I have attended rare 
dementias support groups, contributed to a BBC Horizon programme that featured some 
of the work of the YOAD study, and reviewed the content of the NHS Choices dementia 
website.   
Finally, on a personal level the work in this thesis represents the foundations on which I 
intend to build a career long commitment to research and clinical practice in cognitive 
neurology.  
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1. Introduction: Alzheimer’s disease 
Alzheimer’s disease is a progressive neurodegenerative condition leading invariably to 
cognitive impairment of sufficient severity to impact on an individual’s activities of daily 
living.  It is the commonest cause of dementia worldwide and a major cause of 
dependence, disability and mortality. The prevalence of dementia is expected to more 
than triple by 2050 as life expectancy increases and the population ages.  It is estimated 
that without disease modifying treatment 24% of men and 35% of women born in 2015 
will develop dementia within their lifetime [1]. 
1.1 History and epidemiology 
In 1906, Alois Alzheimer published on “a peculiar disease of the cerebral cortex” by 
describing plaques, neurofibrillary tangles and arteriosclerotic changes in the brain of a 
woman, Auguste D, with presenile dementia who presented at the age of 51 years [2].  
She had presented to his clinic with profound language deficits, behavioural disturbance 
including anxiety and paranoid delusions, and episodic memory loss.  In doing so, he 
described the neuropathology of the disease that was to subsequently bear his name 
[3]. For the next fifty years the term ‘Alzheimer’s disease’ was restricted to severe forms 
of presenile dementia with abundant plaques and neurofibrillary tangles until reports 
based on large clinicopathological series demonstrated that the neuropathological 
manifestations of presenile and senile dementia were qualitatively the same and hence 
it was not warranted to define them as separate diseases [4].  Senile dementia was no 
longer accepted as a ‘normal’ consequence of aging and Alzheimer’s pathology is now 
recognised as the single biggest cause of dementia, accounting for between 50% to 75% 
of all cases of dementia.   
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Age is the single greatest risk factor for sporadic Alzheimer’s disease. Incidence of 
probable Alzheimer’s disease for people aged 60 to 69 years is <1% but this increases 
steadily with age to approximately 7% for those age 85 to 89 years [5].  The prevalence 
of Alzheimer’s disease roughly doubles for every 5 years after age 65 [6].  In the UK, this 
equates to a prevalence of about 2% for people aged between 65 and 69 years, rising 
to 20% for those aged between 85 to 89 years [7].  Despite the low incidence of dementia 
in people under 65 years, over 42,000 people have early-onset dementia in the UK. 
1.2 Pathology  
1.2.1 Macroscopic pathology 
Alzheimer’s disease invariably leads to neuronal cell death which manifests 
macroscopically as atrophy.  This atrophy is typically symmetrical resulting in cortical 
thinning, widening of sulcal spaces and increased size of the ventricles.  The rate of 
brain atrophy varies depending on brain region; the medial temporal lobe structures such 
as the entorhinal cortex and hippocampus are prominently affected, and the primary 
motor, sensory and visual cortices and relatively spared until advanced disease.   
1.2.2 Microscopic pathology 
Alzheimer described the microscopic pathological hallmarks of Alzheimer’s disease in 
his original paper: amyloid plaques and neurofibrillary tangles (Figure 1.1).  
Amyloid plaques are dense, extracellular predominantly insoluble deposits of amyloid-β 
peptide (Aβ1-42), and neurofibrillary tangles are intracellular paired helical filaments 
composed of hyperphosphorylated microtubule-associated protein tau (Figure 1.2). 
Neutropil threads, dystrophic neurons, astrogliosis and microglial activation are also 
seen, and cerebral amyloid angiopathy frequently coexist [8]. These pathological 
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processes lead to downstream neurodegeneration with progressive loss of neurons and 
synapses culminating in macroscopic atrophy.  
 
Figure 1.1 Alois Alzheimer’s sketch of neurofibrillary tangles in the advanced 
stages of Alzheimer’s disease 
From his paper in 1911, published in Zeitschrift für die gesamte Neurologie und 
Psychiatrie: Originalen. 
 
Figure 1.2 Photomicrographs of the core pathological lesions observed in 
Alzheimer’s disease  
(A) H&E stained section of frontal cortex showing an amyloid plaque; (B) H&E stained 
section showing a tangle in a hippocampal pyramidal neuron.  (C) Silver stain showing 
both a plaque and a tangle.  Reproduced from Serrano-pozo et al., 2011 [8].   
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Tau is a normal and essential protein expressed in nerves which contributes to their 
structural and functional integrity by stabilising the cytoskeleton and facilitating axonal 
transport [9].  It exists in six different isoforms, three of which have three repeats in the 
extracellular domain (‘three-repeat tau’, 3R-tau), with the remaining three have four 
(‘four-repeat tau’, 4R-tau). Alzheimer’s disease is associated with hyperphosphorylation 
of both 3R-tau and 4R-tau, distinguishing it at the molecular level from other 
‘tauopathies’; Picks disease is only associated with 3R-tau, and corticobasal 
degeneration and progressive supranuclear palsy with 4R-tau.   
Other pathologies, such as vascular disease, TDP43, and Lew Body Disease often co-
exist [10, 11], particularly in older individuals, however it is hard to know what their 
relative contribution to cognitive impairment for an individual is. 
Amyloid and tau are found throughout the brain of people with Alzheimer’s disease in 
broadly predictable distributions.  Amyloid plaques are typically found throughout the 
isocortex, and only involve subcortical structures in advanced disease. Amyloid 
pathology reaches a plateau early in the symptomatic phase of the disease [12] so tends 
not to correlate well with clinical features and severity of clinical disease.  Tau tangles 
tend to be found initially in the entorhinal cortex and hippocampus before spreading to 
the association cortices whereas primary motor, sensory and visual cortex tends to be 
unaffected.  Neurofibrillary tangles parallel synaptic and neuronal loss more closely than 
amyloid-β [8] and hence tends to correlate with the clinical stage of disease. 
1.2.3 Neuropathological criteria 
With pathological diagnosis being the ‘gold standard’ there are several criteria for the 
neuropathological diagnosis and staging of Alzheimer’s disease.  Both the Braak criteria 
[13] and Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria 
[14] quantify the burden of amyloid plaques.  The later Thal criteria [15] recognised that 
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amyloid exists in forms other than plaques, and that deposition in the brain occurs 
following a distinct sequence in regions that are hierarchically involved (Figure 1.3).  Tau 
pathology is staged using Braak criteria for neurofibrillary tangles [16] (Figure 1.4).  
Criteria using only amyloid plaques or NFT have low sensitivity and specificity for 
Alzheimer’s disease [17], so the National Institute of Ageing and the Reagan Institute 
combined the CERAD neuritic plaque score with the Braak and Braak NFT staging to 
derive a criteria with three categories of diagnostic certainty: high, intermediate or low 
likelihood of Alzheimer’s disease [18].  The more recent National Institute on Aging and 
the Alzheimer’s Association NIA-AA) [19] neuropathological guidelines also address the 
potential disconnect between the clinical phenotype and neuropathological changes, as 
some individuals at post mortem are found to have a high degree of Alzheimer’s disease 
pathology without ever having had clinical symptoms during life. 
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Figure 1.3 Spatiotemporal pattern of amyloid plaque deposition according to Thal et al. [15] 
Coronal (A), axial (B), and sagittal (C) views of the brain. Five stages of amyloid deposition are summarised in three stages: (i) amyloid deposits 
accumulate isocortical areas (red), followed by limbic and allocortical structures (orange), and finally in subcortical structures such as the basal ganglia, 
selected nuclei in the midbrain and medulla and the cerebellar cortex (yellow).  Amyg, amygdala; EC, entorhinal cortex; Hipp, hippocampus; Cg, 
cingulate cortex; Cd, caudate nucleus; Put, putamen; Gpe, globus pallidus externus; Gpi, globus pallidus internus; Cl , claustrum; Ins, insular cortex; 
Die, diencephalon; Mid, midbrain; Med, medulla oblongata; Cblm, cerebellum.  Figure reproduced from Serrane-Pozo et al., 2011 [8]. 
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Figure 1.4 Spatiotemporal pattern of neurofibrillary degeneration in Alzheimer’s 
disease 
Spatiotemporal pattern of neurofibrillary degeneration in Alzheimer’s disease, based on 
Braak et al., 1991 and 2006 [13, 16].  Shading indicates the distribution of NFTs - darker 
colours represent increasing densities. Amyg, amygdala; EC, entorhinal cortex; CA1, 
Cornus ammonis 1 hippocampal subfield; Cg, cingulate cortex; Prec, precuneus; 4, 
primary motor cortex; 3-1-2, primary sensory cortex; 17, primary visual cortex; 18, 
associative visual cortex.  Figure reproduced from Serrane-Pozo et al., 2011 [8]. 
1.3 Aetiology 
1.3.1 Genetic determinants 
Alzheimer’s disease has a complex and heterogeneous genetic component. Three 
genes have been identified as the cause of early onset familial Alzheimer’s disease, 
which represents less than 1% of cases.  Early onset familial Alzheimer’s disease 
behaves in an autosomal dominant manner affecting people typically when they are less 
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than 65 years old, but can be as early as their thirties. In contrast, late onset Alzheimer’s 
disease is typically ‘sporadic’ with no apparent familial recurrence. The genetic 
component of this late onset form has been the target of a large number of studies 
looking to identify genetic risk factors (see below).  Furthermore, the genetic architecture 
of young onset Alzheimer’s disease (symptom onset <65 years) occurring in the absence 
of one of the autosomal dominant mutations remains relatively unknown. 
1.3.1.1 Autosomal dominant, causal, genes 
In the early 1990s linkage analyses studying families with early onset Alzheimer’s 
disease identified the only fully penetrant mutations known to date to be pathogenic.  
The localisation of the gene encoding the Aβ precursor protein (APP) to chromosome 
21, coupled with the earlier observation that trisomy 21 (Down’s syndrome) leads 
invariably to the neuropathology of Alzheimer’s disease [20] set the stage for the 
proposal that perturbations in Aβ homeostasis are a primary event in Alzheimer’s 
disease pathogenesis.  Three genes were found to carry Alzheimer’s disease 
pathogenic mutations: amyloid precursor protein gene (APP, chromosome 21q21.3) 
[21], presenilin 1 gene (PSEN1, chromosome 14q24.3) [22] and presenilin 2 gene 
(PSEN2, chromosome 1q31-q42) [23].  More recently duplications of the APP gene have 
been identified as an additional cause of familial Alzheimer’s disease [24].   
The identification of these causative genes led to an understanding of the molecular 
pathology, culminating in the amyloid hypothesis [25] (outlined in the next section) which 
is also proposed to apply to apparent ‘sporadic’ disease.  
1.3.1.2 Risk factor genes 
• Apolipoprotein ε4: A low frequency variant conferring moderate risk 
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The early linkage analyses also identified a strong risk factor for late onset Alzheimer’s 
disease: possession of an ε4 allele of APOE (Apolipoprotein E, APOE, chromosome 
19q13.2) [26].  APOE encodes a glycoprotein synthesized predominantly in the liver, 
brain (by neurons and astrocytes), macrophages and monocytes [27].   
The APOE gene consists of four exons and three introns and is polymorphic, with three 
common alleles (epsilon 2, epsilon 3, epsilon 4) coding for three isoforms (ε2, ε3, ε4). 
The isoforms differ from each other by a single amino acid substitution, and also differ 
in their binding affinity for APOE receptors.  The frequencies of the 2, 3, and 4 alleles 
are estimated at 0.07, 0.79, and 0.14, respectively, but can vary widely among 
populations (meta-analysis http://www.alzgene.org/ [28]).  The ε4 allele confers an 
increased risk of Alzheimer’s disease seen across different ethnic groups of ~3-fold for 
heterozygous carriers and up to 15-fold for individuals who are ε4 homozygotes relative 
to ε3homozygotes [29]. APOE is known to act in a dose dependent manner: with the risk 
for Alzheimer’s disease increasing, and the mean age of onset decreasing from 84 to 68 
years with an increasing number of ε4 alleles [30].  
APOE is implicated in mobilisation and redistribution of cholesterol, neuronal growth and 
repair [31], immunoregulation and activation of enzymes for lipolysis [32].  However, the 
critical mechanism by which APOE ε4 confers a high risk of Alzheimer’s disease is 
unclear.  APOE ε4 is involved in Aβ transport, and proteins encoded by the different 
APOE polymorphisms have different effects on its clearance.  APOE ε4 is less effective 
at clearing Aβ than APOE ε2 or 3, so it may be through this effect that the risk of AD is 
enhanced [33]. 
The identification of the three autosomal dominant genes, and APOE represented a 
huge leap forward in the understanding of Alzheimer’s disease genetics, however these 
genes have been estimated to account for less than 30% of the genetic variance in early 
31 | P a g e  
 
onset and late onset Alzheimer’s disease [34] suggesting that numerous additional 
Alzheimer’s disease risk factor genes exist and environmental factors are important. 
• Genome Wide Association Study: Common variants conferring small increased risk 
The development of whole-genome genotyping platforms has allowed the involvement 
of common variants conferring low risk in Alzheimer’s disease to be studied.  Genome 
wide association studies (GWAS) are large observational studies comparing the DNA 
of participants with a particular trait or phenotype with individuals who do not.  If one 
genetic locus is more frequent in people with the disease than controls, that region is 
said to be associated with the disease. 
To date over 20 genetic loci with low risk effects for Alzheimer’s disease have been 
identified by GWAS [35], including CLU, PICALM, CR1, BIN1, CD33, ABCA7, MS4A6A 
and MS4A4E, CD2AP, EPHA1, HLA-DRB5/DRB1, SORL1, PTK2B, SLC24A4, 
ZCWPW1, CELF1, FERMT2, CASS4, INPP5D, MEF2C, and NME8.  These risk loci 
implicate some common biological pathways in the pathogenesis of Alzheimer’s 
disease, with clear significant overrepresentation of association signals in pathways 
related to cholesterol metabolism, the immune response and endosomal vesicle 
recycling [36].  
• Triggering receptor expressed on myeloid cells 2: A rare variant conferring 
moderate risk 
In 2013, a rare gene conferring moderate risk for Alzheimer’s disease was identified.   
Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane 
glycoprotein which associates with DAP12; also known as TYRO protein tyrosine 
kinase binding protein (TYROBP). The association between these two proteins controls 
two streams of signalling to regulate microglial activation. Variants in TREM2 had 
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previously been associated with Nasu-Hakola disease, a rare autosomal recessive 
form of dementia presenting with bone cysts [37].  Prompted by the identification 
of different rare TREM2 homozygous mutations causing frontotemporal dementia [38], 
the role of TREM2 was investigated in other dementias.  In studying Alzheimer’s 
disease cases and controls a heterozygous rare variant (p.R47H) was found to be 
associated with an increased risk (OR > 3) for the development of Alzheimer’s disease 
[39, 40], making it the most significant, albeit much rarer, risk factor gene for sporadic 
Alzheimer’s disease to be identified since APOE.  TREM2 is emerging as a molecular 
determinant in how the brain responds to Aβ deposition [41, 42]. 
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Figure 1.5 The genetic landscape of Alzheimer’s disease  
The internal colour relates to the current thinking regarding gene function.  Where there are two internal colours, the gene has been 
implicated in more than one pathway. Genes circled in yellow are additionally thought to influence amyloid precursor protein metabolism; 
genes circled in red are thought to influence tau metabolism.  Reproduced from Lane et al., 2018 [43].
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1.3.2 Other Risk Factors 
There are a number of environmental and life course risk factors that have been 
associated with sporadic Alzheimer’s disease.  Risk factors for cardiovascular health in 
mid-life such as obesity [44], hypertension [45], smoking [46, 47] and 
hypercholesterolaemia [48] have been associated with higher rates of clinically 
diagnosed Alzheimer’s disease, whilst physical exercise [49, 50] and a diet low in 
saturated fats may be protective.  Remaining socially and cognitive active may also be 
protective against dementia in general [51], and increased educational and occupational 
attainment may reduce the risk of incident Alzheimer’s disease, perhaps by imparting a 
reserve that delays the onset of clinical manifestations [52] whilst low educational 
attainment is a risk factor, perhaps conversely reflecting a lower cognitive reserve.   
Numerous case control studies have associated traumatic brain injury (TBI) with an 
increased risk of Alzheimer’s disease, with a systematic review finding that TBI more 
than doubled the risk of future development of Alzheimer’s disease in men [53]: however 
this has not been replicated in studies looking for association between a history of TBI 
and neuropathological features of Alzheimer’s disease post mortem [54], or with 
changes in cognition or Alzheimer’s disease biomarkers using florbetapir positron 
emission tomography (PET) scans [55]. 
1.4 Pathophysiology 
1.4.1 The Amyloid Hypothesis 
The discovery of mutations in the gene encoding APP led to the development of the 
amyloid cascade hypothesis [25], which remains the major theory to explain Alzheimer’s 
disease pathophysiology over 25 years later.  This hypothesis places dysregulation in 
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APP processing and the subsequent accumulation of abnormal amyloid plaques as the 
key initiating event in Alzheimer’s disease.  
The hypothesized mechanism for erroneous amyloid processing leading to plaque 
formation is summarised in Figure 1.6.  Several enzymes are involved in the cleavage 
of APP.  Normal processing occurs via alpha secretase enzyme cleavage leading to the 
production of non-amyloidogenic protein product.  In Alzheimer’s disease there is 
sequential cleavage of APP by β- and γ-secretases, producing an abnormal protein 
product which is 42 amino acids in length [56] – Aβ1-42; the major constituent of the 
extracellular amyloid plaque. 
 
Figure 1.6 The major pathways of amyloid precursor protein processing 
Non amyloidogenic pathway (green dashed box): amyloid precursor protein (APP) is 
cleaved by α-secretase resulting in sAPP-alpha (sAPPα) and a shorter C8 fragment.  
Amyloidogenic pathway (red dashed box): Sequential cleavage of APP by Aβ cleaving 
enzyme (BACE) and γ-secretase to yield protein products of varying length, including an 
abnormal protein product 42 amino acids in length: Aβ1-42. The Aβ1-42 peptides are 
larger than Aβ1-40 and more prone to self-aggregate.  Figure adapted from Mudher and 
Lovestone, 2002 [57]. 
36 | P a g e  
 
Accumulation of these abnormal amyloid protein moieties are thought to trigger a 
sequence of events leading to synaptic dysfunction, microglial and astrocytic activation, 
abnormal tau deposition, reduction in neurotransmitters, neuronal death, and atrophy 
which together causes cognitive symptoms and dementia (Figure 1.7). 
Strong genetic support for a central role for Aβ in Alzheimer’s disease subsequently 
came from the realisation that mutations in presenilin genes affect proteins involved in 
the active catalytic sites of gamma secretase enzymes [58, 59], hence all mutations 
causing familial Alzheimer’s disease result in overproduction of abnormal forms of 
amyloid.  Furthermore, a variant in the APP gene (A673T, a missense mutation) that 
results in reduced BACE cleavage has been shown to be protective against the 
development of Alzheimer’s disease [60].  The amyloid hypothesis also has mechanistic 
plausibility for sporadic disease as APOE and many of the other risk genes identified 
(Figure 1.5) are thought to have roles in amyloid clearance.   
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Figure 1.7 Major pathogenic processes in Alzheimer’s disease, as proposed by 
the Amyloid Hypothesis 
Aβ oligomers may directly damage synapses and neurites and induce tau 
hyperphosphorylation directly (indicated by the curved blue arrow), in addition to 
activating microglia and astrocytes.  Diagram reproduced from Selkoe and Hardy, 2016 
[61]. 
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1.4.2 Limitations of the amyloid hypothesis and emerging concepts 
Whilst the amyloid hypothesis explains much of our current understanding of Alzheimer’s 
disease pathology, there are also many unanswered questions.   
The toxic Aβ species 
Whilst Aβ1-42 deposition is necessary for a diagnosis of Alzheimer’s disease according 
to neuropathological criteria, a significant proportion of elderly individuals have abundant 
Aβ1-42 plaques at post mortem without ever having manifest cognitive impairment in 
life.  This indicates that Aβ1-42 deposition alone is not sufficient to cause Alzheimer’s 
disease.  Soluble amyloid oligomers may be the more pathological form of amyloid, 
rather than the plaques containing dense fibrillary amyloid.  Aβ oligomers purified from 
the brains of people with Alzheimer’s disease can inhibit long term potentiation, cause 
synaptic dysfunction and neuronal death when applied to neurons in vitro [62].  Plaques 
may be a ‘reservoir’ from which amyloid oligomers diffuse.  Alternatively, given that 
individuals with diffuse plaques in the absence of dementia were found to have lower Aβ 
oligomer levels per plaque than in people with manifest Alzheimer’s disease [63], 
perhaps plaques act as a ‘sink’ sequestering toxic Aβ species in a non-diffusible less 
neurotoxic state until a saturation point is reached [61].  
The role of tau 
Tau is also a vital part of the neuropathological definition of Alzheimer’s disease, and the 
close relationship between regional neurofibrillary tangles and neurodegeneration 
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indicates it is a key component of pathogenesis.  Longitudinal studies have shown that 
phosphorylated tau pathology in the ventromedial temporal lobe develops prior to the 
onset of clinical dementia and neurofibrillary tangle density correlates with episodic 
memory impairment [64].   
The tau and tangle hypothesis proposed impairment of the normal role of tau in 
stabilising microtubules as the primary initiating and pathological event in Alzheimer’s 
disease. However, whilst tau mutations have been found to lead to pathological 
accumulation of tau and dementias within the frontotemporal dementia spectrum [65], 
tau mutations alone are not associated with amyloid plaques and do not manifest as 
Alzheimer’s disease.  The fact that APP and presenillin mutations give rise to both 
plaques and tangles strongly suggests that amyloid pathology occurs upstream of the 
essential coexistent tau pathology.  There is emerging evidence that Aβ oligomers can 
induce hyperphosphorylation of tau in neurons in vitro [66] providing one potential 
mechanism to explain how amyloid and tau interact in Alzheimer’s disease 
pathogenesis, however this relationship remains incompletely understood. 
Amyloid plaque burden correlates poorly with cognitive deficits 
Amyloid plaque burden does not to correlate as well with the degree of observed 
cognitive impairment as neurofibrillary tangles do [67].  As the natural history of 
Alzheimer’s disease is becomes better understood, Aβ1-42 deposition is increasing 
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thought to be an early and widespread event that sets off a downstream cascade of 
events that ultimately leads to neuronal death and a clinically manifest dementia. 
Clinical trials of anti-amyloid agents have not yet lead to a disease modifying therapy 
Until recently, the amyloid hypothesis has been the overarching theory for nearly all 
attempts to develop therapeutics for Alzheimer’s disease.  Numerous clinical trials of 
agents altering amyloid production or enhancing amyloid clearance are ongoing but 
there has been limited success thus far [68, 69] suggesting that either the most relevant 
targets have not yet been identified, or intervention is not occurring at the optimum stage 
in the disease process.  This may change, as recent preliminary data from a stage 2B 
trial of BAN2401 (an anti-Aβ1-42 protofibril immunotherapy) shows promising amyloid 
reduction and a downstream improvement in cognitive function assessed using the 
ADAS-Cog and ADCOMS composite measure [70] in individuals with mild cognitive 
impairment due to Alzheimer’s disease and mild Alzheimer’s disease [71, 72].   
No anti-amyloid treatment has yet been licenced for clinical use.     
1.5 The Natural History of Alzheimer’s disease pathogenesis 
Advances in understanding the temporal relationship of pathological and clinical events 
in Alzheimer’s disease have been greatly aided by the development of cerebrospinal 
fluid (CSF) and imaging biomarkers for amyloid-β pathology and tau related 
neurodegeneration in vivo.  The application of these biomarkers to clinical diagnosis is 
outlined in section 1.7. 
CSF biomarkers 
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Three core CSF biomarkers for Alzheimer’s disease have been identified and replicated 
across many studies [73]: (i) Aβ1-42, which is found at low concentrations in Alzheimer’s 
disease due to cortical amyloid deposition [74], (ii) total tau (T-tau), which is raised due 
to cortical neuronal loss [75-77], and (iii) phosphorylated tau (P-tau), which is found at 
high concentration reflecting cortical tangle formation [74, 78].  These CSF biomarkers 
have good diagnostic accuracy for Alzheimer’s disease in life, with sensitivity and 
specificity of 85-90%, and also for patients with mild cognitive impairment due to 
underlying Alzheimer’s disease pathology [79].  
Structural imaging biomarkers 
Volumetric structural T1 MRI demonstrates areas of brain atrophy, and serial registered 
scans can be used to measure rates of atrophy using methods such as the boundary 
shift integral [80].  Regional brain atrophy profiles in YOAD are further described in 
chapters 2 and 3. 
Positron emission tomography (PET) biomarkers  
18F-fluorodeoxyglucose (18FDG) PET visualises cerebral glucose metabolism which 
increases with regional synaptic activity and decreases with synaptic dysfunction and 
tau related neurodegeneration. 
Amyloid PET ligands bind fibrillar Aβ deposits to detect and quantify Aβ neuritic plaques 
in the brain during life.   Amyloid PET measures of amyloid pathology correlate well with 
amyloid burden at post mortem [81-83], and amyloid PET can also be used to detect 
longitudinal change in amyloid plaque load over time [84].   
The first PET ligand specific for Aβ was 11C Pittsburgh Compound B (PIB) [85] which 
has been used in several large multisite studies [86, 87].  The 11C ligand half-life is 
approximately 20 minutes, which limits it use to imaging centres with an on-site cyclotron.  
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Subsequently developed 18F amyloid ligands, which include florbetapir, flutemetamol 
and florbetaben, have a longer half-life of around 2 hours making central production and 
distribution to other research sites possible.      
PET ligands to bind tau have also been developed, such as AV1451 (flortaucipir) [88], 
and a range of second generation ligands which may be more specific.  Regional tau 
binding recapitulates the topographical distribution of neurofibrillary tangle pathology as 
described by Braak [89], and regional differences in tau deposition mirror the clinical 
symptoms and atrophy profiles seen in individuals with atypical phenotypes of 
Alzheimer’s disease [90, 91].  
Modelling dynamic biomarkers of the Alzheimer’s disease pathological cascade 
Longitudinal studies of families carrying autosomal dominant Alzheimer’s disease 
mutations have examined the time course of fluid biomarker, neuroimaging and clinical 
changes prior to the expect onset of Alzheimer’s disease symptoms, based on the age 
of symptom onset in a parent with the same mutation [92].  Aβ1-42 levels in CSF may 
first become elevated then decline as early as 25 years before expected clinical symptom 
onset, followed by PIB-PET evidence of fibrillary amyloid deposits, raised CSF tau levels 
and progressive brain atrophy on MRI approximately 15 years before symptoms 
manifest.  Neuronal hypometabolism and the earliest detectable clinical memory 
impairment on neuropsychological assessment appear approximately 10 years before 
clinical symptoms of severity to fulfil a diagnosis of dementia. Data modelling from a 
longitudinal study in individuals with sporadic Alzheimer’s disease has suggested a 
similar time course of pre-symptomatic Aβ deposition [93].   
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Jack et al., have used these biomarker studies to formulate a model for the sequence of 
pathogenesis in Alzheimer’s disease [94, 95] (Figure 1.8).  
 
Figure 1.8 Dynamic biomarkers of the Alzheimer’s pathological cascade 
Aβ is identified using CSF Aβ1-42 or PET amyloid imaging.  Tau-mediated neuronal 
injury and dysfunction is identified by raised CSF tau levels or altered 
fluorodeoxyglucose-PET.  Brain structure is measured using structural MRI.  MCI, mild 
cognitive impairment.  Figure reproduced from Jack et al., 2010 [94] 
1.6 Clinical Presentation   
1.6.1.1 Late onset Alzheimer’s disease 
Alzheimer’s disease typically presents in elderly people with slowly progressive episodic 
memory impairment, difficulty with route finding and loss of confidence. Cognitive 
impairment become more severe and spreads to other cortical domains as the disease 
progresses interfering with activities of daily living and leading to an increasing 
dependence on care.  In advanced Alzheimer’s disease people can experience 
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behavioural and psychological symptoms such as apathy, depression, irritability, 
agitation and anxiety [96] as well as hallucinations, seizures, falls, and altered sleep 
patterns.  Disease duration in Alzheimer’s disease is typically around 8.5 years from 
clinical presentation to death [97].   
1.6.1.2 Young onset Alzheimer’s disease 
Young onset Alzheimer’s disease (defined as symptom onset < 65 years) [98] is 
markedly less common, but Alzheimer’s disease is still the most common cause of young 
onset dementia.  Reported prevalence of young onset Alzheimer’s disease within young 
onset dementia varies across studies but can be up to 67% [99]. 
People with familial Alzheimer’s disease due to an autosomal dominant mutation 
typically present with memory impairment, but at a much younger age – in their 30s, 40s 
or 50s.  Some autosomal dominant mutations have prominent additional features such 
as the myoclonus, seizures and spastic paraparesis observed in people carrying PSEN1 
variants [100]. 
Young onset Alzheimer’s disease can also occur on an apparent sporadic basis, and 
these are the individuals studied in this thesis.  Atypical (non-memory) syndromes are 
more commonly seen in this demographic and include posterior cortical atrophy (PCA), 
logopenic aphasia (LPA) and the frontal variant of Alzheimer’s disease.  PCA typically 
presents with breakdown of parieto-occipital function in the context of relatively 
preserved memory and language functions [101].  Patients have prominent visuospatial 
and visuoperceptual problems with apraxia, dyscalculia, alexia and agraphia.  The 
language led Alzheimer’s disease variant; LPA, is dominated by long word finding 
pauses, anomia and deficits of working memory [102].  Frontal presentations of 
Alzheimer’s disease are the rarest and characterised by executive impairment, 
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behavioural change and psychiatric symptoms [103, 104] in the presence of Alzheimer’s 
disease pathology [105, 106].  
This clinical heterogeneity and possible underlying mechanisms are discussed further in 
Chapter 2. 
1.7 Clinical Diagnostic Approach 
A diagnosis of dementia is based on the clinical history, the pattern of cognitive deficits 
and neurological signs on examination, and supportive investigations and biomarkers of 
underlying disease pathology. Accurate and timely diagnoses are important clinically for 
guiding patient management and prognosis, and will be increasingly important in the 
future for targeting treatment with the advent of disease modifying therapies.   
Diagnosis presents a particular challenge in younger patients who are less than 65 years 
due to the broad differential diagnosis, increased prevalence of atypical phenotypes and 
higher burden of genetic causes [98].  Alzheimer’s disease needs to be distinguished 
from both non-neurodegenerative disease mimics such as obstructive sleep apnoea, 
depression or rarer inflammatory, infective or autoimmune causes, as well as from other 
neurodegenerative diseases including frontotemporal dementia, dementia with Lewy 
Bodies and vascular dementia.   
Atypical Alzheimer’s disease phenotypes pose their own diagnostic challenges, are the 
subject of this thesis, and are discussed in detail in Chapter 2.  Individuals with PCA may 
have presented to opticians and ophthalmologists reporting visual symptoms, and it can 
take some time and significant investigation to recognise that their difficulties do not arise 
from a problem in the anterior visual pathways. Equally individuals with language or 
frontal variants may initially be diagnosed with frontotemporal dementia, primary 
psychiatric or functional disorders. 
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1.7.1 Clinical assessment 
The clinical assessment should assess the pattern of cognitive and behavioural deficits, 
and the impact on the person’s life.  A good collateral history is essential as patients may 
lack insight to some of their difficulties.  Depression and other psychiatric symptoms 
should be elicited, and people screened for symptoms suggesting other dementia 
mimics, such as obstructive sleep apnoea. 
A bedside cognitive assessment begins whilst taking a history.  For example, a person 
with episodic memory impairment due to Alzheimer’s disease generally has a well 
preserved social façade but may appear passive during the interview, turning to their 
partner to answer questions; the ‘head turning sign’ [107].  The individual’s behaviour 
and interaction with others should be observed as impulsiveness, perseveration, loss of 
emotional reactivity, or disinhibition suggest a disease processing involving the frontal 
lobes. 
The Mini Mental State Examination (MMSE) [108], Montreal Cognitive Assessment 
(MOCA) [109] and Addenbrooke’s Cognitive Examination (ACE) [110] offer structured 
tools for assessing different domains of cognitive function. Dyspraxia and a visual 
apperceptive agnosia suggest organic disease implicating the dominant and non-
dominant parietal lobes respectively.  Cortical dementias such as Alzheimer’s disease 
are characterised by errors in specific domains with relatively preserved speed of 
processing, where as profound slowing of cognition and a frontal dysexecutive syndrome 
is typical of subcortical dementias.    
Physical examination should establish any features of ‘dementia plus syndromes’ [98] 
which may manifest as neurological signs (e.g. ataxia, pyramidal signs, dystonia, chorea, 
peripheral neuropathy, myoclonus, gaze palsies, deafness or dysautonomia) or systemic 
47 | P a g e  
 
features (e.g. cataracts, splenomegaly, bone cysts, tendon xanthomas, renal, liver or 
respiratory failure, anaemia, metabolic or infectious crises, or hyponatraemia). 
1.7.2 Neuropsychology 
Neuropsychological testing aims to quantitatively assess the extent and pattern of an 
individual’s cognitive impairment using tests of graded difficulty with well-established age 
related normative data and considering the person’s likely premorbid ability (estimated 
using reading ability which is relatively unaffected by the early stages of Alzheimer’s 
disease, details of educational attainment and employment history).  Serial assessment 
may be used to determine interval change over time, with the caveat that ‘practice 
effects’ may need to be taken into account, especially in high functioning individuals.   
Although neither 100% sensitive or specific for a given disease, the pattern of cognitive 
impairment demonstrated can help identify the syndrome. 
1.7.3 Blood tests 
Blood tests are performed routinely to exclude potentially treatable or reversible causes 
of dementia, or conditions contributing to cognitive symptoms.  The UK NICE clinical 
guidelines recommend checking a full blood count, renal and liver function, serum 
electrolytes including calcium, glucose, thyroid function, vitamin B12 and folate [111].  
They do not recommend routine testing for syphilis serology or HIV unless there are 
specific risk factors or suggestive clinical features.  Depending on the clinical scenario it 
may also be appropriate to investigate for other rarer causes of dementia e.g. anti-
nuclear antibodies, anti-neuronal antibodies or antibodies implicated in autoimmune 
encephalitis for patients with rapid-onset dementias or in those with systemic disease, 
white cell enzymes and very long chain fatty acids to screen for various metabolic 
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disorders that present in early adulthood, or multiple blood films if neuroacanthocytosis 
is suspected.   
There are currently no Alzheimer’s disease specific blood based biomarkers for clinical 
use [112]. 
1.7.4 Neuroimaging 
Structural, metabolic and molecular imaging are all approved for use in clinical diagnosis 
of Alzheimer’s disease.   
1.7.4.1 Structural 
Structural imaging with CT or MRI is used to rule out potentially treatable causes of 
cognitive impairment, such as space occupying lesions and subdural haematomas, and 
is recommended in the diagnostic work up of all suspected dementias [111].   
MRI has the additional benefits of being able to assess the presence and extent of 
cerebrovascular disease which can mimic or coexist with Alzheimer’s disease, and 
volumetric sequences are being increasingly used in clinical practice to assess regional 
atrophy profiles in neurodegenerative diseases [98].  Specific patterns of atrophy reflect 
the characteristic selective neuronal vulnerability in different neurodegenerative 
diseases, such as focal symmetrical medial temporal lobe atrophy in typical Alzheimer’s 
disease [113] verses atrophy of the frontal and temporal lobes, insula and anterior 
cingulate cortex atrophy in behavioural variant frontotemporal dementia [114].  Within 
Alzheimer’s disease different phenotypes are associated with different regional atrophy 
profiles.  This is discussed further in Chapter 2. 
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Longitudinal imaging enables changes over time to be visualised.  In clinical practice an 
interval of one year would be typical to expect to see qualitative change in the degree of 
atrophy, unless the dementia was very rapidly progressive. 
1.7.4.2 Metabolic Imaging 
Hypometabolism on 18FDG PET in the parieto-temporal association areas, posterior 
cingulate and precuneus supports a diagnosis of Alzheimer’s disease [115].  Frontal 
hypometabolism can be useful to identify patients with early frontal lobe dysfunction in 
whom established atrophy on structural MRI is not clear.   
FDG-PET is useful in differentiating Alzheimer’s disease from other dementias with 
speciﬁcity higher than 95% in early onset cases where an atrophy profile has not yet 
developed [41]. 
1.7.4.3 Molecular Imaging 
Amyloid PET imaging has three agents approved by the European Medicines Agency 
and the US Food and Drug Administration. Florbetapir, flutemetamol and florbetaben all 
work by binding fibrillary Aβ and PET imaging results closely correlate with pathological 
Aβ burden at post-mortem [81-83].  Although recognised in diagnostic criteria as 
evidence of brain β amyloid protein deposition [116, 117] routine clinical access to 
amyloid PET is limited in the UK.  A number of ongoing studies are currently evaluating 
its clinical utility and cost-effectiveness [118, 119] so its use in clinical practice may 
expand in the future.  
Tau PET imaging, using tracers such as AV1451 [88], is a recent research development 
which has not yet entered clinical diagnostic practice. 
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Often a combination of imaging modalities is used to support identification of an 
Alzheimer’s disease syndrome and underlying pathology (Figure 1.9). 
 
Figure 1.9 Structural, metabolic and molecular imaging posterior cortical atrophy 
due to Alzheimer’s disease  
(A) Volumetric T1 MR brain imaging shows prominent posterior volume loss. (B) 18-FDG 
PET scanning shows cortical hypometabolism (cool colours) most prominent in both 
parietal lobes.  (C) Amyloid PET scanning shows widespread cortical amyloid deposition.  
For clinical purposes, 18F-florbetapir images are interpreted on a grey (rather than 
colour) scale. Figure reproduced from Slattery et al. [120] 
1.7.5 CSF biomarkers 
NICE clinical guidelines recommend the use of cerebrospinal fluid examination if 
Creutzfeldt-Jakob disease (CJD) or other forms of rapidly progressive dementia are 
suspected [111].  Specifically considering patients with young onset dementia, both the 
American Academy of Neurology and European Federation of Neurological Societies 
guidelines recommend CSF examination [121-123].   
CSF examination can screen for inflammatory or infective conditions mimicking 
dementia, and contribute to a positive molecular diagnosis of Alzheimer’s disease 
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pathology.  In Alzheimer’s disease, the typical pattern is a low Aβ1-42 (due to cortical 
amyloid deposition), with elevated levels of tau (due to cortical neuronal loss) and 
phosphorylated tau (reflecting cortical tangle formation).  Each of these biomarkers have 
been reported to differentiate patients with Alzheimer’s disease from healthy elderly 
individuals with 80-90% sensitivity and specificity [124].   
1.7.6 Neurophysiology 
Electroencephalomyography (EEG) can show early slowing or loss of alpha rhythm in 
Alzheimer’s disease, but arguably is more useful in clinical practice for identifying 
characteristic EEG changes seen in rarer Alzheimer’s disease mimics such as periodic 
complexes in some prion diseases and subacute sclerosing panencephalitis, or 
subclinical epileptiform changes in patients having partial seizures that may present as 
an amnestic syndrome [98]. 
1.7.7 Genetics 
Genetic testing, with appropriate consent, can be used to identify autosomal dominant 
causes of Alzheimer’s disease where these are suspected in clinically affected 
individuals.  Genetic panels using next generation sequencing are increasingly availably 
and mean large numbers of genes can be tested concurrently at reasonable cost.  
Pre-symptomatic testing for autosomal dominant causes of dementia is only undertaken 
after specific genetic counselling. 
Routine testing of genetic risk factors (e.g. APOE status) is not currently recommended 
[123] due to the uncertainty of what this means for an individual. 
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1.8 Treatment 
1.8.1 Symptomatic 
Acetylcholinesterase inhibitors (AChEIs) (donepezil, galatamine and rivastigmine) are 
the mainstay of symptomatic treatment and exert their therapeutic action by inhibiting 
the enzyme acetylcholinesterase.  This increases the brain availability of acetylcholine 
by preventing its breakdown in the synapse. Several studies have demonstrated AChEIs 
have modest beneficial effects in mild to moderate Alzheimer’s disease with all drugs in 
the class having similar efficacy [125].  There is also some evidence that cholinesterase 
inhibitors have some benefit in moderate to severe Alzheimer’s disease, as the 
DOMINO-AD study demonstrated that withdrawal of donepezil lead to increased risk of 
requiring nursing home placement in the following 12 months [126].        
Memantine, a low affinity N-methyl-D-aspartate receptor antagonist, works by reducing 
L-glutamate excitatory neurotoxicity.  It has been shown to have small but clinically 
significant effects on cognition and function in patients with moderate to severe 
Alzheimer’s disease, and may reduce the likelihood of patients developing agitation 
[127]. 
Dual AchEI and memantine therapy appears to lead to some improvement in behavioural 
symptoms in moderate to severe Alzheimer’s disease but there is only weak evidence 
for improvement in cognition [128].  
1.8.2 The search for disease modifying therapy 
Models suggest that a disease modifying treatment that could slow dementia 
progression by 25% would reduce the number of people with severe dementia by almost 
half [129].  Such a treatment f 
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or Alzheimer’s disease has proved elusive however.  There is currently no treatment that 
can alter the underlying pathology or slow the course of the disease. 
A number of major phase 3 clinical trials using monoclonal antibodies targeting cerebral 
β-amyloid have failed to reach their primary outcome measures leading to scepticism 
about the validity of the amyloid hypothesis (table 1.1). However, many of these studies 
have been troubled by concerns about target and patient selection [68], as a proportion 
of individuals recruited for some of these trials did not have any evidence of underlying 
Alzheimer’s disease pathology [61].  Furthermore, most studies have targeted patients 
with later-stage Alzheimer’s disease, when β-amyloid may no longer be the most 
appropriate target, or too much irreversible damage may have occurred to change 
clinical outcomes.  
Our better understanding of the natural history of Alzheimer’s disease offers an earlier 
window for intervention.  
A trial of aducanumab, targeting Alzheimer’s disease at an earlier stage has encouraging 
preliminary findings showing reduction in amyloid burden and delay in disease 
progression at 1 year in prodromal and mild Alzheimer’s disease patients [130] and there 
are several other ongoing studies in mild cognitive impairment and mild Alzheimer’s 
disease in progress including the BAN2401 stage 2B trial [71, 131]. Strategies to clear 
amyloid using immunotherapy or prevent the formation of pathological forms with β-site 
APP cleaving enzyme (BACE) or γ-secretase inhibitors/modulators are being testing in 
the pre-clinical phase before any symptoms have manifest.  The DIAN-TU [132] and API-
ADAD [133] studies are using genetic screening to identify individuals at risk for familial 
Alzheimer’s disease. The Generation study is recruiting APOE ε4 individuals [134]; and 
the A4 study is recruiting healthy elderly individuals with asymptomatic amyloidosis 
[135].  
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Drug Name Proposed Mechanism of 
Action 
Phase 3 Clinical Trial Results 
Tramiprosate Aβ aggregation inhibitor 1,052 mild–moderate AD patients randomized to 3 groups: placebo, 100, 150mg/kg BD for 78 
weeks. No significant effects on primary outcome measures on ADAS-cog and CDR-SB [136]. 
Tarenflurbil γ-secretase modulator 1,684 mild AD patients randomized to placebo, 800mg BD tarenflurbil for 18 months. No significant 
effects on primary outcome measures on ADAS-cog and ADCS-ADL [137]. 
Semagacestat γ-secretase inhibitor 2,600 mild–moderate AD patients randomized to placebo, 100, 140mg semagacestat OD for 76 
weeks in 2 trials (ClinicalTrials.gov identifiers NCT00594568, NTC00762411). Trials were halted 
after interim analysis showed increased incidence of skin cancer and worsening of cognition and 
activities of daily living [138]. 
Bapineuzumab Humanized monoclonal 
antibody directed at amino 
acids 1–5 of Aβ peptide. 
Amyloid plaque clearance 
4,500 mild–moderate AD patients randomized to placebo and 0.5mg/kg IV every 13 weeks for 18 
months in APOE4 carriers, and randomized to placebo, 0.5, 1.0mg/kg IV every 13 weeks for 18 
months in APOE4 noncarriers in 4 trials (ClinicalTrials.gov identifiers lNCT00575055, 
NCT00574132, NCT00676143, NCT00667810). Trials were halted after completion of 2 trials 
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Table 1.1 Outcomes of Phase 3 Clinical Trials of Amyloidocentric Drugs 
ADAS-cog, Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study–Activities of Daily Living 
Inventory; BD, twice daily; CDR-SB, Clinical Dementia Rating–Sum of Boxes; CSF, cerebrospinal fluid; IV, intravenous; OD, once per day.  Table 
adapted from Karan and Hardy, 2014 [68]. 
mediated by microglial 
activation 
demonstrated a failure to meet primary outcome measures on ADAS-cog and activities of daily 
living [139]. 
Solanezumab Humanized monoclonal 
antibody directed at amino 
acids 16–24 of Aβ peptide. 
Amyloid plaque clearance 
mediated via peripheral sink 
mechanism 
2,000 mild–moderate AD patients randomized to placebo and 400mg solanezumab monthly IV 
for 18 months (ClinicalTrials.gov identifiers NCT00905372, NCT00904683). Trials failed to meet 
their primary outcome measures on ADAS-cog and ADCS-ADL. A secondary analysis of mild 
AD patients pooled from both trials showed a significant effect on cognition [140]. 
Gammagard Intravenous immunoglobulin 390 mild–moderate AD patients randomized to 0.2g/kg/2 weeks and 0.4g/kg/2 weeks vs placebo 
for 18 months (ClinicalTrials.gov Identifier NCT00818662). Gammagard failed to reach its co-
primary outcomes of ADAS-cog and ADCS-ADL [141]. 
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Alternative targets including tau pathology have also attracted interest, with a number of 
clinical trials ongoing [142].   
Genetic studies have highlighted pathways such as the innate immune system, 
microglia activation/inflammation and brain cholesterol metabolism as having potential 
for therapeutic intervention.  This may lead to the identification of novel drug targets, 
however to date there have been no positive clinical trials targeting neuroinflammation 
[143].   
For a review of potential therapies in the current AD treatment pipeline please see 
Cummings et al., 2018 [144]. 
1.8.3 A new era of Alzheimer’s disease therapeutics 
If a disease-modifying treatment with proven clinical benefit is found it will mark a new 
era in the management of Alzheimer’s disease, however will also bring its own 
challenges for UK healthcare.   
A treatment for people with established Alzheimer’s disease would need to be affordable 
and accessible to all those who would benefit, yet this would be a significant challenge 
for the NHS in its current state to deliver.    
A treatment for the pre-clinical phase would require accurate and timely identification of 
those ‘at risk’ of Alzheimer’s disease through a national screening programme. However, 
in addition to identifying those ‘at risk’, we would need risk models and biomarkers to 
predict when an individual ‘at risk’ will manifest clinical disease, else it will be difficult to 
counsel people about the optimal time to start treatment.  This will be important initially 
for treating people within the context of clinical trials, and subsequently if we are able to 
use a personalised ‘preventative medicine’ approach to Alzheimer’s disease.  
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2 Pathology to phenotype: Clinical Heterogeneity in 
Alzheimer’s disease 
Alzheimer’s disease is clinically heterogeneous, but the mechanisms underlying this 
remain incompletely understood.  Selective vulnerability, by which subpopulations of 
neurons in different brain networks show variable susceptibility to dysfunction and death 
in response to specific insults, may explain some of the observed phenotypic differences.  
This chapter reviews attempts to classify the different Alzheimer’s disease syndromes 
and discusses potential means by which the same underpinning neuropathology can 
manifest in such markedly different clinical presentations.    
2.1 Early descriptions of Alzheimer’s disease heterogeneity: subgroups vs stages 
Alois Alzheimer’s first case would now be recognised as having an atypical form of 
Alzheimer’s disease.  Auguste D was a 51 year old woman who presented with profound 
language deficits, behavioural disturbance including anxiety and paranoid delusions.  
Her episodic memory was impaired, but this was not the most prominent cognitive 
feature.  DNA analyses from the original histological slides prepared in Alzheimer’s 
laboratory have subsequently shown she had pathological c.526T>C PSEN1 variant 
[145].      
Early descriptions of phenotypic heterogeneity in Alzheimer’s disease came from 
observing dementia patients in geriatric hospitals.  McDonald noted some individuals 
had difficulties predominantly with praxis, visual construction, and cortical sensation 
which he termed a 'parietal group'. Other patients had predominantly memory 
dysfunction, later age of onset, and slower disease progression than the ‘parietal group’.  
He described them as having 'benign memory dysfunction of aging' [146].  
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This early classification of subtype variability did not generate widespread recognition 
however, perhaps as the prevailing theory of the time held that clinical variation arose 
from observing the disease at different stages of progression (‘phase hypothesis’), rather 
than truly distinct disease phenotypes (‘subtype hypothesis’) [147].   
Regional cerebral glucose metabolism studies using 18F-fluorodeoxyglucose positron 
emission tomography subsequently lent credence to the ‘subtype hypothesis’ as they 
demonstrated that clinically distinct profiles of Alzheimer’s disease had distinct 
topographic patterns of hypometabolism in the brain.  Individuals with profound language 
impairment clinically showed more marked asymmetry with left hemisphere 
hypometabolism and patients with predominant visuo-constructive dysfunction had a 
‘hypometabolic focus’ in the right parietal cortex [148, 149].  Longitudinal follow up 
studies went on to demonstrate that different clinical syndromes and their metabolic 
imaging correlates could still be distinguished with disease progression over time [150]. 
However, some studies found language predominant presentations were associated 
with an earlier age of clinical disease onset [151, 152] which could be seen to support 
the phase hypothesis. Using the CERAD (Consortium to Establish a Registry for 
Alzheimer's Disease) database, which included standardised neuropsychology 
assessments, subtypes of Alzheimer’s disease were identified [153, 154] showing that 
individuals with variant presentations, predominantly anomia and impairment of 
constructional praxis, mirrored the ‘left’ and ‘right’ subgroups of the earlier PET studies, 
respectively.  Within the cohort studied, these variant subtypes did not differ significantly 
in their age of clinical disease onset or duration of illness, strongly suggesting that these 
observed differences were not alternative stages of disease, but true variants of 
Alzheimer’s disease. As with the PET studies, longitudinal analysis revealed stable 
subgroup-specific neuropsychological progression patterns, again supporting the idea of 
true distinct subtypes of disease [155].   
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It is now recognised that there is significant clinical heterogeneity within Alzheimer’s 
disease.  This is particularly apparent in individuals with sporadic young onset 
Alzheimer’s disease (YOAD), defined as symptom onset at less than 65 years [98] and 
the group studied in this thesis. 
2.2  ‘Typical Alzheimer’s disease’ 
As outlined in Chapter 1, the majority of people with Alzheimer’s disease present when 
over 65 years of age with insidious onset of progressive episodic and topographic 
memory impairment.  Whilst patients may lack insight this typically presents with relatives 
reporting repeated questioning, losing track of day-to-day events, or becoming 
disorientated whilst navigating a route. In early to moderate disease, social façade is 
typically preserved [156].  Some individuals have a very amnestic dominant phenotype 
and demonstrate the slowest decline in cognition [157], but others can also develop 
parietal dysfunction, such as problems with praxis and word finding difficulty.  
Neuropsychology often further reveals poor attention, working memory and executive 
dysfunction. As the disease progresses other cortical domains become involved leading 
to widespread cognitive impairment that impairs activities of daily living and an increasing 
dependence on care.  Pathologically, there is a subgroup of patients with the purer 
amnestic syndrome who have plaques and tangles limited to the medial temporal lobes 
with little or no spread to the neocortical areas [158].   
2.3 ‘Atypical’ Alzheimer’s disease 
Despite the common underlying histopathology as outlined above, individual patients 
with Alzheimer’s disease have different constellations and degrees of cognitive 
symptoms. Some have sufficiently unusual phenotypes to be considered as being 
distinct variants within a continuum.   
60 | P a g e  
 
Whilst an amnestic syndrome is still the commonest in YOAD, some patients present 
with profound impairment of language, higher order visual symptoms, marked behaviour 
change and dysexecutive syndrome, or combinations of these features. These atypical 
presentations of Alzheimer’s disease are seen in at least 5% of patients with late onset 
disease and approximately a third of patients presenting with YOAD [159] and in the 
absence of autosomal dominant mutations in APP, PS1 or PS2 genes. Three canonical 
atypical syndromes are described: posterior cortical atrophy (PCA), logopenic aphasia 
(LPA) and frontal Alzheimer’s disease. 
2.3.1 Posterior cortical atrophy  
PCA is the commonest syndrome of the atypical Alzheimer’s disease presentations [159, 
160] and presents with breakdown of parieto-occipital function in the context of relatively 
preserved memory and language functions [101] (see Table 2.1 for the diagnostic criteria 
for the syndrome of PCA).  Patients have combinations of dominant and non-dominant 
parietal impairment: visuospatial and visual apperceptive agnosias, visual 
disorientations, apraxia, dyscalculia, alexia and agraphia.  They may have features of 
Balint’s syndrome (simultagnosia, oculomotor apraxia, optic apraxia, environmental 
agnosia) or Gerstmanns syndrome (acalculia, agraphia, left/right disorientation and 
finger agnosia). Visual field defects, dyspraxia, myoclonus, extrapyramidal features or 
the motor signs of corticobasal syndrome may be evident on clinical examination [161]. 
Alzheimer’s disease pathology is the most common histological substrate for PCA 
phenotypes.  Pathological series identified Alzheimer’s disease pathology in over 60% 
of cases of PCA [162].  Amyloid PET imaging [163] and CSF neurodegenerative markers 
[164] are also consistent with Alzheimer’s disease in the majority of cases.  However, 
other pathologies can underlie a PCA phenotype, such as corticobasal degeneration, 
dementia with Lewy Bodies and prion disease [162, 165].   
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Core features of PCA 
• Insidious onset and gradual progression  
• Presentation with visual complaints, in the absence of significant primary ocular 
disease to explain the symptoms 
• Absence of stroke or tumour 
• Absence of early parkinsonism and hallucinations 
• Relative preservation of anterograde memory and insight (early in the disorder) 
Plus any of the following symptoms  
• Simultagnosia with or without optic ataxia or ocular apraxia  
• Constructional dyspraxia 
• Visual field defects  
• Environmental disorientation 
• Any of the elements of Gerstmann syndrome 
Supportive clinical features  
• Alexia  
• Presenile onset 
• Ideomotor or dressing apraxia 
• Prosopagnosia 
Investigations  
• Neuropsychological deficits relating to parietal and/or occipital regions  
• Focal or asymmetric atrophy in parietal and/or occipital regions on structural 
imaging 
• Focal or asymmetric hypoperfusion or hypometabolism in parietal and/or occipital 
regions on functional imaging 
Table 2.1 Diagnostic criteria for posterior cortical atrophy 
Adapted from Tang Wai et al., 2004 [165], the current research criteria during study 
design and recruitment.  In 2017 Crutch et al. published an updated consensus 
classification of posterior cortical atrophy [166].  
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2.3.2 Logopenic aphasia  
The language led Alzheimer’s disease variant; LPA, is one of the primary progressive 
aphasias, and dominated by long word finding pauses (anomia) and impaired 
phonological short-term memory. On cognitive examination this manifests as reduced 
auditory digit span and greater difficulty in repeating and comprehending sentences than 
single words [102].  There is initially relatively preserved episodic memory and non-
dominant posterior cortical function.  Alzheimer’s pathology has been demonstrated in 
over two thirds of cases [167, 168].  See Table 2.2 for diagnostic criteria for the syndrome 
of LPA. 
2.3.3 Frontal Alzheimer’s disease 
Frontal presentations of Alzheimer’s disease are the rarest and characterised by 
executive impairment and behavioural change [103, 104] in the presence of Alzheimer’s 
disease pathology [105, 106].  The have proved the most difficult to define, and present 
a significant diagnostic challenge during life as patients may also fulfil the diagnostic 
criteria for behavioural variant frontotemporal dementia (bvFTD). The clinical profile is 
variable but includes aspontaneity, perseveration and psychiatric symptoms. These may 
coexist with less prominent memory and posterior cortical deficits.   
2.3.4 Syndromic convergence 
The initial focal deficits of patients with these atypical Alzheimer’s disease presentations 
overlap closely with those that tend to develop in the later stages of typical Alzheimer’s 
disease, and patients with atypical forms usually develop more classic memory deficits 
as the disease progresses.    
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Diagnosis of Primary Progressive Aphasia 
 
All three of the following factors must be present: 
• The most prominent clinical feature is difficulty with language 
• Aphasia should be the most prominent deficit at symptom onset and for the initial 
phases of the disease 
• The language deficits are the principal cause of impairment in daily living activities 
All four of the following factors must be absent: 
• The pattern of deficits is better accounted for by other non-degenerative nervous 
system or medical disorders than by PPA 
• Cognitive disturbance is better accounted for by a psychiatric diagnosis than by PPA 
• Prominent initial episodic memory, visual memory, and visuoperceptual impairments 
• Prominent initial behavioural disturbance 
Diagnosis of logopenic variant PPA  
 
Both of the following core features must be present: 
• Impaired single word retrieval in spontaneous speech and naming 
• Impaired repetition of sentences and phrases 
 
At least three of the following four clinical features must be present:  
• Speech (phonologic) errors in spontaneous speech and naming 
• Spared single-word comprehension and object knowledge  
• Spared motor speech 
• Absence of frank agrammatism 
 
The clinical diagnosis of logopenic variant PPA can be supported by imaging findings of at 
least one of the following features: 
• Predominant left posterior perisylvian or parietal atrophy on MRI 
• Predominant left posterior perisylvian or parietal hypometabolism on single-photon 
emission CT or PET 
 
Logopenic variant PPA with definite pathology  
 
In patients with a clinical diagnosis of logopenic variant PPA, definite pathology is 
demonstrated by either of the following features:  
• Histopathological evidence of a specific neurodegenerative pathology (including 
Alzheimer disease, frontotemporal lobar degeneration with tau pathology, 
frontotemporal lobar degeneration with TDP-43 pathology) 
• Presence of a known pathogenic mutation 
Table 2.2 Diagnostic criteria for logopenic variant PPA 
Adapted from Gorno-Tempini et al, 2011 [102].  
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2.4 Research diagnostic criteria 
Both the 2011 US National Institute on Aging–Alzheimer’s Association (NIA-AA) [117] 
and the 2014 International Working Group (IWG) [116] published recommendations for 
the diagnosis of Alzheimer’s disease have recognised and attempted to define the varied 
clinical phenotypes of Alzheimer’s disease.  
2.4.1 US National Institute on Aging–Alzheimer’s Association criteria  
Atypical presentations, including those with early and prominent language, visuospatial 
and executive impairment, are included in the 2011 criteria for probable Alzheimer’s 
disease dementia (see Table 2.3). 
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Core clinical criteria for Probable Alzheimer’s disease dementia 
 
A. Insidious onset. Symptoms have a gradual onset over months to years, not sudden 
over hours or days; 
 
B. Clear-cut history of worsening of cognition by report or observation; and 
 
C. The initial and most prominent cognitive deficits are evident on history and 
examination in one of the following categories: 
 
i. Amnestic presentation: It is the most common syndromic presentation of 
Alzheimer’s disease dementia. The deficits should include impairment in 
learning and recall of recently learned information. There should also be 
evidence of cognitive dysfunction in at least one other cognitive domain, as 
defined earlier in the text. 
ii.  
iii. Non-amnestic presentations: 
1. Language presentation: The most prominent deficits are in 
word-finding, but deficits in other cognitive domains should 
be present. 
2. Visuospatial presentation: The most prominent deficits are 
in spatial cognition, including object agnosia, impaired face 
recognition, simultagnosia, and alexia. Deficits in other 
cognitive domains should be present. 
3. Executive dysfunction: The most prominent deficits are 
impaired reasoning, judgment, and problem solving. Deficits 
in other cognitive domains should be present. 
 
D. The diagnosis of probable Alzheimer’s disease dementia should not be applied 
when there is evidence of: 
 
(a) substantial concomitant cerebrovascular disease, defined by a history of a 
stroke temporally related to the onset or worsening of cognitive impairment; or the 
presence of multiple or extensive infarcts or severe white matter hyperintensity 
burden; or  
(b) core features of Dementia with Lewy bodies other than dementia itself; or  
(c) prominent features of behavioural variant frontotemporal dementia; or  
(d) prominent features of semantic variant primary progressive aphasia or non-
fluent / agrammatic variant primary progressive aphasia; or  
(e) evidence for another concurrent, active neurological disease, or a non-
neurological medical comorbidity or use of medication that could have a 
substantial effect on cognition. 
 
Table 2.3 NIA-AA 2011 criteria for Probable Alzheimer’s Disease Dementia 
Adapted from McKhann et al., 2011 [117]. 
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2.4.2 International working group (IWG) criteria  
IWG criteria for a research diagnosis of typical Alzheimer’s disease require the presence 
of a medical temporal lobe amnestic syndrome, that can be associated with various 
cognitive or behavioural changes, and evidence indicative of in-vivo Alzheimer’s 
pathology (see Table 2.4).  
 A diagnosis of atypical Alzheimer’s disease can be made in the presence of a clinical 
phenotype consistent with one of the known atypical presentations (posterior variant, 
logopenic variant of primary progressive aphasia, frontal variant) and at least one marker 
of in-vivo Alzheimer’s pathology (Table 2.5).  
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A. Specific clinical phenotype  
 
Presence of an early and significant episodic memory impairment (isolated or 
associated with other cognitive or behavioural changes that are suggestive of a mild 
cognitive impairment or of a dementia syndrome) that includes the following features: 
 
• Gradual and progressive change in memory function reported by the patient or 
the informant over more than 6 months 
• Objective evidence of an amnestic syndrome of the hippocampal type, based on 
significantly impaired performance on an episodic memory test with established 
specificity for AD, such as cued recall with control of encoding task. 
 
B. In-vivo evidence of Alzheimer’s pathology (one of the following) 
 
• Decreased Aß together with increased T-tau or P-tau in CSF 
• Increased tracer retention on amyloid PET 
• AD autosomal dominant mutation present (in PSEN1, PSEN2, or APP). 
 
Exclusion criteria for typical AD 
 
History  
• Sudden onset 
• Early occurrence of the following symptoms: gait disturbance, seizures, major 
and prevalent behavioural changes 
 
Clinical features 
• Focal neurological features 
• Early extrapyramidal signs 
• Early hallucinations 
• Cognitive fluctuations  
 
Other medical conditions severe enough to account for memory and related symptoms 
• Non-AD dementia 
• Major depression  
• Cerebrovascular disease 
• Toxic, inflammatory, and metabolic disorders, all of which may require specific 
investigations  
• MRI FLAIR or T2 signal change in the medical temporal lobe that are consistent 
with infectious or vascular insults. 
 
Table 2.4 2014 IWG-2 criteria for typical Alzheimer’s disease (A plus B at any stage) 
Reproduced from Dubois et al., 2014 [116]. 
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A. Specific clinical phenotype (one of the following) 
 
Posterior variant of AD (including) 
• An occipitotemporal variant defined by the presence of an early, predominant, 
and progressive impairment of visuoperceptual functions or of visual 
identification of objections, symbols, words or faces 
• A biparietal variant defined by the presence of early, predominant and 
progressive difficulty with visuospatial function, features of Gerstmann syndrome, 
of Balint syndrome, limb apraxia, or neglect 
 
Logopenic variant of AD defined by the presence of early, predominant, and 
progressive impairment of single word retrieval and in repetition of sentences, in the 
context of spared semantic, syntactic, and motor speech abilities 
 
Frontal variant of AD defined by the presence of early predominant, and progressive 
behavioural changes including association of primary apathy or behavioural 
disinhibition, or predominant executive dysfunction on cognitive testing. 
 
Down’s syndrome variant of AD defined by the occurrence of a dementia characterised 
by early behavioural changes and executive dysfunction in people with Down’s 
syndrome 
 
B. In-vivo evidence of Alzheimer’s pathology (one of the following) 
 
• Decreased Aß together with increased T-tau or P-tau in CSF 
• Increased tracer retention on amyloid PET 
• AD autosomal dominant mutation present (in PSEN1, PSEN2, or APP) 
 
Exclusion criteria for atypical AD 
 
History  
• Sudden onset 
• Early and prevalent episodic memory disorders 
 
Clinical features 
• Focal neurological features 
• Early extrapyramidal signs 
• Early hallucinations 
• Cognitive fluctuations  
 
Other medical conditions severe enough to account for memory and related symptoms 
• Major depression  
• Cerebrovascular disease 
• Toxic, inflammatory, and metabolic disorders 
 
Table 2.5 2014 IWG-2 criteria for atypical Alzheimer’s disease (A plus B at any 
stage) 
Reproduced from Dubois et al., 2014 [116]. 
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2.4.3 NIA-AA 2018 Research Framework  
The recent 2018 update to the NIA-AA diagnostic recommendations defines Alzheimer’s 
disease as an “aggregate of neuropathological changes and thus is defined in vivo by 
biomarkers and post-mortem examination, not by clinical symptoms [169].  It shifts the 
definition of Alzheimer’s disease in living people away from the cognitive syndrome to a 
purely biological construct using biomarkers of Aβ1-42 deposition, pathologic tau, and 
neurodegeneration [AT(N)].  Cognitive impairment is treated as a symptom and/or sign 
of disease rather than the definition. 
This may help clinical trials, for example, if only individuals with proven Alzheimer’s 
disease pathology are recruited, however the clinical heterogeneity remains important 
as different imaging and cognitive end points would be needed for individuals with 
atypical presentations. 
2.5 Patterns of neuronal injury - evidence for selective vulnerability 
Selective vulnerability in the nervous system may explain differences in the clinical 
presentation of Alzheimer’s disease.  It refers to the observation that subpopulations of 
neurons within different brain systems are show variable susceptibility to dysfunction or 
cell death in response to specific types of pathological states or injury [170].   
Regional neuronal injury, reflecting this selective vulnerability, has been studied in vivo 
in Alzheimer’s disease variants using MRI to examine cross sectional or longitudinal 
atrophy, and 18F-fluorodeoxyglucose (FDG)-PET to demonstrate areas of brain 
hypometabolism.  These structural and functional imaging studies have shown that the 
dominant clinical features of atypical Alzheimer’s disease syndromes arise fairly 
predictably from the regional pattern of neurodegeneration.  
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2.5.1 MRI atrophy 
Within Alzheimer’s disease, different phenotypes are associated with different regional 
atrophy profiles (see Figure 2.1).   
Patients with late onset disease (manifesting after 65 years of age) typically present with 
an amnestic syndrome and correspondingly more medial temporal lobe degeneration 
relative to young onset cases [171].  In contrast, individuals with younger onset disease 
appear to have more neo-cortical predominant atrophy [172].   
Those with an amnestic presentation have bilateral atrophy of the hippocampi and 
medial temporal lobes, posterior cingulate and precuneus cortices, temporo-parietal 
cortex, whereas in PCA there is typically parieto-occipital brain atrophy with relative 
sparing of the hippocampi [101, 173] early in the disease course.  Patients with LPA 
classically have asymmetric involvement of the dominant hemisphere temporo-parietal 
junction [174-176].  The associated regional atrophy profile of the frontal lobes in people 
with behavioural or dysexecutive Alzheimer’s disease is less striking than the other 
variant Alzheimer’s disease syndromes.  Volume loss in the posterior cingulate and 
precuneus is more prominent in patients with frontal syndromes underpinned by 
Alzheimer’s disease pathology [106, 177] than other diseases causing frontal 
presentations.   
Despite the apparent focality of atrophy, particularly early on in the clinical disease 
course, there is significant overlap between atrophy in disease variants, and often 
common involvement of the parieto-temporal and posterior cingulate cortex [178].  
Furthermore, as the disease progresses clinically to involve other cognitive domains, the 
patterns of disease atrophy converge making it more difficult to detect any variant-
specific differences [179] and variation between early onset and late onset disease [180]. 
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(a) Typical amnestic Alzheimer’s disease  
	 	 	
	 	 	
 
(b) Atypical Alzheimer’s disease - Posterior cortical atrophy 
	 	 	
 
(c)Atypical Alzheimer’s disease – logopenic aphasia 
	 	 	
 
(d) Atypical Alzheimer’s disease – frontal Alzheimer’s	
	 	 	
Figure 2.1 Alzheimer’s disease atrophy profiles by phenotype 
(a) Typical amnestic Alzheimer’s disease: A 62 year old man with 6 year symptom 
duration and CSF tau:Aß ratio suggestive of Alzheimer’s disease.  MMSE 25/30. (b) 
Posterior cortical atrophy: A 57 year old woman with 8 year symptom duration and CSF 
tau:Aß ratio suggestive of Alzheimer’s disease.  MMSE 22/30.  (c) Logopenic aphasia: 
A 65 year old man with 3 year symptom duration.  MMSE 23/30. (d) Frontal Alzheimer’s: 
53 year old man with 11 year symptom duration and CSF tau:Aß ratio suggestive of 
Alzheimer’s disease.  MMSE 15/30.  All patients were recruited into the study described 
in Chapter 5.  The right cerebral hemisphere is displayed on the right in all panels.  
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2.5.2 Hypometabolism on 18F-fluorodeoxyglucose (FDG)-PET 
The patterns of regional hypometabolism in Alzheimer’s disease variants accord largely 
with the observed atrophy profiles.  Typical Alzheimer’s disease is associated with 
hypometabolism of the hippocampi bilaterally, medial temporal lobe, posterior cingulate, 
precuneus and temporo-parietal cortex on 18F-fluorodeoxyglucose (FDG)-PET brain 
imaging.  PCA has a parieto-occipital distribution of hypometabolism, as well as relative 
sparing of the medial temporal lobes, relative to patients with typical Alzheimer’s disease 
—at least early in the disease course [101].  LPA is characterised by left temporo-parietal 
hypometabolism [181].  Medial and orbital frontal hypometabolism is more pronounced 
in Alzheimer’s disease patients who have prominent behavioural and dysexecutive 
features [182]. 
2.6 Drivers of clinical heterogeneity  
The histopathological factors and genetic determinants leading to this regional 
neurodegeneration in Alzheimer’s disease are currently incompletely understood, 
limiting our understanding of the pathogenesis of atypical Alzheimer’s disease and how 
it gives rise to such a diverse repertoire of symptoms.    
2.6.1 Amyloid pathology 
As discussed in Chapter 1, accumulation of Aβ1-42 is required but not sufficient to lead 
to clinical manifestations of Alzheimer’s disease. However, Aβ1-42 distribution is 
relatively diffuse throughout the neocortex in people with clinically manifest Alzheimer’s 
disease so appears to explain relatively little about phenotypical variation, and does not 
mirror clinical symptoms.   
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Imaging studies using positron emission tomography with (11)C-labelled Pittsburgh 
compound B in typical amnestic Alzheimer’s disease and posterior cortical atrophy have 
not shown significant differences in amyloid deposition [183-185], and CSF Aβ1-42 
levels do not vary significantly between phenotypes [186, 187].   
The results of these studies imply that the distribution of amyloid deposition is unlikely to 
be the key determinant of phenotypic variation in Alzheimer’s disease. However, these 
studies have been performed on individuals with established disease, so given that Aβ1-
42 accumulation is an early pathological event in Alzheimer’s disease pathogenesis [95] 
it remains possible that there is regional variation in Aβ1-42 pathology in pre-
symptomatic individuals who will go on to develop focal clinical syndromes.  
2.6.2 Tau pathology 
Pathological studies have shown that tau pathology is more closely correlated with 
regional neurodegeneration and cognitive impairment than Aβ1-42, suggesting a more 
causal role in heterogeneity.  Even given the tendency for post mortem studies to be 
performed on patients with longer disease durations (and hence more syndromic 
convergence) there is some post mortem evidence for regional differences in tau 
pathology in Alzheimer’s disease variants. There is excess deposition of neurofibrillary 
tangles in occipital and parietal cortices in patients with PCA[165], in the dominant-
hemisphere perisylvian language cortices in those with logopenic variant [188, 189] and 
in the frontal cortex in individuals with frontal variant Alzheimer’s disease [105]. 
CSF phosphorylated tau concentrations correlate with neurofibrillary tangle pathology in 
Alzheimer’s disease [74, 78].  However, this reflects global tau burden in the brain and 
does not provide any insights to the regional distribution of tau, limiting its usefulness as 
a biomarker for studying selective vulnerability.  It remains unclear whether CSF total 
and phosphorylated tau vary within Alzheimer’s disease phenotypes, with some studies 
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finding no difference [190] and other suggesting that individuals with posterior cortical 
atrophy have lower levels of total and phosphorylated tau than those with frontal 
dysexecutive presentations [187], perhaps reflecting the varying burden of neocortical 
neuronal injury with PCA being a more focal syndrome than frontal Alzheimer’s disease 
at equivalent disease durations. 
The recent advent of advent of the positron emission tomography tracer 18F-AV1451 
[88] now enables the regional distribution of tau to be studied during life.  Pathological 
aggregation of tau mirrors patterns of neurodegeneration and clinical manifestations of 
Alzheimer’s disease.  Relative to controls, individuals with posterior cortical atrophy 
show increased 18F-AV1451 uptake in the clinically affected posterior brain regions, 
those with logopenic aphasia show higher 18F-AV1451 uptake in the left relative to right 
cerebral hemisphere, and patients with amnestic predominant presentations show 
highest 18F-AV1451 signal in the medical temporal and lateral temporo-parietal 
regions[90].   
2.6.3 Other co-existing pathologies 
Post mortem studies show that very few patients with Alzheimer’s disease have ‘pure’ 
disease, i.e. coexistent vascular disease, TAR DNA-binding protein 43 and α-synuclein 
pathologies are highly prevalent alongside Aβ1-42 and tau [10, 191].  It is unclear how 
these additional pathologies interact and whether for example accumulation of TDP-43 
and α-synuclein in neurons could make them more susceptible to damage from tau or 
amyloid, and how any cognitive impairment arising from these other pathologies clouds 
the clinical phenotype.  
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2.6.4 Genetic factors  
There is evidence for both autosomal dominant and risk factor genes modifying the 
clinical phenotype of Alzheimer’s disease and the age at which disease manifests. 
2.6.4.1 Monogenic ‘Familial’ Alzheimer’s disease 
Patients with autosomal dominant mutations account only for a small percentage of the 
total Alzheimer’s disease burden, however they have disproportionate neurobiological 
significance as an opportunity to gain insight into the much commoner sporadic disease.  
Mutations in PSEN1, PSEN2 or APP genes all alter the intracellular processing of 
amyloid precursor protein and promote formation and accumulation of Aβ1-42, hence, 
perhaps unsurprisingly the most striking and consistent phenotypic effect is early 
symptom onset. Age of clinical disease onset are lowest in families 
with PSEN1 mutations, typically falling between 35 and 55 years.  APP mutations tend 
to give rise to symptom onset slightly later, between 40 and 65 years 
and PSEN2 mutations between 40 and 70 years [192].  However, there is still significant 
phenotypic heterogeneity with regard to age of onset and clinical features both between 
families sharing a common mutation and within the affected individuals of a single family. 
Despite amyloid not being though to be a principle driver of heterogeneity, and all the 
autosomal dominant mutations affecting amyloid pathways, there are differences in 
phenotype observed between the different mutations.  Whilst the majority of individuals 
with familial Alzheimer’s disease do have similar clinical presentations to those with 
sporadic disease, atypical cognitive presentations are seen more commonly in PSEN1 
than APP mutations [100].  For reasons not understood, PCA and logopenic aphasia 
seem very rare in dominantly inherited Alzheimer’s disease, however behavioural 
presentations are described [100, 193].  
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Myoclonus and seizures tend to occur earlier and more prominently in very young 
symptomatic patients with dominantly inherited Alzheimer’s disease (<40 years) than in 
individuals with typical sporadic Alzheimer’s disease.  Spastic paraparesis, parkinsonism 
and cerebellar ataxia tend to be associated with PSEN1 mutations that cause severe 
amyloid plaque deposition in relevant anatomical areas [192].   
2.6.4.2 Sporadic Alzheimer’s disease: The case of the missing ɛ4 allele 
APOE ɛ4, the most significant genetic risk factor for Alzheimer’s disease is also 
associated with a younger age of onset in late onset Alzheimer’s disease.  Individuals 
homozygous for the ɛ4 allele can develop Alzheimer’s disease up to 10 years earlier 
than individuals who do not carry an ɛ4 allele [194].  However, the ɛ4 allele also appears 
to have its maximum impact between the ages of 60 and 70 years as it is relatively rarer 
for people with young onset Alzheimer’s disease to carry the APOE ɛ4 allele [195, 196]. 
Individuals carrying ɛ4 alleles have more profound memory loss [197, 198] and greater 
medial temporal lobe vulnerability evidenced by increased atrophy [199-201], more 
marked FDG PET hypometabolism[202, 203] and post mortem tau pathology compared 
to non-carriers [204].  Individuals without ɛ4 alleles are more likely to be predisposed to 
vulnerability of cerebral networks beyond the medial temporal lobes presenting with non-
amnestic phenotypes [205, 206]. 
2.7 Potential mechanisms underlying selective vulnerability  
Potential mechanisms underlying selective vulnerability of neural populations that lead 
to clinical heterogeneity in Alzheimer’s disease need to explain the mismatch between 
widespread amyloid deposition and more focal downstream neurodegeneration.     
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2.7.1 The network paradigm of neurodegenerative disease 
Alzheimer’s disease, and neurodegenerative diseases in general, are characterised by 
mis-folding of proteins, which may be intraneuronal inclusions (such as tau neurofibrillary 
tangles), and/or extracellular protein aggregates (such as amyloid plaques) leading 
ultimately to cell death.  The specific clinical phenotype that manifests arises from the 
individual proteins implicated and the specific pattern of damage across a distributed 
neural network.  This selective ‘disconnection’ is the basis of the neural network 
paradigm of neurodegenerative disease [207-210].  Diffusion weighted imaging 
modalities, such as diffusion tensor imaging (DTI) and neurite orientation and dispersion 
imaging (NODDI), and functional MRI can be used to study both structural and functional 
aspects of brain networks.  These techniques are described in Chapter 3 and used in 
Chapters 10 and 11. 
Cell models [211], animal models [212] and studies in humans [213] have consistently 
shown that Aβ1-42 production is related to neuronal activity, and Aβ1-42 largely 
accumulates in metabolically active highly connected brain regions, including but not 
limited to those making up the default mode network [214, 215].  This core network has 
been delineated using resting-state functional MRI.  It encompasses the medial temporal 
limbic structures, their efferent and afferent connections to the anterior and posterior 
cingulate cortices respectively, posterior temporal cortex, lateral parietal and prefrontal 
cortices, and thalamic nuclei [210, 216].  Default mode network activity has been linked 
to task-free activity whilst at rest, hence it’s historical definition in ‘negative terms’ [217].  
It is deactivated during various externally driven cognitive tasks and is actively involved 
in internally focused activity, such as episodic memory retrieval, thinking about the future, 
daydreaming and inferring the perceptions of others [214].  
Dysfunction of this core default mode network may help distinguish Alzheimer’s disease 
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from other neurodegenerative disease, such as frontotemporal dementia [209, 218].  
Altered DMN function has also been found in people with mild cognitive impairment with 
underlying Alzheimer’s disease pathology [219], and in pre-symptomatic individuals 
carrying APOE ɛ4 alleles [220] providing more evidence for its role in Alzheimer’s 
disease pathogenesis.  
Furthermore, involvement of the default mode network appears consistent across the 
spectrum of Alzheimer’s disease phenotypes [177, 178, 221] however the extent to 
which various parts of the network are involved and damaged may differ between 
phenotypes.  This could explain some of the phenotypic differences if the core network 
is a neuroanatomical and functional chassis on which genetic and environmental factors 
can modulate the expression of Alzheimer’s disease pathology [222]. 
However, network dysfunction in Alzheimer’s disease is also likely to involve functional 
and/or structural disruption of other networks that closely associate with the default mode 
network.  The extent of such network interactions could vary, and may be another 
mechanism by which heterogeneity in Alzheimer’s disease arises; by different patterns 
of tau related neuronal injury in specific functional networks.  Evidence for this hypothesis 
comes from the observation that different patterns of neuronal injury in Alzheimer’s 
disease variants broadly map onto established functional brain networks [223].  As 
discussed earlier, Aβ1-42 aggregation appears to be driven by neuronal activity in highly 
connected cortical ‘hub’ regions, hence is diffusely and symmetrically distributed 
throughout the brain.  Noting that tau pathology more closely correlates with regional 
neurodegeneration patterns, one possibility is that tau develops in specific vulnerable 
networks and spreads trans-neuronally, perhaps via a prion-like mechanism [224], to 
interconnected networks, possibly facilitated and augmented by amyloid pathology.   
These two theories – differential involvement within a core network, or common 
79 | P a g e  
 
involvement of a core network with selective dysfunction of associated networks – raise 
a number of further questions.  If other networks are implicated, it remains unclear what 
predisposes them to tau related injury in some individuals but not others.  It is also 
unclear where the neurodegeneration starts – in a specific vulnerable network, or in the 
hub of the core network which then spreads. 
2.7.2 Nexopathies: from protein abnormality to network signature 
The molecular nexopathies paradigm attempts to explain how a specific disease 
phenotype could arise from the interaction between particular characteristics of a 
vulnerable network and the properties of the abnormal protein that aggregates in that 
particular neurodegenerative disease [207, 225].  Components of this theory include 
networks having variable intrinsic vulnerability to due to regional protein expression, or 
the type of synaptic connections present in a certain network.  The pattern of daily activity 
in a neural network may predispose it to neurodegeneration, for example amyloid 
deposition in the metabolically active default mode network, and both amyloid and tau 
trafficking has been shown to change with the perturbations in the sleep wake cycle 
[226].  A proteinopathy might spread through the local neural circuit by causing 
connected brain regions to develop the same intracellular protein abnormality, or 
indirectly by affecting the function of the connected regions.   
Pathogenic proteins could promote neural network breakdown by various mechanisms 
including disruption of synaptic function or repair, axonal transport, cell-cell signalling 
abnormalities or interruption of downstream trophic functions.  Developmental patterns 
of protein expression or connectivity may make certain networks more vulnerable or 
resilient to disease effects.  Different types of neural connections may vary in their 
vulnerability to certain pathogenic proteins, for example shorter range dendritic and 
interneuronal connections appear especially susceptible to damage from some 
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tauopathies whereas longer range axonal projections appear more likely to be damaged 
by oligomers from APP [227].  The effect of damage to a network from accumulation of 
a specific faulty protein may be either a net toxic gain or function or loss of function.  The 
specific interaction between the vulnerable network and the pathogenic protein 
subsequently gives rise to the observed pattern of regional neurodegeneration and the 
macroanatomical signature of disease.  Specifically, in variant forms of Alzheimer’s 
disease, differential involvement of cortico-cortical projection zones that are part of a 
core Alzheimer’s disease vulnerable network may explain the atypical phenotypes that 
characterise posterior cortical atrophy and logopenic aphasia.   
2.7.3 “Catastrophic cliffs” 
Part of the basis of selective vulnerability in neurodegenerative disease is theorised to 
be due to neurons with specific functions being closer to different types of catastrophic 
failure, that can be precipitated by downstream effects of particular genetic mutations 
[228].   For example, in FTD, motor neurons and pyramidal neurons are close to a ‘cliff’ 
of ubiquitin proteasome system overload, and that the aberrant products of the C9orf72 
locus overwhelm this system and cause it to fail.  In DLB and FTD pyramidal neurons 
appear to be close to lysosomal failure, and hence are predestined to ‘catastrophe’ by 
genetic mutations in the endosome and lysosome system, such as those in GRN and 
CHMP2B [229].  It is possible that the cholinergic neurons that fail in Alzheimer’s disease 
do so as they tip over a ‘catastrophic cliff’ relating to directly to APP or tau metabolism, 
or more indirectly to immune mediated pathways or cholesterol metabolism.  How this 
relates to heterogeneity in sporadic Alzheimer’s disease remains to be explored. 
2.7.4 Resilience factors  
The converse to selective vulnerability is that there may be some individuals who, for 
whatever genetic or environmental predisposition, have brain networks with connectivity 
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patterns less susceptible to either the initiation or spread of a proteinopathy.  This may 
help explain the incomplete penetrance of some genetic mutations.  Equally, some 
neurons and brain networks are more resilient to Alzheimer’s pathology, for example the 
primary motor and sensory cortices are relatively spared.   
2.8 The challenge and opportunity of clinical heterogeneity 
The focus of research in Alzheimer’s disease on the ‘prototypic’ presentation represents 
the majority of people with the disease, and hence the bulk of the disease burden.  
However, recognising, characterising and understanding the rare Alzheimer’s disease 
variants and the influence of other common pathologies is important.  Much as the study 
of familial Alzheimer’s disease led to the discovery of autosomal dominant genetic 
mutations and the conception of the amyloid hypothesis, studying common and 
discordant genetic (and environmental) risk factors for typical and atypical Alzheimer's 
disease, combined with neuroimaging, cerebrospinal fluid and other biomarkers, may 
provide fundamental insights into Alzheimer's disease pathogenesis.  It is entirely 
plausible that different risk factors modulate the rate, timing and site of amyloid 
deposition; whether or when amyloid deposition leads to neurodegeneration; and which 
neuronal networks bear the brunt of the disease.  This in turn may influence how 
pathology spreads through the brain, and what symptoms predominate.   
Armed with this knowledge of syndromic inhomogeneity we may disentangle its 
confounding effects in clinical trials, as efforts to exclude atypical subtypes are not 
always successful and can affect outcome measures.  Furthermore, understanding the 
pathogenesis of atypical Alzheimer’s disease variants may lead to new targets for 
therapy and allow us to better tailor existing therapies to individuals. 
Finally, from a clinical perspective, clinicians should be alert to the fact that Alzheimer's 
disease can present with unusual phenotypes and not overlook the existence or 
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emergence of impairments in visual and other non-memory functions even in patients 
presenting with amnestic Alzheimer's disease.  These are important to recognise to allow 
prompt diagnosis and appropriate treatment, and tailored support and guidance for an 
individual patient.  
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3 Neuroimaging in Alzheimer’s disease 
One key tool to explore the heterogeneity in Alzheimer’s disease, and a technique 
utilised in this thesis is magnetic resonance imaging (MRI).  MRI is a safe, non-invasive 
and high-resolution imaging modality which utilises the interaction of biological tissue 
with electromagnetic fields and can be applied to the study of both brain structure and 
function.  It is well established as a key part of the diagnostic work up in the diagnosis of 
dementia [230] and ongoing technical advances offering higher resolution, new 
modelling techniques for MRI data and faster acquisition protocols means that MRI 
continues to be a dominant technique at the forefront of dementia research.  Chapters 8 
to 11 of this thesis use MRI to investigate aspects of heterogeneity in young onset 
sporadic Alzheimer’s disease.  This chapter discusses the principles of MRI and our 
current understanding of MRI in sporadic YOAD.  
3.1 Principles of MRI 
In the simplest terms, magnetic resonance imaging is based on the fact that protons 
placed in a magnetic field and excited by a radiofrequency (RF) pulse emit a radio signal 
which can be measured and used to construct an image of the brain.   
The human body is largely composed of water molecules, each of which contain two 
hydrogen nuclei, or protons.  A person is placed in the magnetic field of an MRI scanner, 
which generates a magnetic field (B0) typically in the range from 1.5 to 3.0 Tesla, 
although field strengths up to 7.0 T are now being used in clinical practice.  The unpaired 
protons become aligned with this field depending on the strength of the field and their 
thermal energy and precess (spin) in the direction of the field with a frequency (f0) 
determined by the Lamor equation:  
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f0 = gB0 
where g is the constant defined by the magnetic property of the nuclei.  A short RF pulse 
in the order of 50mT is transmitted at the resonant frequency of the proton and these 
protons absorb energy and are promoted to a higher energy level (decreasing 
longitudinal magnetisation) and such that they precess in phase (establishing transverse 
magnetisation).  When the RF pulse is subsequently switched off the excited protons 
realign with the magnetic field and emit energy in form of radio-waves.  The resulting 
increase in longitudinal magnetisation gives rise to the T1 curve (the time constant T1 is 
the longitudinal or “spin-lattice” relaxation time) and the loss of transverse magnetisation 
gives rise to the T2 curve (the time constant T2 is the transverse or “spin-spin” relaxation 
time and is much shorter than the T1 time constant).   
The time from one excitation pulse to the next is denoted as the repetition time (TR) and 
the time from one pulse to the maximum signal induction is the echo time (TE).  As the 
magnetic field within the scanner is not uniform but instead generated as a gradient, the 
radio waves emitted from the protons are additionally dependent upon their position 
within the gradient field, meaning the radio waves can be converted into spatial 
information.   
Altering the MRI acquisition parameters enables the different T1 and T2 properties of 
tissues to be utilised to generate images highlighting a specific tissue type.  T1 is 
characterised by short TR and short TE, and used in this thesis to image the structure of 
the brain.  
3.2 Volumetric structural MRI 
Volumetric structural MRI involves imaging the entire brain as a whole entity, acquiring 
isotropic voxels or thin slices with high spatial resolution to allow multi-planar 
85 | P a g e  
 
reconstructions in all planes. This thesis uses a Siemens 3D gradient echo sequence: a 
T1 weighted magnetically prepared rapid acquisition gradient echo sequence (MP-
RAGE) [231]. 
Volumetric structural MRI can be used cross-sectionally to image heterogeneity in 
regional brain atrophy using visual assessment tools (e.g. Scheltens medial temporal 
lobe scale [232]), volumetric measures which involve outline a predetermined region of 
interest on several sequential slices of a volumetric scan, and for voxel based 
morphometry which employs statistical parametric mapping to study differences in brain 
tissue composition between groups. 
Serial registered scans can be used to measure rates of brain or regional atrophy using 
methods such as the boundary shift integral (BSI) [80].   This technique determines the 
total volume through which the boundaries of a given cerebral structure have moved 
from a baseline to follow up scan, and, hence estimates the volume change, directly from 
voxel intensities.  The mean annual rate of brain atrophy using BSI in people with AD is 
approximately 2.78% compared with.024% in with healthy controls.  Other methods for 
measuring brain atrophy in longitudinal studies include Structural Image Evaluation, 
using Normalization, of Atrophy (SIENA) [233], Tensor-Based Morphometry (TBM) [234] 
and FreeSurfer-longitudinal (FS) [235].  
Volumetric structural imaging in young onset Alzheimer’s disease 
As discussed in section 2.5.1, different AD phenotypes are associated with different 
regional atrophy profiles (illustrated in Figure 2.1).  Volumetric structural imaging is used 
both in clinical practice to aid diagnosis and in AD research. 
Patients with late onset disease tend to have more medial temporal lobe degeneration 
relative to young onset cases [171] whereas individuals with younger onset disease 
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appear to have more neo-cortical predominant atrophy [172].  Those with an amnestic 
presentation have bilateral atrophy of the hippocampi and medial temporal lobes, 
posterior cingulate and precuneus cortices, temporo-parietal cortex, whereas in PCA 
there is typically parieto-occipital brain atrophy with relative sparing of the hippocampi 
[101, 173] early in the disease course.  Patients with LPA classically have asymmetric 
involvement of the dominant hemisphere temporo-parietal junction [174-176].  The 
associated regional atrophy profile of the frontal lobes in people with behavioural or 
dysexecutive Alzheimer’s disease is less striking than the other variant Alzheimer’s 
disease syndromes.  Volume loss in the posterior cingulate and precuneus is more 
prominent in patients with frontal syndromes underpinned by Alzheimer’s disease 
pathology [106, 177] than other diseases causing frontal presentations.   
Despite the apparent focality of atrophy, particularly early on in the clinical disease 
course, there is significant overlap between atrophy in disease variants, and often 
common involvement of the parieto-temporal and posterior cingulate cortex [178].  
Furthermore, as the disease progresses clinically to involve other cognitive domains, the 
patterns of disease atrophy converge making it more difficult to detect any variant-
specific differences [179] and variation between early onset and late onset disease [180]. 
3.3 Diffusion Tensor Imaging 
Diffusion tensor imaging (DTI) is a magnetic resonance technique for exploring the 
structural integrity of white matter in vivo using water diffusion to distinguish different 
microstructural environments that has been applied to the study of many neurological 
diseases[236].  It provides voxel-level estimates of fractional anisotropy (FA), axial 
diffusivity (AxD) and radial diffusivity (RD) within structural brain networks.  
Cerebral white matter consists of myelinated axons which water tends to diffuse along 
with limited diffusion perpendicularly.  A mathematical model to describe this process, 
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termed the diffusion tensor [237] uses a 3 x 3 matrix to describe the degree and direction 
of diffusion displacement over time. From the diffusion tensor matrix three eigenvalues 
(λ1, λ2 and λ3) and their eigenvectors (ε1, ε2 and ε3) are derived. Within each brain 
voxel the tensor is imagined as an ellipsoid with the eigenvectors defining the principal 
direction of diffusion along the axis of the ellipsoid and the eigenvalues defining the 
radius of the ellipsoid.  
When a property is highly isotropic (e.g. in water), each eigenvalue will be similar to one 
another (i.e. λ1≈λ2≈λ3) however when an object is highly anisotropic (e.g. a white matter 
tract) each eigenvalue will differ in order of magnitude (i.e. λ1>λ2>λ3).  To allow us to 
understand complex 3D changes in both the magnitude and directionality of diffusion a 
number of scalars have been derived. Fractional anisotropy (FA) describes the degree 
of directionality of diffusion and is calculated as follows:  
 
 
Other scalars better represent the magnitude of diffusion such as its average mean 
diffusivity (MD):  
 
Axial diffusivity (AX) is a measure of the magnitude of diffusion parallel to the orientation 
of the white matter tract being studied, which should be the dominate direction, as 
diffusion of water in this direction should be relatively unimpeded given the orientation of 
the structure: 
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Radial diffusivity RD, which is a measure of the magnitude of diffusion perpendicular to 
the orientation of the white matter tract being studied, should detect only minor diffusion, 
as the movement of water molecules in this direction is more impeded by tract fibres: 
 
FA is the most commonly reported metric within the 
literature, reflecting the overall integrity of a white matter tract by reporting the degree of 
isotropy within it (a value approaching one signifies highly anisotropic diffusion of water, 
often associated with a tract being more structurally intact, whilst lower values signify 
increasingly isotropic diffusion tending to be associated with tract pathology). However, 
FA cannot fully explain all the changes within the diffusion tensor, in particular the 
magnitude of change e.g. increases of similar magnitudes in each eigenvalue can result 
in no change to FA. Hence it is important to also consider the absolute changes in 
diffusion as measured by AX, RD and MD.  
 
   
Figure 3.1 Diffusion tensor imaging in Alzheimer’s disease 
 (a) fractional anisotropy, (b) axial diffusivity, (c) radial diffusivity, (d) mean diffusivity.  
Data are from an individual in this thesis. 
Diffusion tensor imaging in young onset Alzheimer’s disease 
(a) (b) (c) (d) 
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DTI is used as a research tool in AD.  Relative to late onset presentations, young onset 
Alzheimer’s disease is associated with more marked and extensive white matter 
abnormalities, involving the interhemispheric connections, limbic network and major 
associative tracts, sparing the corticospinal tracts, brainstem and cerebellar white 
matter. In contrast, individuals with late onset disease showed more localised pattern of 
white matter damage mainly involving the corpus callosum [238].  White matter diffusion 
abnormalities in young onset Alzheimer’s disease are more extensive than cortical 
atrophy so have been hypothesised to reflect the pathologic dissemination through 
structural connections from atrophic to unaffected cortical regions[239].   
Diffusion abnormalities between atypical Alzheimer’s disease phenotypes show 
significant spatial overlap in a structural network involving the fornix, corpus callosum, 
posterior thalamic radiations, superior and inferior longitudinal fasciculi, inferior fronto-
occipital fasciculus and uncinate fasciculus [240]. However, syndrome specific 
signatures of white matter damage are also detected, with diffusion abnormalities 
particularly in the fornix and cingulum in individuals with memory predominant 
symptoms, the left inferior fronto-occipital and uncinated fasciculi in those with logopenic 
aphasia, and the posterior thalamic radiations, superior longitudinal fasciculus, posterior 
cingulate and splenum of the corpus callosum in those with posterior cortical atrophy.  
Limitations of DTI 
The DTI model is based on there being a single fibre orientation in each voxel, whereas 
in the brain the majority of voxels contain fibres of different orientations and crossing 
fibres.  DTI cannot account for this, the scalars reported are summary measures for the 
voxel.  Furthermore, diffusion in is the brain is affected by the presence of membranes 
and myelin.  Whereas in DTI water diffusion is modelled as behaving in a Gaussian 
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manner, this does not reflect the true hindrance and restriction cause by the underling 
tissue microstructure [241].   
There are several more complex diffusion models of tissue microstructure that try to 
provide indices closer to what actually happens at the tissue level, one of which uses 
a three-compartment model and is used in this thesis: neurite orientation dispersion 
and density imaging (NODDI). 
3.4 Neurite Orientate Dispersion and Density Imaging 
Neurite orientation dispersion and density imaging (NODDI) [242] is one of a number of 
advanced diffusion MRI techniques designed to probe tissue microstructure beyond a 
composite view of each voxel by modelling water diffusion in multiple compartments 
[243] (Figure 3.2).  
(i) Diffusion that is restricted in axons and dendrites – modelled as a set of 
cylinders with zero radius, reflecting free diffusion along their length and 
restricted diffusion perpendicularly.   
(ii)  Hindered in the extra-neurite space i.e. the space around neurites that is 
occupied by glial cells, the extracellular matrix and neuronal cell bodies in 
grey matter.  
(iii) Isotropic in cerebrospinal fluid (CSF)  
NODDI derives a neurite density index (NDI), orientation dispersion index(ODI) and the 
fraction of free water (Fiso).  Examples of these NODDI metrics are shown in Figure 3.3 
as NODDI maps.  NDI is an estimate of neurite density, and may therefore be a useful 
marker of the axonal loss in Alzheimer’s disease that leads to breakdown of brain 
structural networks and the development of cognitive symptoms.   
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ODI estimates the spread of dispersion of neurite orientations.  It ranges from 0 (all 
neurites perfectly parallel to 1 (neurites orientated randomly in all possible orientations).  
The NODDI model allows axonal loss in white matter (NDI) to be distinguished from 
altered patterns of axonal organization (ODI) on a voxel-by-voxel basis, thereby 
disentangling two key factors contributing to changes in FA.   
A key strength of NODDI, compared to alternative multi-compartment techniques, is the 
use of standard MRI acquisition similar to DTI, making it accessible for routine clinical 
studies.  To date, it is the only multi-compartment technique whose utility has been 
widely demonstrated in a broad range of applications, including Parkinson’s disease 
[244], epilepsy [245], normal ageing [246], brain development [247], and neurogenetic 
disorders [248]. 
At the time of investigation during this PhD, NODDI had not been applied to Alzheimer’s 
disease.  
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Figure 3.2 Diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI) models for diffusion weighted MRI 
DTI models each voxel using a single tensor, hence gives a composite view of tissue microstructure.  NODDI models each voxel as three compartments: 
intraneurite (restricted diffusion), extraneurite (hindered diffusion) and cerebrospinal fluid (isotropic diffusion).  Dendrites and axons, collectively known 
as ‘neurites’, are projections of neurons.  NODDI can estimate neurite density index (NDI) and orientation dispersion index (ODI), specifically in the 
intraneurite compartment, without partial volume effects from free water.       
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Figure 3.3 Neurite Orientation Dispersion and density imaging maps in 
Alzheimer’s disease 
(a) neurite density index, NDI (b) orientation dispersion index, ODI (c) fraction of free 
water, Fiso. Data are from an individual in the YOAD cohort. 
 
3.5 Activation functional MRI 
Functional MRI (fMRI) estimates and localises brain activation using the blood 
oxygenation level dependent signal (BOLD).   
This BOLD signal results from dynamic changes in blood flow and oxygenation (the ratio 
of deoxyhaemoglobin to oxyhaemoglobin) due to neuronal and synaptic activity, and as 
such is an indirect measure of neural activity [249].     
Regional changes in the BOLD signal influence the transverse relaxation rate T2 and 
T2*. Reduction of local magnetic gradients and increased blood volume prolong 
parenchymal T2*, which is recorded as a ‘positive’ BOLD signal by means of T2* 
weighted MRI.  
Fluctuations in BOLD without an external trigger, the so-called resting state fMRI, allows 
indirect inference about intrinsic brain connectivity.   Haemodynamic responses due to 
(a) (b) (c) 
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experimental external events result in task-activated BOLD fMRI from which inferences 
have been made with regard to cognitive function.  
Functional MRI has three potential advantages over structural MRI: 
(i) It may be more sensitive than conventional structural metrics and can hence 
detect disease-associated functional alterations prior to the onset of 
irrecoverable brain damage [94]. 
(ii) It can measure functional connections between brain regions which may 
occur via indirect structural connections and would otherwise not be 
appreciated. 
(iii) As well as identifying areas of decreased brain activity, it can uncover disease 
mediated aberrant and compensatory increases. 
Functional fMRI is well hence suited for studying the mechanisms by which brain 
networks break down in dementia and for testing specific pathophysiological hypotheses 
such as the relevance of pathogenic protein deposition[250].   
Limitations of activation fMRI 
There are also a number of challenges in using this technique including a lack of 
methodological consistency between studies, the presence of physiological noise, and 
unclear applicability to individual participants. Furthermore, the application of task based 
fMRI to patients with cognitive impairment can be challenging and usually requires 
customised protocols based on short scanning sessions and minimal in scanner task 
demands, (e.g. in Chapter 11 I use a task free paradigm). 
Activation fMRI studies in Alzheimer’s disease 
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As memory impairment and hippocampal atrophy are the commonest findings in patients 
with Alzheimer’s disease, most fMRI studies of task related activity in Alzheimer’s 
disease have focused on memory tasks and memory related brain activation.  Reduced 
hippocampal activation in Alzheimer’s disease patients verses controls has been 
demonstrated in several studies using memory encoding tasks [251-254].  However, 
increased hippocampal activity is also reported, especially in studies looking at patients 
with early stages of disease [255].  Furthermore, whilst hippocampal activity may be 
diminished in later disease, coexistent hyperactivation is seen in other parts of the DMN, 
such as the parietal and posterior cingulate regions[254].  The nature of this 
hyperactivation compared to control participants remains debated.  Hippocampal 
hyperactivity may be a compensatory mechanism which occurs early in the disease 
process, followed by hippocampal failure as the disease progresses, or may vary 
between individuals reflecting the degree, load and spatial profile of pathology within the 
wider DMN.   
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4 Thesis aims and outline 
The aims of this thesis are to describe clinical and genetic heterogeneity in a deeply 
phenotyped prospectively recruited cohort of individuals with young onset sporadic 
Alzheimer's disease (YOAD).  
Chapter 5 outlines how the YOAD study was set up to recruit a cohort to explore this 
heterogeneity.  
Chapter 6 describes the clinical and neuropsychological features of the YOAD cohort. 
Chapters 7 and 8 explore genetic underpinnings of YOAD.  The presence of any 
autosomal dominant mutations and APOE ε4 status for individuals in the YOAD cohort 
are reported in Chapter 7.  Chapter 8 addresses the prevalence of p.R47H: a rare genetic 
variant in TREM2 and a moderate genetic risk factor for Alzheimer’s disease first 
described during the timespan of this thesis, in both the YOAD cohort and a larger 
genetic cohort of individuals with dementia using Sanger Sequencing. The clinical 
phenotype of individuals with Alzheimer’s disease carrying an R47H variant is also 
described.   
Chapter 9 investigates macrostructural brain changes associated with different APOE ε4 
statuses including brain and hippocampal volumes and voxel based morphometry. 
 Chapter 10 looks into microstructural changes derived from diffusion imaging – including 
diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging 
(NODDI), relationships with APOE ε4 status, and between regional metrics and cognitive 
performance. 
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Finally, Chapter 11 seeks to understand the brain basis of memory impairment in 
Alzheimer’s disease by using behavioral measures and activation fMRI to investigate the 
neuroanatomical basis of musical memory in individuals with memory led and visual led 
presentations of young onset Alzheimer’s disease. 
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5 Methods overview - Cohorts 
The data analysed in this thesis is drawn from both the young onset Alzheimer’s disease 
(YOAD) study cohort – a new cohort set up and run as part of the work of this thesis 
(Chapters 7-11) and the pre-existing UCL Department of Neurodegenerative disease 
genetics cohort (Chapter 8). 
5.1 The YOAD cohort 
The YOAD Study was designed to explore phenotypic differences in a population of 
individuals with sporadic young onset Alzheimer’s disease using multimodal imaging and 
correlative neuropsychology, genetic and cerebrospinal fluid biomarker data.  The aim 
was to recruit ~50 patients with mild to moderate Alzheimer’s disease representing a 
variety of disease phenotypes, and ~25 age and sex matched controls.   
Work preceding the analyses in this thesis included writing study protocols, information 
sheets, data capture sheets, trialling imaging protocols and successful application for 
approval from Ethics and Research and Development committees.  
5.1.1 Participants 
Individuals with YOAD 
All patients were recruited from the Specialist Cognitive Disorders Clinic at the National 
Hospital for Neurology and Neurosurgery: a national referral centre for patients with 
cognitive disorders with a particular expertise in young onset dementia and genetic forms 
of dementia.   
All patients approached about the study had previously indicated that they would be 
interested in research or completed a Data Protection Act form to be included on the 
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UCL Dementia Research Centre Research Register.  All patients had a diagnosis of 
Alzheimer’s disease, which had been explained to them and their next of kin.   
Prior to recruitment to the study, patients underwent thorough neurological assessments 
as part of their clinical care.  This included a detailed medical history and collateral history 
from someone who knows them well, and general medical and neurological 
examinations.  Patients also underwent detailed neuropsychological testing to map the 
pattern of cognitive deficits and an MRI brain to exclude space occupying lesions, 
subdural haematoma and/or significant vascular disease as alternative causes for their 
cognitive presentations.  Standard screening blood tests including renal and liver 
function, vitamin B12 levels and thyroid function (in addition to any further felt necessary 
by the clinical consultant) to exclude other treatable causes of cognitive impairment were 
done.   
Patients with cerebrospinal fluid biomarker evidence of underlying Alzheimer’s disease 
pathology were preferentially, but not exclusively, recruited.  As part of their clinical work 
up, selected patients had cerebrospinal fluid samples for neurodegenerative markers 
collected in polypropylene tubes between 9am and 3pm according to local protocols.  
Total tau (T-Tau) and Aβ1-42 were analysed using INNOTEST enzyme-linked 
immunosorbent assays (ELISAs) (Fujirebio Europe N.V., Gent, Belgium).  Assays were 
carried out in batches according to local clinical NHNN neuroimmunology laboratory 
standard operating procedures to achieve coefficient of variation of <10%.  A tau/ Aβ1-
42 ratio cut-off of 0.52, shown to provide good sensitivity and specificity of underlying 
Alzheimer’s disease pathology [256] was used to guide decisions about patient eligibility 
for the study, in combination with a CSF Aβ1-42 <550pg/ml (based on patient and control 
CSF normative valves used locally). 
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All patients recruited had a prior diagnosis of Alzheimer’s disease that had been 
explained to them and their next of kin. 
Informants 
Patient participants were asked to identify a family member or friend who knew them well 
to act as an informant.  Informants were invited together with the participant to complete 
a number of questionnaires relating to the participant’s health and wellbeing and their 
own experiences of caring for a person with dementia. This involvement was 
independent of participation in the study as a healthy control. 
Healthy controls  
Unaffected partners of study patient participants were preferentially recruited as healthy 
controls for practical reasons and to aid accurate matching of the groups in terms of 
background, age and education.   
Partners of other patients seen at the Cognitive Disorders Clinic or attending the Rare 
Dementias Support Group (http://www.ucl.ac.uk/drc/support-groups), or people directly 
contacting the UCL Dementia Research Centre to volunteer were also recruited as study 
controls.   
5.1.2 Case Selection: inclusion and exclusion criteria 
Inclusion criteria for patient participants included:  
• age at reported symptom onset < 65 years;  
• fulfils criteria for probable Alzheimer’s disease dementia of intermediate or high 
certainty based on NIA-AD criteria incorporating biomarkers[117];  
• has capacity to give informed consent and be able to attend with a carer;  
• MMSE score [108] at recruitment of >12/30;  
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• on the basis of a medical history and physical examination the participant is 
considered to be otherwise healthy;  
• be a fluent English speaker;  
• stable for at least 3 weeks on any medication for dementia (cholinesterase inhibitors 
and/or memantine).   
Inclusion criteria for control participants included:  
• age and sex matched individuals willing to participate and give informed consent;  
• no known neurological or severe psychiatric disorders;  
• and no history of significant cognitive decline. 
Exclusion criteria for all participants included: 
• inability to tolerate MRI scanning; 
• any contraindication to MRI scanning; 
• member of a known autosomal dominant dementia family testing positive for a 
disease-causing mutation;  
• trisomy of chromosome 21; 
• and for patients, current or recent (<6 months) participation in a clinical trial of an 
investigation medicinal product for Alzheimer’s disease.  
5.1.3 Consent and Ethical Considerations 
This study was approved by the local research ethics committee at The National Hospital 
for Neurology and Neurosurgery, Queen Square, London (13/LO/0005).  Informed 
written consent was obtained from all participants.  Participants were all informed that 
taking part in the study was entirely voluntary and that they could withdraw at any time.  
It was emphasized that participants would not be provided with individual results, 
however if their MRI revealed an unrelated but clinically significant abnormality such as 
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a cerebral neoplasm their general practitioner would be informed.  All patient participants 
had capacity to consent at enrolment to the study.   
Data was stored in accordance with the Data Protection Act 1998.  
5.1.4 Study design 
The YOAD study involved assessment at baseline with additional assessment for interval 
change after one year (Table 5.1). The longitudinal data analyses are beyond the scope 
of this thesis and not further considered here. 
 Baseline visit One year visit 
Clinical Assessment x x 
Neuropsychology x x 
MMSE x x 
Neuroimaging   
3D T1 x x 
Diffusion tensor imaging x x 
Neurite orientation dispersion and density 
imaging 
x x 
Activation fMRI x  
Blood sample for genetic analyses x  
Table 5.1 Overview of YOAD study design  
5.1.4.1 Clinical assessment 
All study participants underwent a structured clinical assessment and physical 
examination.  This included a structured interview to assess any current cognitive 
symptoms and relevant background medical information.  With their permission, patients 
were interviewed in the presence of their consultee to ensure accurate data collection, 
noting some patients had significant memory impairment and/or lack of insight.   
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Specific information collected for all subjects included age, sex, handedness, level of 
educational attainment, occupation, smoking history, alcohol consumption and medical 
comorbidities.  An estimate of clinical symptom onset was made for patients from the 
history and from past medical notes available, and information about the use of 
symptomatic treatment (cholinesterase inhibitors or memantine) was collected.  Patients 
and their consultee were asked what their first noted symptom was (noting this may be 
vulnerable to recall bias, and patients often use the phrase ‘memory problems’ to 
describe a variety of cognitive symptoms). All participants were asked to grade any 
current cognitive, behavioural, neuropsychiatric, or motor symptoms. 
Neurological examination recorded whether abnormalities were demonstrable in the 
following domains: visual fields, eye movements, limb tone, limb reflexes, plantar 
response and gait.  The presence or absence of visual inattention, optic ataxia, 
myoclonus, rest tremor, postural tremor, bradykinesia, ataxia and/or dystonia was 
specifically noted.  Limb and orofacial praxis was assessed using subtest 3 of the Adult 
Battery for Adults (ABA-2) [257].  General physical examination recorded lying and 
standing blood pressure using a digital sphygmomanometer, height and weight.  Body 
mass index (BMI) was estimated calculated according to the formula: weight/(height)2.   
All participants were assessed using the MMSE [108]: a widely used 30-point screening 
tool for cognitive impairment within clinical practice assessing multiple cognitive domains 
including (i) orientation to time and place (10 points); (ii) registration (3 points); (iii) 
attention ± calculation (5 points); recall (3 points); (v) language (2 points); (vi) repetition 
(1 point); (vii) reading (1 point); (ix) visuospatial function (1 point); and (x) following a 
three stage command (3 points).  The modified Hachinski ischaemic score[258] was also 
calculated for patient participants – this scale ranges from 0 to 12, with vascular risk 
factors leading to an increased score (contained in YOAD study folder, see appendix 3).  
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5.1.4.2 Neuropsychology  
A neuropsychology battery was specifically designed to capture cognitive deficits in 
domains affected by both typical and atypical Alzheimer’s disease presentations.  The 
battery was designed to be implemented in less than two hours, to be applicable to both 
patients with mild to moderate Alzheimer’s disease and controls.  Material was presented 
both verbally and in written format (where applicable) to control for confounds due to e.g. 
language impairment on tests not primarily assessing language in patients with LPA, and 
visual impairment on tests not primarily assessing vision in PCA patients.   
The battery included assessment of general intellect (vocabulary and matrices subtests 
of the Wechsler Abbreviated Scale of Intelligence, WASI[259]), episodic memory 
(Recognition Memory Test - faces and words subtests, RMT [260]; Camden Paired 
Associate Learning test [261]), working memory (digit span from the Wechsler Memory 
Scale Revised [262]), word retrieval (Graded Naming Test [263]), calculation (Graded 
Difficulty Arithmetic, GDA [264]), spelling (Graded Difficulty Spelling Test, GDST [265]), 
visuospatial and visuoperceptual performance (Visual Object and Spatial Perception 
battery, VOSP[266]), speed of processing and executive function (design fluency and 
category fluency from the Delis-Kaplan Executive Function System, DKEFS [267]; Digit 
Symbol Modalities Test, DSMT [268]).  
5.1.4.3 Phenotype 
Phenotype for each patient participant was determined according to research criteria in 
use at the time of recruitment, as discussed in Chapter 2 [102, 116, 165]. 
5.1.4.4 Genetics 
Patient participants gave separate specific consent to donate blood for genetic analyses.  
Twenty millilitres of blood were collected by venepuncture and DNA extracted using 
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standard techniques.  Patient participant samples were tested for APOE ε4 genotype, 
the presence of any autosomal dominant causes of neurodegenerative disease using 
next generation sequencing, and known risk factor single nucleotide polymorphisms.  
The techniques and results are detailed in Chapters 7 and 8. 
5.1.4.5 Neuroimaging  
Participants underwent MRI scanning so that group differences in brain structure and 
function could be studied.   
All imaging was acquired on a 3T TIM Trio whole-body MRI scanner (Siemens 
Healthcare, Erlangen, Germany).  A 32-channel receiver phased-array head coil was 
used for all modalities, except the activation fMRI protocol (a 12-channel head coil was 
substituted as the participant was required to wear headphones during this sequence).  
Sequences acquired included: 
(i) High resolution 3D T1-weighted volumetric scans; 
(ii) Multi-shell high angular resolution diffusion-weighted MRI (DW MRI);  
(iii) Gradient-echo echo-planar image (GE-EPI) volumes as part of an activation 
functional MRI paradigm.   
An additional B0 field map was also acquired for distortion correction of the DW MRI and 
GE-EPI volumes.  Full details for the acquisition parameters are shown in Table 5.2. 
The technical detail of the acquisitions, image processing and data analyses are 
described in Chapters 8 to 11. The techniques used in each chapter are shown in table 
5.3.
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 MPRAGE  
(3D T1) 
DTI NODDI Diffusion 
field map 
Act-fMRI Act-fMRI 
field map 
Voxel resolution 
(mm3) 
1.1x1.1x1.1 2.5x2.5x2.5 2.5x2.5x2.5 3.0x3.0x3.0 2.0x2.0x2.0 3.0x3.0x3.0 
Matrix size 256x256x208 96x96x55 96x96x55 64x64x55 96x96x48 80x80x48 
FOV (read x PE) 
(mm) 
282x282 240x240 240x240 192x192 192x192 192x192 
Slice coverage (mm) 229 137.5 137.5 165 144 144 
Orientation sagittal transversal transversal transversal transversal transversal 
PE direction A>>P A>>P A>>P R>>L A>>P A>>P 
TE (ms) 2.9 91 91.6 4.92; 7.38 30 4.92; 7.38 
TR (ms) 2200 6900 7000 688 11340 688 
Flip angle (o) 10 90/180/180 90/180/180 60 90 60 
Acq Bandwidth 
(Hz/pix) 
240 1578 1578 260 2264 259 
Sequence specific 
comments 
TI=900ms 1st run: 4 interleaved b=0; 
b=1000 s/mm2 64 dir 
2nd run: 5 interleaved b=0; 
b=1000 s/mm2 64 dir (same 
64 dir as 1st run) 
 
Parallel imaging acquisition 
(GRAPPA with iPAT factor 2)  
3 non-zero b-values 
B=300 s/mm2 8 dir 
B=700 s/mm2 36 dir 
B=2000 s/mm2 72 dir 
13 interleaved b=0 
 
Parallel imaging acquisition 
(GRAPPA with iPAT factor 2) 
 92 volumes in 
each run  
 
Parallel imaging 
acquisition 
(GRAPPA with 
iPAT factor 2) 
 
Total scan time 9min 23s 16min 29s 16min 32s 1 min 31s 35min 58s 
(2 runs 17min 59 s) 
1min 53s 
Table 5.2 MRI sequence parameters 
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MRI modality Analysis technique Chapter 
Volumetric T1 Qualitative descriptive 8 
Brain, hippocampal and total intracranial volumes 8, 9 
Voxel based morphometry 9, 11 
Diffusion weighted 
imaging 
Tract based spatial statistics for DTI and NODDI 10 
ROI analysis for NODDI indices 10 
Activation fMRI Statistical parametric mapping 11 
Table 5.3 MRI modalities and analyses used by chapter 
3D volumetric T1-weighted 
3D T1-weighted volumetric brain images were acquired using a sagittal 3-D 
magnetization prepared rapid gradient echo (MPRAGE) sequence[269] optimised to 
provide strong contrast between white matter and grey matter (repetition time/echo time 
= 2200/2.9ms, dimensions 256x 256x208, voxel size 1.1x1.1x1.1 mm).   
All scans were reviewed by an experienced rater for overall quality and suitability for the 
analysis methods used.  3D T1 scans were specifically checked for blurring, image wrap 
around and contrast problems.   
T1 scans were segmented and brain volumes calculated (see methods in Chapter 9) 
and used for voxel based morphometry (Chapter 9). 
Diffusion-weighted MRI 
Two identical Diffusion Weighted Imaging (DWI) acquisitions were performed using a 
single-shot, spin-echo echo planar imaging sequence (64 diffusion-weighted directions, 
b=1000 s/mm2; 9 b=0 s/mm2 images (referred to as ‘b0’ images); 55 slices; voxel size 
2.5x2.5x2.5mm3; TR/TE=6900/91ms; total acquisition time for both sequences=16:29 
minutes).  A three-shell diffusion sequence optimised for NODDI was acquired (64, 32, 
and 8 diffusion-weighted directions at b=2000, 700 and 300 s/mm2; 14 b=0 images; 55 
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slices; voxel size 2.5x2.5x2.5mm3; TR/TE=7000/92ms; total acquisition time=16:32 
minutes).  Both single-shell (DTI) and multi-shell (NODDI) diffusion weighted sequences 
utilised twice-refocused spin echo to minimise distortion effects from eddy-currents.  
Visual review of diffusion imaging was performed for identification of poor quality images 
by checking for full brain coverage, inter-acquisition motion (using motion plots over the 
acquisition), sufficient correction of geometric distortion and slice-wise signal dropout 
(using correlation plots between adjacent slices).
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Diffusion Tensor Imaging (DTI) 
   
 
Figure 5.1 Representative diffusion images for diffusion weighted imaging (top 
panel) and neurite orientation dispersion and density imaging (lower panels). 
b=0 
unweighted images 
b=1000 
diffusion weighted     fractional anisotropy    mean diffusivity 
	 
diffusion weighted images 
b =300                           b=700                           b=2000 
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NDI                             ODI                             Fiso 
b=0 
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images 
Neurite Orientation Dispersion and Density Imaging (NODDI) 
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Pre-processing involved correction for motion by rigidly registering each diffusion-
weighted image to the first b0 image using FLIRT [270, 271].  Diffusion tensor volumes 
were spatially normalized with DTI-TK (http://dti-tk.sourceforge.net) which bootstraps a 
population-specific tensor template from the input tensor volumes and aligns them to the 
template in an iterative fashion [272] with a tensor-based registration algorithm[273].  
This framework has been shown to improve white matter alignment compared to 
conventional FA-based registration [274]. DTI metrics (FA, AxD, RD) were estimated 
using FSL [275]. NODDI metrics (NDI, ODI, Fiso) were estimated using the NODDI Matlab 
toolbox (http://www.nitrc.org/projects/noddi_toolbox).  
Activation functional MRI 
MRI data were acquired on a 3T TIM Trio whole-body MRI scanner (Siemens 
Healthcare, Erlangen, Germany). 92 gradient-echo echo-planar image (GE-EPI) 
volumes were acquired in each run using a 12-channel RF receive head and body 
transmit coil in sparse (TR 11.3 seconds) acquisition mode (to reduce any interaction 
between scanner acoustic noise and auditory stimulus presentations).  Each EPI volume 
comprised 48 oblique transverse slices with slice thickness 2mm, inter-slice gap 1mm 
and 2x2mm in-plane resolution (TR/TE=11340/30ms; echo spacing=0.69ms; matrix 
size=96x96 pixels; FoV=192x192mm, GRAPPA factor 2 in anterior-posterior phase 
encoding direction).  The initial two brain volumes were discarded to allow for equilibrium 
of longitudinal T1 magnetization. B0 field-maps were acquired using two gradient echo 
sequences (TR=688ms; TE1/TE2=4.92/7.38ms, 3x3x3mm resolution, no inter-slice gap; 
matrix size=80x80pixels; FoV=192x192mm; phase encoding anterior-posterior) to allow 
correction of field inhomogeneity.   
Visual review of fMRI acquisitions was performed for identification of poor quality images 
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Data from the fMRI experiment were pre-processed using SPM8. In brief, scans for each 
participant were realigned using the first image as a reference, and un-warped 
incorporating field-map distortion information. DARTEL processing was used to spatially 
normalise individual scans to a group mean template image in MNI space.  Normalised 
images were smoothed using a Gaussian smoothing kernel 6mm full-width at half-
maximum.   
Pre-processed images were entered into a first-level and second-level design matrices 
to assess effects of specific contrasts within and between participant groups (see 
Chapter 11 for more detail of experimental conditions and contrasts). 
5.1.5 Correction for multiple comparisons 
Conducting a large number of voxel-wise t-tests in SPM or FSL creates a risk of type 1 
error.  Family-wise error correction was used to account for these multiple comparisons, 
either across the whole brain or in study-specific predefined small volumes in the VBM 
and activation FMRI analyses.   
Threshold free cluster enhancement (TFCE) was used in the diffusion imaging analyses. 
5.1.6 Statistical analyses 
STATA version 12 (Stata Corporation, College Station, Texas, 2003) was used to 
perform standard parametric and non-parametric tests to investigate basic linear 
regression and test between group differences for demographics and 
neuropsychological data.   
5.1.7 Data storage 
Study data was stored electronically on a secure password protected database on a UCL 
secure server protected by comprehensive firewalls.   
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Hard copy study data was securely stored within the Dementia Research Centre.   
Personal identifying details were removed from MRI scans and replaced with a unique 
study ID.  All brain imaging was then uploaded to a customised open source imaging 
informatics software platform (www.xnat.org) hosted on the Dementia Research Centre 
secure servers.    
The YOAD study was registered with the UCL Data Protection Office.  All personal 
information was safeguarded in accordance with the UCLH NHS Trust Information 
Governance policy and the Data Protection Act (1998). 
5.2 Other genetic cohorts 
In order to investigate other genetic risk factors with rare or with a small effect, a larger 
University College London Department of Neurodegenerative disease genetic cohort 
was used in Chapter 8 sourced from multiple sites and studies.   
5.2.1 Participants 
Alzheimer’s disease (n=1002) and FTD (n=358) cases were recruited via tertiary 
specialist clinics at the National Hospital for Neurology and Neurosurgery, 
London.  Clinical diagnoses of Alzheimer’s disease and FTD were supported by 
participation in longitudinal research studies at University College London and the 
University of Cambridge, however as these sample collections were acquired over two 
decades the comprehensive use of research diagnostic criteria cannot be confirmed and 
some samples were assigned to these diagnostic categories based on clinical diagnoses 
only.  
All patients of known non-white ethnicity were excluded.  Individuals known to have 
pathogenic disease-causing variants in the amyloid precursor protein, APP; Presenillin 
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1, PSEN1; Presenillin 2, PSEN2; prion protein, PRNP, chromosome 9 open reading 
frame 72, C9orf72; microtubule associated protein tau, MAPT; or progranulin, PGRN 
genes were excluded although the entire sample collection was only partially screened 
for mutations in these genes.   
Control samples were obtained from the Human Random Control panel (European 
Collection of Cell Cultures n=534) and the UK 1958 Birth cohort (n=2381) (University of 
Leicester). 
5.2.2 Consent and Ethical Considerations 
All participants gave written informed consent at the recruiting centre.  
5.3 Techniques for investigating genetic heterogeneity 
5.3.1 Sanger sequencing 
Sanger sequencing[276] is based on the selective incorporation of chain-terminating 
dideoxynucleotides by DNA polymerase during in vitro DNA replication, and useful for 
sequencing single genes (e.g. in Chapter 8 looking for TREM2 variants in patient 
cohorts) 
The method requires a single-stranded DNA template (to be sequenced), a short DNA 
primer complementary to the template DNA, DNA polymerase, standard 
deoxynucleosidetriphosphates (dNTPs), and modified di-deoxynucleotidetriphosphates 
(ddNTPs) which terminate DNA strand elongation and may be radioactively or 
fluorescently labelled. After many rounds of template DNA extension there are DNA 
fragments terminated by labelled ddNTPs of many different lengths.  The DNA fragments 
are heat denatured and separated by size using gel electrophoresis in a DNA sequencer.  
The fragments migrate according to size and each is detected as it passes a laser beam 
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at the bottom of the gel.  Each type of labelled ddNTP emits coloured light of a 
characteristic wave length and is recorded as a coloured band on a simulated gel image.  
This is then interpreted by a computer program to output an electrophergram with each 
coloured peak representing each letter in the sequence.  Variants in the sequence can 
then be identified.  
5.3.2 Next generation sequencing 
Next-generation sequencing (NGS), or ‘high-throughput sequencing’, is the term used to 
describe a number of different modern sequencing technologies that allow longer DNA 
and RNA templates to be sequenced much more quickly and cheaply than Sanger 
sequencing.  
In contrast to Sanger Sequencing, Ion torrent NGS (as used in Chapter 7) does not use 
optical signals. Instead, the method utilises the fact that addition of a dNTP to a DNA 
polymer releases an H+ ion.  The DNA sequencing machine records tiny changes in pH 
to determine which bases have been added at each point in the template replication. 
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6 Recruitment to the YOAD study 
6.1 Introduction 
The aim of this work described in this Chapter was to recruit 50 patients with young onset 
sporadic Alzheimer’s disease and 25 controls, and to define this cohort in detail using a 
range of clinical measures, standardised batteries and neuropsychological testing.  
6.2 Methods 
Detailed methods including inclusion and exclusion criteria, clinical and neurological 
assessments are described in Chapter 5. 
6.3 Results 
In total, 45 patients with young onset Alzheimer’s disease and 24 controls were recruited 
over a two-year period. One additional patient and one additional control were assessed 
but did not take participate further as they were unable to tolerate the first MRI scan due 
to claustrophobia.  Recruitment was closed at this point to allow sufficient time for 
analysis of data during the lifetime of this PhD.   
6.3.1 Clinical characteristics 
Baseline clinical characteristics of each participant are shown in appendix 1. 
6.3.1.1 All Participants 
Age 
The mean age at entry to the study was 60.6 (SD 5.8; range 48.8-68.1) years for controls 
and 61.7 (SD 5.1; range 51.8-73.8) years for patients with young onset Alzheimer’s 
disease (no significant difference).  
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Sex 
Of the 24 controls, 11 (48%) were male, and of the 45 patients, 20 (44%) were male (no 
significant difference).   
Handedness 
There was no significant difference in the rate of left-handedness between the groups; 
3/24 (13%) controls were left-handed, compared with 2/45 (4%) of patients (p=0.47, 
Fisher’s exact test). 
Education  
Both groups had a high level of education, with 15/24 (63%) controls and 20/45 (44%) 
patients having a university degree; controls had a mean of 16.7 (SD 3.0, range 11-22) 
years of education, and patients with YOAD a mean of 15.1 (SD 2.9, range 10-20), 
p=0.05 (t-test).  
Employment 
The majority of controls were in full time employment (18/24, 75%), whereas the majority 
of patients were not (5/45, 11% employed) p<0.0001 (Fisher’s exact test).  The patients 
still in work were all under 65 years and tended to be in self-employed roles (freelance 
journalist, socialist party treasurer, partner in the family business, shop owner, priest).  
Smoking 
Of the controls, 15/24 (63%) were life-long non-smokers. There was no significant 
difference with the YOAD cohort: 29/45 (64%) (p=1.00, Fisher’s exact test). 
Alcohol consumption 
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More controls than patients exceeded the recommended weekly alcohol consumption 
(≥14 units per week): male participants - 7/11 (64%) controls vs 7/20 (35%) patients, 
p=0.15; female participants - 6/13 (46%) controls vs 3/25 (12%) patients, p=0.04. 
Medical comorbidities 
There were no significant differences between controls and patients (cardiac disease, 
p=0.12; head injury, p=0.73; stroke, p=1.00; diabetes mellitus, p=0.61; psychiatric 
diagnoses, p=1.0; hypertension, p=0.50; hypercholesterolaemia, p=0.09; all Fisher’s 
exact test).   
Cognitive symptoms 
Controls reported no or very mild symptoms in all domains apart from 3 individuals who 
reported mild depression, 2 individuals with mild anxiety and 1 with moderate anxiety. 
As expected, patients with YOAD had a wide range of cognitive symptoms; and higher 
level of anxiety, apathy and depression (Table 6.1) 
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Symptom Absent Very mild Mild Moderate Severe 
n (%) n % n % n % n % 
Controls 
Cognitive 
Memory impairment 19 (79) 5 (21) 0 (0) 0 (0) 0 (0) 
Language impairment 23 (96) 1 (4) 0 (0) 0 (0) 0 (0) 
Behavioural 
Apathy 21 (88) 3 (12) 0 (0) 0 (0) 0 (0) 
Neuropsychiatric 
Depression 17 (71) 4 (17) 3 (12) 0 (0) 0 (0) 
Anxiety 16 (67) 5 (21) 2 (8) 1 (4) 0 (0) 
Motor 
Tremor 23 (96) 1 (4) 0 (0) 0 (0) 0 (0) 
Slowness 23 (96) 1 (4) 0 (0) 0 (0) 0 (0) 
Weakness 22 (92) 2 (8) 0 (0) 0 (0) 0 (0) 
YOAD patients 
Cognitive 
Memory impairment 4 (9) 1 (2) 14 (31) 18 (40) 8 (18) 
Language impairment 15 (33) 2 (4) 8 (18) 17 (38) 3 (7) 
Visuoperceptual/ visuospatial 9 (20) 2 (4) 9 (20) 19 (42) 15 (33) 
Dyspraxia 22 (49) 5 (11) 6 (13) 7 (16) 5 (11) 
Impaired judgement/ problem solving 11 (24) 2 (4) 6 (13) 17 (38) 8 (18) 
Impaired attention/ concentration 6 (13) 5 (11) 13 (29) 15 (33) 6 (13) 
Behavioural 
Disinhibition 36 (80) 2 (4) 2 (4) 3 (7) 1 (2) 
Apathy 16 (36) 5 (11) 14 (31) 7 (16) 3 (7) 
Loss of sympathy/ empathy 34 (76) 3 (7) 2 (4) 1 (2) 4 (9) 
Ritualistic/ compulsive behaviour 32 (71) 3 (7) 6 (13) 1 (2) 2 (4) 
Hyperorality/ appetite changes 34 (76) 3 (7) 5 (11) 2 (4) 0 (0) 
Neuropsychiatric 
Visual hallucinations 40 (89) 3 (7) 0 (0) 2 (4) 0 (0) 
Auditory hallucinations 44 (98) 1 (2) 0 (0) 0 (0) 0 (0) 
Tactile hallucinations 44 (98) 1 (2) 0 (0) 0 (0) 0 (0) 
Delusions 44 (98) 1 (2) 0 (0) 0 (0) 0 (0) 
Depression 25 (56) 7 (16) 8 (18) 4 (9) 1 (2) 
Anxiety 17 (38) 6 (13) 8 (18) 10 (22) 4 (9) 
Motor 
Dysarthria 35 (78) 4 (9) 3 (7) 3 (7) 0 (0) 
Tremor 41 (91) 2 (4) 1 (2) 1 (2) 0 (0) 
Slowness 40 (89) 0 (0) 2 (4) 3 (7) 0 (0) 
Weakness 44 (98) 0 (0) 1 (2) 0 (0) 0 (0) 
Gait disorder 42 (93) 1 (2) 1 (2) 1 (2) 0 (0) 
Falls 41 (91) 2 (4) 2 (4) 0 (0) 0 (0) 
Table 6.1 Reported cognitive, behavioural, neuropsychiatric and motor symptoms 
in YOAD study participants 
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Mini Mental State Examination (MMSE, maximum score 30) 
Controls had a mean MMSE score of 29.5 (SD 0.7, range 28-30); patients with YOAD 
had a mean MMSE score of 21.5 (SD 4.6, range 13-29); the difference (as expected) 
was highly significant (p<0.0001, t-test).  Within the patient group, 18 individuals scored 
between 10/30 and 20/30 indicating moderate dementia (within this group, 2 individuals 
had moderately severe dementia, scoring between 10-14/30), 16 individuals scored 
between 21/30 and 16/30 indicating mild dementia [277].  There were 9 individuals who 
scored between 27/30 and 29/30 which would be classified as a ‘normal’ MMSE score, 
but these individuals fulfilled research criteria for Alzheimer’s disease [117] so were 
included. 
No individual scored less than 12/30, as per the study inclusion criteria. 
Neurological signs 
Neurological signs in patients and controls are shown in Table 6.2.  The commonest 
neurological findings in patients were visual extinction (10/45, 22%), optic ataxia (9/45, 
20%), and postural tremor (8/45, 18%), all of which were significantly different to the 
frequency observed in the control group (p=0.01, p=0.02 and p=0.04 respectively, 
Fisher’s exact test).  
One control had an eye movement abnormality (broken smooth pursuit) and one control 
had brisk upper limb reflexes, but no other upper motor neuron signs
120 | P a g e  
 
 
Control n=24 YOAD n=45 P 
n (%) n (%)  
Field defect  0 (0) 5 (11) 0.16 
Optic ataxia 0 (0) 9 (20) 0.02 
Visual extinction 0 (0) 10 (22) 0.01 
Eye movement abnormality 1 (4) 6 (13) 0.41 
Myoclonus 0 (0) 5 (11) 0.16 
Rest tremor 0 (0) 0 (0) n/a 
Postural tremor 0 (0) 8 (18) 0.04 
Bradykinesia 0 (0) 1 (2) 1.00 
Ataxia 0 (0) 3 (7) 0.55 
Dystonia 0 (0) 0 (0) n/a 
UL spasticity 0 (0) 0 (0) n/a 
LL spasticity 0 (0) 1 (2) 1.00 
UL hyper-reflexia 1 (4) 4 (9) 0.65 
LL hyper-reflexia 0 (0) 2 (4) 0.54 
Up-going plantars 0 (0) 0 (0) n/a 
Abnormal gait 0 (0) 0 (0) n/a 
Table 6.2 Neurological signs in YOAD study participants 
Apraxia 
All 24 controls scored 50/50 on the apraxia score (right upper limb, left upper limb and 
orofacial).  Patients were significantly impaired relative to controls on apraxia scores of 
the right upper limb (mean 48.5, SD 2.5, range 40-50, p=0.0002), left upper limb (mean 
48.1, SD 3.3, range 34-50, p=0.0001), and for orofacial movements (mean 49.2, SD 1.8, 
range 42-50, p=0.009), (Wilcoxon rank sum).  
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Blood pressure 
Blood pressure was recorded for and 24 controls and 44 patients. There were no 
significant groups differences in mean lying systolic (p=0.4), diastolic blood pressure 
(p=0.2), or mean arterial pressure (diastolic + 1/3 (systolic – diastolic)) (p=0.3, all t tests).  
The observation there is no excess hypertension in the patient group supports there 
being no excess cardiovascular disease. 
 n Mean systolic BP  
mmHg 
Mean diastolic BP 
mmHg 
Mean Arterial Pressure 
mmHg 
Controls 24 138 (26) 76 (11) 97 (15) 
Patients 44 134 (19) 73 (11) 93 (13) 
Table 6.3 Blood pressure of study participants 
Body mass index 
Body mass index (BMI) was recorded for 24 controls and 44 patients.  The mean for 
controls was 27.6 (SD 4.4, range 21.8-36.2), and for the patients 25.2 (SD 3.9, range 
18.9-36.8).  Patients had significantly lower BMIs than controls (p=0.03, t-test).  
6.3.1.2 Patients 
The following information was collected only for the patient group. 
Age at clinical disease onset  
The mean age of symptom onset, as reported retrospectively by the patient and 
corroborated by their consultee, was 56 yrs (SD 4.7, range 42-64).  
 
 
122 | P a g e  
 
Years of symptoms 
The mean clinical disease duration (i.e. time elapsed between age of clinical symptom 
onset and recruitment to the study) was 5.7 (SD 2.9, range 1.5-14.5) years. The 
individual with the longest disease duration was a 70 year old female who experienced 
visuospatial and visuoperceptual difficulties from age 56 years and had a PCA 
phenotype.  She was APOE ε3ε4 genotype and scored 22/30 on the MMSE at entry to 
the study. 
Modified Hachinski ischaemic score 
No YOAD participant had significant vascular risk: 3/45 (7%) had a score of 0; 19/45 
(42%) had a score of 1; 15/45 (33%) had a score of 2; 5/45 (11%) had a score of 3; and 
3/45 (7%) had a score of 4. 
Cerebrospinal fluid 
35/45 (78%) patients recruited had clinical CSF samples done prior to recruitment to the 
study.  An additional 5 participants had CSF taken as part of the YOAD study.  Of these 
patients only one patient had a clinical CSF sample that did not have a raised tau:Aβ1-
42 ratio (Aβ1-42 511 pg/ml, tau 203 pg/ml, tau:Aβ1-42 ratio 0.40).  She presented with 
a phenotype clinically consistent with Alzheimer’s disease: her first reported symptom 
was dyscalculia, neuropsychology showed memory, naming, executive, speed and 
attention deficits, and there was bilateral hippocampal atrophy on her clinical MRI scan.  
Her Aβ1-42 was low (i.e. in keeping with Ab deposition in the brain) for someone aged 
62 years, but her tau was not raised. The referring clinician and study PI confirmed that 
this was consistent with Alzheimer’s disease.    
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Leading symptom  
The most common leading symptom, as retrospectively reported by the patient and their 
consultee was memory problems (24/45, 53%).  Other leading symptoms were higher 
visual problems (12/45, 27%), language impairment (3/45, 7%), difficulty with manual 
dexterity (2/45, 4%) and impaired judgement and/or problem solving (2/45 4%).  For two 
patients (4%), memory problems and impaired judgement and problem solving were 
reported to have started simultaneously.  
Phenotype according to research criteria 
28/45 (63%) patients met criteria for typical amnestic Alzheimer’s disease, and the 
remaining 17 (38%) had an atypical presentation: 14 (31%) met criteria for posterior 
cortical atrophy, 2 (4%) had a primary progressive aphasia, and 1 (2%) had a behavioural 
/ dysexecutive syndrome. 
6.3.2 Neuropsychology 
As expected, there were significant differences between the number of patients and 
controls individuals performing at or below the 5% centile relative to published norms in 
the following cognitive domains: episodic memory, working memory, word retrieval, 
calculation, visuospatial and visuoperceptual function, and executive and speed of 
information processing.  These are illustrated in Table 6.4. 
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 Controls YOAD P† 
n  Mean 
(SD) 
(< 5% centile) n  Mean 
(SD) 
 (< 5% centile) 
n (%) n (%) 
Episodic Memory 
RMT – words ( /25) 24 24 (1) 1 (4) 44 18 (4) 30 (68) <0.0001 
RMT – faces ( /25) 24 25 (1) 0 (0) 45 20 (4) 12 (27) 0.006 
Camden Paired Associates learning ( /24) 24 20 (3) 0 (0) 44 5 (6) 27 (61) <0.0001 
Working memory 
WMS-R Digit Span Forwards ( /12) 24 9 (2) 0 (0) 45 6 (3) 13 (29) 0.003 
WMS-R Digit Span Backwards ( /12) 24 8 (1) 0 (0) 44 4 (2) 12 (27) 0.006 
Word Retrieval  
Graded naming test ( /30) 24 25 (4) 1 (4) 45 16 (9) 17 (38) 0.003 
Calculation 
Graded arithmetic test (oral) ( /24) 24 14 (7) 2 (8) 43 3 (5) 28 (65) <0.0001 
Spelling 
Graded difficulty spelling test (oral) ( /30) 24 26 (4) 0 (0) 43 14 (9) 6 (14) 0.08 
Visuospatial and visuoperceptual performance 
VOSP – object decision ( /20) 24 18 (1) 0 (0) 45 14 (4) 16 (36) 0.0006 
VOSP figure ground discrimination ( /20) 23 19 (1) 4 (17) 42 18 (2) 22 (52) 0.008 
VOSP dot counting ( /10) 24 10 (0) 0 (0) 42 7 (3) 19 (45) <0.0001 
VOSP fragmented letters ( /20) 23 20 (1) 0 (0) 42 11 (7) 28 (67) <0.0001 
Executive and speed of information processing 
Category fluency (animals, n)  24 23 (5) 0 (0) 44 11 (5) 29 (66) <0.0001 
WAIS-R Digit Symbol (n) 24 54 (11) 1 (4) 41 14 (16) 36 (88) <0.0001 
A Cancellation (s) 24 21 (6) 1 (4) 42 52 (25) 35 (83) <0.0001 
Table 6.4 Neuropsychological characteristics of YOAD study participant groups 
Mean (standard deviation) values show raw data; maximum scores on neuropsychological tests are given in parentheses.  † Fisher’s exact test.  
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6.3.3 Symptomatic treatment for Alzheimer’s disease 
All but one of the patients (44/45, 98%) was on a symptomatic treatment for Alzheimer’s 
disease (40 on a cholinesterase inhibitor, one on memantine, three on dual 
cholinesterase inhibitor and memantine).  
6.4 Discussion 
The patient and control cohorts recruited were well matched for the key demographics, 
with comparable and non-significant differences in age, sex-ratios, handedness, blood 
pressure, smoking history and levels of educations.  However, as expected there were 
clear differences in performances on tests of cognition, with the patient group performing 
less well on both the screening MMSE and on a wide range of formal neuropsychological 
tests.   
Both the control group and patient groups recruited were highly educated. This is 
consistent with other studies run locally through the Dementia Research Centre, and 
perhaps reflects high-functioning individuals (or those with high-functioning spouses) 
being motivated to find research studies to participate in.  There was a trend towards the 
patients having a slightly lower number of years of education, which could be seen to be 
consistent with epidemiological studies that report higher levels of education being 
associated with a lower risk of developing dementia, perhaps through increased 
cognitive reserve [52].  
As previously discussed, a definitive diagnosis of Alzheimer’s disease is not possible 
without histopathological confirmation.  Diagnosis in life therefore relies on the use of 
diagnostic criteria, the most commonly and recently updated criteria used at the time this 
study was set up was the NIA-AA 2011 criteria for Probable Alzheimer’s disease 
Dementia [117].  All patients recruited fulfilled criteria for ‘probable Alzheimer’s disease’, 
126 | P a g e  
 
and the majority had biomarker evidence of underlying Alzheimer’s disease pathology 
from cerebrospinal fluid analyses.  Given the increasing emphasis on biomarker 
evidence of Alzheimer’s disease in research criteria, it would have been ideal for all 
patient participants to have supporting molecular biomarker evidence, but some 
individuals did not wish to have a lumbar puncture and there was no access to amyloid 
PET imaging, so where individuals otherwise met criteria they were recruited. 
Individuals with young onset Alzheimer’s disease are, in general, less likely to have 
significant co-existent confounding vascular disease.  No participants with known 
cerebrovascular disease were recruited, and indirect evidence from results on the 
Hachinski score support this in the YOAD cohort. No patient had a modified Hachinski 
ischaemic score >3; a cut-off over 4 has been demonstrated to improve the 
differentiation of Alzheimer’s disease from vascular dementia[278].   
Weight loss is a well-recognised and consistent manifestation of Alzheimer’s disease 
[279] and the lower BMI observed our patients participants relative to controls is in 
keeping with this. It is likely that reduction in food intake (forgetting to eat or decreased 
interest in food), or increased catabolism is responsible for this, although in the absence 
of premorbid weight it is not possible to explore the relationship between weight loss and 
disease onset.  
There was no evidence in this small sample for blood pressure in patients to be either 
higher or lower than that of controls.  This is in keeping with previous reports as although 
midlife systolic hypertension is a risk factor for the development of late onset Alzheimer’s 
disease [280],  by the time of diagnosis the blood pressure is either normal or low.  Blood 
pressure in the aetiology of YOAD in less well studied due to the relative rarity of the 
disease, but these data albeit in a small sample does not suggest that there is 
aetiological link. 
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Within the patient cohort, two thirds had an amnestic presentation, and the remaining 
had atypical presentations, with posterior cortical atrophy being the most common.  This 
is broadly consistent with previous studies that have reported approximately 1/3 of young 
onset Alzheimer’s disease patients having a variant presentation [159]. 
Patient participants had a mean MMSE score of 21/30, with a wide range from 13 to 29.  
The patient who scored 29 was an individual with PCA who had had very focal symptoms 
for 3 years.  Despite scoring 29/30 he was sufficiently impaired on activities of daily living 
to justify inclusion as a participant with Alzheimer’s disease. 
The mean age of clinical disease onset in the patient cohort was 56 years, nearly a 
decade younger than that required to meet the criteria for ‘young onset’, with some very 
young individuals (youngest age 42 years at symptom onset).  No individual had a family 
history to suggest an autosomal dominant cause, but it is important to screen for these 
mutations in young onset cases due to the possibility of censored family histories, 
potential non-paternity, or de novo mutations.  This is addressed in Chapter 7. 
This cohort is a representative sample of patients with sporadic YOAD with evidence for 
Alzheimer’s disease pathology, absence of significant vascular disease, absence of 
autosomal dominant family history, and a representative range of phenotypes including 
amnestic, PCA, LPA and frontal Alzheimer’s disease, paving the way for the investigation 
of phenotypic diversity in subsequent chapters. 
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7 Genetic heterogeneity in the YOAD cohort 
7.1 Introduction 
Factors initiating and potentiating selective vulnerability and differential expression of 
pathology across the brain in sporadic YOAD are likely to be driven, at least in part, by 
genetic influences.  This chapter describes work that I undertook to screen for any 
autosomal dominant mutations in the YOAD cohort, and look at APOE alleles and how 
this relates to age at clinical disease onset, leading symptom and neuropsychology 
results. 
7.2 Methods 
7.2.1 Participants 
Participants were recruited to the YOAD cohort as outlined in Chapter 5.  In addition to 
the study consent, specific consent was obtained from participants to enter a further 
genetic study being run at the DRC.  Twenty millilitres of blood were collected by 
venepuncture and DNA extracted using standard techniques.   Whilst individual results 
were not given, patients were given the option to know if their participation in the 
research led to the development of a clinical genetic test for their condition.    
Control subjects did not have genetic analyses performed.   
7.2.2 Dementia Panel NGS 
Acknowledging the diagnostic challenges presented by atypical Alzheimer’s disease 
phenotypes, all patient participants underwent next generation sequencing for 
autosomal dominant causes of neurodegenerative disease.  
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An Ion Torrent Personnel Genome Machine (PGM) sequencer (Life Technologies 
Corporation, CA, USA) was used with Ampliseq PCR amplicon-based library preparation 
(Life Technologies) to sequence approximately 17.7Kb across 16 dementia related 
genes (variants in PRNP, PSEN1, PSEN2, APP, GRN, MAPT, TREM2, CHMP2B, 
CSF1R, FUS, ITM2B, NOTCH3, SERPINI1, TARDBP, TYROBP, VCP)[281].   
7.2.3 Sanger Sequencing 
C9orf72 was Sanger sequenced to look for any pathological expansions, as this type of 
intronic expansion cannot be sequenced by the NGS dementia panel. 
7.2.4 APOE ε4 status 
APOE status for patient participants was ascertained by Minor Groove Binding probe 
and fluorescent polymerase chain reaction. 
7.3 Results 
7.3.1 Autosomal dominant variants 
There were no pathological expansions in the C9orf72 gene in any members of the 
YOAD cohort.  Three patients had variants identified in autosomal dominant genes 
known to cause neurodegenerative diseases (Table 7.1). These cases were all reviewed 
in the Dementia Research Centre neurogenetics multidisciplinary meeting.  Neither the 
VCP nor the SQSTM1 variant had been previously reported, and on the basis of 
evolutionary conservation, predicted amino acid change and predicted possible impact 
of an amino acid substitution on the structure and function of the protein encoded [282] 
were not consider pathogenic.  The PSEN1 variant was thought to be pathogenic (see 
7.4 for details)  
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This individual found to have a pathogenic PSEN1 variant had indicated on their consent 
form that they would not wish to be informed should a genetic cause for their dementia 
be identified. The other two individuals with non-pathogenic mutations were not notified 
of these findings as they are of no clinical significance. 
Participant ID APOE ε4 status Variant phenotype AAO 
01-037 34 PSEN1 Leu235Val Memory led 52 
01-004 34 VCP Pro137Ser PCA 61 
01-068 44 SQSTM1 Glu155Lys LPA 56 
 Table 7.1 Variants identified in genes causing autosomal dominant Alzheimer’s 
disease  
7.3.2 APOE ε4 status 
APOE genotyping was performed on all patient participants.  28/45 (62%) of patients 
had one or more ε4 allele (22 (49%) heterozygotes, 6 (13%) homozygotes). 6/45 (13%) 
possessed an ε2 allele.  The individual with a PSEN1 variant was genotyped as ε3ε4 
and was excluded from the analyses in the rest of this chapter. 
Based on the allele frequency of the general population (ε2: 0.07; ε3: 0.79; ε4: 0.14;  
(meta-analysis http://www.alzgene.org/[28]), the expected frequency of each genotype 
was calculated and compared with that found in this patient cohort (Table 7.2).  Patients 
with Alzheimer’s disease were significantly less likely to have an E3E3 genotype than 
expected from population based results.  Patients were significantly more likely to carry 
one or more ε4 alleles (ε2 ε4, ε3ε4 or ε4ε4 genotype) than expected (expected: 12/45, 
observed: 28/45, p=0.001). 
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Genotype Expected 
frequency 
Observed 
frequency 
pa Age at onset 
n (%) n (%) Mean (SD) 
ε2ε2 0 (1) 0 (0) - - - 
ε2ε3 5 (12) 2 (4) 0.4 56.5 2.1 
ε2ε4 1 (2) 4 (9) 0.4 57.5 2.4 
ε3ε3 27 (61) 15 (33) 0.02 54.7 3.4 
ε3ε4 10 (22) 17 (40) 0.2 55.4 5.3 
ε4ε4 1 (2) 6 (13) 0.1 57.3 4.3 
Table 7.2 Expected and observed APOE genotype and mean age at onset 
a Fisher’s exact test 
7.3.2.1 APOE ε4 status and age at onset 
Individuals with APOE ε3ε3 genotype had the earliest age of onset, with ε4 homozygotes 
having the latest age at onset (Table 7.2), despite ε4 being a major risk factor for 
developing Alzheimer’s disease, and having been reported to reduce age at onset in late 
onset disease.  Dividing the patient cohort into those with at least one ε4 allele (n=27) 
and those without (n=17) showed a similar directional but non-significant difference in 
age of onset (ε4–ve mean AAO 59.8 ± 3.8yrs, ε4+ve mean AAO 61.8 ± 5.0yrs, p=0.2 t 
test).   
7.3.2.2 APOE ε4 and clinical phenotype 
Memory impairment as a leading symptom was more common in individuals with at least 
one ε4 allele than those without: ε4+ve 18/27 (67%) vs ε4-ve 7/17 (41%), but this did not 
reach statistical significance (p=0.1, Fishers exact test).  The majority of ε4-ve individuals 
(10/17, 59%) had non-amnestic presentations (language impairment, visuospatial or 
visuoperceptual, dyspraxia, executive impairment).   
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Phenotype according to research criteria was 9/17 (53%) typical amnestic Alzheimer’s 
disease and 8/17 (47%) PCA in the ε4-ve group.  Typical amnestic Alzheimer’s disease 
represented a greater proportion of cases in the ε4+ve group: 18/27 (67%), with the 
remaining individuals having PCA (6/27, 22%), LPA (2/27, 7%) and frontal Alzheimer’s 
disease (1/27, 4%).  Of the 6 ε4 homozygotes, 4 had a typical amnestic presentation, 1 
had a LPA phenotype and 1 had PCA.  
There was no significant difference in neurological signs between the groups of 
individuals with and without an ε4 allele (Table 7.3), or in apraxia scores (ε4+ve mean 
48.6 ± SD 2.4, ε4-ve 48.3 ± 2.5, p=0.6 Wilcoxon rank sum). 
 ε4+ve n=27 ε4-ve n=17 P† 
n (%) n (%)  
Field defect  3 11 2 12 1.0 
Optic ataxia 5 19 4 24 0.7 
Visual extinction 4 15 6 35 0.1 
Eye movement abnormality 4 15 2 12 1.0 
Myoclonus 3 11 2 12 1.0 
Rest tremor 0 0 0 0 n/a 
Postural tremor 4 15 4 24 0.7 
Bradykinesia 1 4 0 0 1.0 
Ataxia 3 11 0 0 0.3 
Dystonia 0 0 0 0 n/a 
UL spasticity 0 0 0 0 n/a 
LL spasticity 0 0 1 6 0.4 
UL hyper-reflexia 4 15 1 6 0.6 
LL hyper-reflexia 2 7 0 0 0.5 
Extensor plantars 0 0 0 0 n/a 
Abnormal gait 0 0 0 0 n/a 
Table 7.3 Neurological signs in YOAD cohort ε4+ve and ε4-ve individuals 
† Fisher’s exact test. 
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7.3.2.3 APOE ε4 status and neuropsychology profile  
APOE ε4+ve individuals performed slightly better on the MMSE but this did not reach 
statistical significance (ε4+ve mean MMSE score 22/30 ± SD 4.7, ε4-ve 20/30 ± 4.5, 
p=0.2, Wilcoxon rank sum). 
Neuropsychology results for YOAD patient participants by APOE ε4 status are show in 
Table 7.4.  APOE ε4-ve individuals performed significantly less well than those with an 
ε4 allele on the digit symbol modalities test (DSMT) and the ‘A’ cancellation task, both of 
which reflect executive functioning.  Poor performance on the ‘A’ cancellation test is 
indicated by taking a longer time to complete the task, this test is confounded by any co-
existent visuospatial deficit impairing the ‘visual search’.  APOE ε4-ve individuals were 
also significantly more impaired on the written spelling task (GDST).  
There was a trend for APOE ε4-ve individuals to perform significantly less well on the  
backward digit span (reflecting executive function and sequencing ability) and the shape 
detection and fragmented letters subtests of the visual object and space perception 
battery indicating inefficiency of higher visual processing by the parieto-occipital lobes.
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Neuropsychological 
assessment 
APOEε4+ve 
Mean (SD) 
APOEε4-ve 
Mean (SD) 
P 
Episodic memory    
RMT words (short, /25) 18.7 (3.6) 18.2 (3.8) 0.68 a 
RMT faces (short, /25) 18.9 (4.9) 20.5 (3.2) 0.22 a 
 
Executive skills 
   
WASI matrices ( /35) 11.1 (8.5) 7.4 (6.9) 0.14 a 
WMS-R digit span forward ( /12) 6.6 (2.7) 5.4 (2.3) 0.10 a 
WMS-R digit span backwards (/12) 4.4 (2.2) 3.1 (2.0) 0.05 a 
DSMT ( /93) 22.9 (18.1) 10.0 (9.3) 0.01 a 
A cancellation (s) 45.8 (22.7) 61 (20.7) 0.03 a 
 
Verbal skills 
   
NART ( /50) 28.8 (13.8) 29.2 (9.7) 0.92 a 
WASI vocabulary ( / 80) 53.4 (19.0) 51.7 (21.5) 0.80 a 
GNT ( /30) 16.7 (8.4) 14.6 (9.4) 0.46 a 
 
Literacy and numeracy skills 
   
GDST written ( /30) 16.1 (8.4) 10.8 (7.0) 0.04 a 
GDST oral ( /30) 15.5 (9.8) 11.4 (6.6) 0.11 a 
GDA ( /24) 4.0 (5.4) 1.9 (2.6) 0.23 b 
 
Visuoperceptual skills 
   
VOSP object decision ( /20) 14.9 (5.0) 13.8 (3.9) 0.44 a 
VOSP shape detection ( /20) 17.8 (4.1) 17.6 (1.3) 0.07 b 
VOSP fragmented letters ( /20) 13.2 (7.4) 8.8 (6.4) 0.05 a 
VOSP dot counting ( /10) 7.8 (2.8) 7.1 (3.5) 0.61 b 
Table 7.4 Neuropsychological profiles of YOAD cohort patient participants by 
APOE ε4 status 
Raw data are shown for neuropsychological tests (maximum scores in parentheses). 
Bold indicates significant difference in performance between patient groups (p<0.05).  
a t test, b Wilcoxon rank sum. 
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7.4 Discussion 
Only individuals without a family history suggesting autosomal dominant disease were 
recruited.  However, one individual without a family history was found to harbour a 
PSEN1 variant.  The PSEN1 variant identified (leu235val, rs63751130) is a missense 
point mutation in a coding region of exon 7 (Chr14:73659506 C>G) that results in a 
leucine being changed to a valine.   This mutation has previously been reported in a UK 
family with 4 affected individuals with a mean age of onset at 52 years (range 44-
59)[100], and the diagnosis has been confirmed post mortem in at least one case[283].  
This L235V mutation has also been reported in a family from Mexico with a familial 
dementia, with age of onset around 48 years.  Asymptomatic mutation carriers in this 
family had a higher incidence of depression than non-carriers, even when they did not 
know their mutation status, suggesting that depression may be an early clinical feature 
related to Alzheimer’s disease pathology in this variant [284].  This association of L235V 
with depression has been explored in cell models using murine hippocampal cells 
suggesting that this variant in PSEN1 affects neurotransmitter metabolism through an 
interaction with mono-amine-oxidase-A, an enzyme that degrades serotonin and 
noradrenaline [285].  The individual carrying this variant in the YOAD cohort reported 
mild depression in the absence of any other psychiatric symptoms and was taking 
citalopram. 
The individual with a pathogenic PSEN1 variant was excluded from the APOE analyses 
in this chapter, and has not been included in the VBM structural analysis (Chapter 9).  
However, the genetic results were not available at the time the DTI/NODDI (Chapter 10) 
and activation fMRI (Chapter 11) experiments were run, and so was included.  The 
potential effect of including this individual is discussed further in the respective chapters. 
136 | P a g e  
 
Identifying novel variants of uncertain clinical significance, such as the SQSTM1 and 
VCP variants here described, is an increasingly common occurrence in both research 
and clinical genetic testing as genetic sequencing technology becomes increasingly 
sophisticated, accessible and inexpensive.  However, predicting the significance of these 
variants and deciding what to do with this knowledge is challenging for researchers, 
clinicians and patients alike [286].  The genetic consent used in the YOAD study foresaw 
both the eventualities of variants of uncertain clinical significance, and identification of 
an (unexpected) autosomal dominant mutation.  Participants were consented that they 
could chose at study entry whether they would want to be informed of clinically significant 
genetic results, and were informed that variants of no clinical significance would not be 
disclosed.  The genetics multidisciplinary meeting was set up to discuss variants of 
uncertain significance to come to consensus opinion on the clinical relevance.   
As expected, the APOE ε4 allele was over represented in the YOAD cohort relative to 
population data.  However, individuals homozygous for ε4 did not have the youngest age 
of clinical disease onset, in keeping with previous observations that young onset 
Alzheimer’s disease can also develop in the absence of an APOE ε4 allele and that 
individuals with one or two ε3 alleles may be even younger than ε4 carriers with early 
onset disease [196].  This suggests other genetic and/or environmental factors play a 
more significant role in young onset Alzheimer’s disease.  
There were no differences in neurological signs observed in the YOAD patient cohort.  A 
larger cohort of 168 patients with YOAD has previously found that individuals carrying a 
ε4 allele were more likely to experience myoclonus and less likely to have tremor than 
individuals with a non-ε4 genotype [287]. A postural tremor was significantly associated 
with YOAD relative to controls (Table 6.2), but this was not present differentially between 
patient groups based on ε4 genotype.  Perhaps the lack of difference in neurological 
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signs reported in this chapter reflects a smaller cohort being underpowered to detect 
subtle group differences.   
A typical amnestic phenotype was more common in the group of individuals carrying an 
ε4 allele in the YOAD cohort although all 4 canonical phenotypes were represented, and 
variant AD presentations were more common in the ε4-ve cohort.  This is consistent with 
previous studies which have consistently shown that patients who do not carry an APOE 
ε4 allele are more likely to present with a non-memory phenotype that those who do 
[160, 206, 288].  There was one individual in the YOAD cohort with a PCA phenotype 
who was homozygous for the ε4 allele.  APOE is a risk factor for PCA, but a weaker risk 
factor than it is for more typical amnestic Alzheimer’s disease [289]. 
There was no difference on neuropsychological tests of memory between ε4+ve and ε4-
ve groups, although previous studies have shown carriers of the ε4 allele perform worse 
on memory tasks than non-carriers [197, 198].  APOE ε4-ve individuals were more 
impaired than ε4+ve individuals on neuropsychological tasks of executive function, 
speed, and literacy, with a trend to poorer performance on higher order visual processing 
tasks consistent with findings from several previous studies whereby ɛ4- patients were 
shown to be more impaired in non-memory cognitive domains [195, 288-290]. 
This chapter has demonstrated that APOE ε4 genotype may account for some of the 
observed heterogeneity in YOAD age of onset and cognitive profiles, but it cannot 
account for the full spectrum of phenotypic differences. Chapter 8 investigates another 
significant risk factor gene for Alzheimer’s disease: the p.R47H variant of TREM2 that 
was first identified whilst this PhD was being undertaken[39, 40].  Chapters 9 to 11 then 
explore the effect of APOE ε4 on macroscopic and microscopic brain structure in YOAD 
using brain volumes, voxel based morphometry, diffusion tensor imaging, and neurite 
orientation and dispersion imaging.
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8 Rare genetic variants: TREM2  
8.1 Introduction 
In 2013, whole genome association analyses led to the identification of p.R47H 
(rs75932628), a rare variant in the triggering receptor expressed on myeloid cells 2 gene 
(TREM2) causing an arginine-47-histidine substitution in the extracellular 
immunoglobulin domain, as a significant risk factor for late onset Alzheimer’s disease in 
two large cohorts of European descent [39, 40].  This variant increases the risk of 
developing Alzheimer’s disease by two to three times, i.e. similar to that conferred by 
one copy of the APOE ε4 allele. 
The associated phenotype of individuals with Alzheimer’s disease carrying a p.R47H 
TREM2 variant is relatively unknown.  The presence of this variant has been associated 
with lower age of clinical disease onset: 3.18 years for individuals in an Icelandic 
population, and 3.65 years for those in at Dutch population[40].  The p.R47H TREM2  
has also been described as a risk factor specifically for young onset Alzheimer’s disease 
[291]. 
The TREM2 gene is located on chromosome 6p21.1 (chr6:41,126,244-41,130,924, 
hg19) and encodes a transmembrane receptor which is expressed on myeloid cells, 
including microglia and osteoclasts that participates in modulation of the immune system 
[292]. TREM2 importance in brain function is also highlighted by its known involvement 
in other neurodegenerative diseases.  p.R47H has since been associated with 
frontotemporal dementia (FTD) [293] and Parkinson’s disease [293, 294].  Enrichment 
of other rare TREM2 variants has also been observed in both individuals with 
Alzheimer’s disease and FTD relative to controls [295, 296].  Polycystic lipomembranous 
osteodysplasia with sclerosing leukoencephalopathy (PLOSL), is a recessively inherited 
early onset frontal dementia with bone cysts and basal ganglia calcification [297, 298] 
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due to variants in either TREM2 or TYROBP (TYRO protein tyrosine kinase binding 
protein) [37, 299, 300]. PLOSL associated homozygote TREM2 variants (p.Q33X, 
p.T66M and p.Y38C) are also described in 3 individuals with typical cognitive 
impairment, white matter change and frontal atrophy, but without bone cysts [38].  Similar 
immune modulation is also proposed as pathological mechanism in other 
neurodegenerative diseases.  Microglial proliferation and CSF1R (colony stimulating 
factor 1 receptor) activation, implicated in the same inflammatory pathway as the 
TREM2/TYROBP complex, are thought to be a major component of prion related 
neurodegeneration [301] and a partial loss of function variant in CSF1R causes 
hereditary diffuse leukoencephalopathy with spheroids [302].  Given that this microglial 
mediated inflammation is implicated in several dementias, p.R47H TREM2 effects may 
be associated with neurodegeneration across multiple dementias.  
In this chapter I aimed to examine the frequency of TREM2 variants in an Alzheimer’s 
disease cohort enriched for YOAD, comparing them to large a cohort of individuals with 
FTD, and to describe the clinical phenotype in individuals with p.R47H associated 
Alzheimer’s disease.  
8.2 Methods 
8.2.1 Cohorts 
8.2.1.1 YOAD cohort 
Participants were recruited to the YOAD cohort as outlined in Chapter 5.  In addition to 
the study consent, specific consent was obtained from participants to enter a further 
genetic study being run at the DRC.  Twenty millilitres of blood were collected by 
venepuncture and DNA extracted using standard techniques.   Whilst individual results 
were not given, patients were given the option to know if their participation in the 
research led to the development of a clinical genetic test for their condition.    
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Control subjects did not have genetic analyses performed.   
8.2.1.2 DRC genetic cohort 
DNA samples from individuals with clinical diagnoses of Alzheimer’s disease (n=1002) 
and FTD (n=358), were identified from the Medical Research Council Prion Unit research 
sample database (1990 onwards). These individuals had been recruited via tertiary 
specialist clinics at the National Hospital for Neurology and Neurosurgery, London.  
Clinical diagnoses of Alzheimer’s disease and FTD were supported by participation in 
longitudinal research studies at University College London and the University of 
Cambridge, however as these sample collections were acquired over two decades the 
comprehensive use of research diagnostic criteria cannot be confirmed and some 
samples were assigned to these diagnostic categories based on clinical diagnoses only.   
All patients of known non-white ethnicity were excluded.  Individuals known to have 
pathogenic disease-causing variants in the amyloid precursor protein, APP; Presenillin 
1, PSEN1; Presenillin 2, PSEN2; prion protein, PRNP, chromosome 9 open reading 
frame 72, C9orf72; microtubule associated protein tau, MAPT; or progranulin, PGRN 
genes were excluded, although the entire sample collection was only partially screened 
for mutations in these genes.   
Control samples were obtained from the Human Random Control panel (European 
Collection of Cell Cultures n=534), and the UK 1958 Birth cohort (n=2381) (University of 
Leicester).   
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8.2.2 Genetics  
8.2.2.1 Sanger sequencing  
Exon 2 of the TREM2 gene was Sanger sequenced for individuals in the YOAD cohort 
who do not have any autosomal dominant mutations known to cause Alzheimer’s 
disease (n=44), and from the DRC genetic cohort with Alzheimer’s disease (n=971), FTD 
(n=358) and UK controls (n=534).  
Polymerase-chain-reaction (PCR) amplification used 20ng of genomic DNA, 2xPCR 
MegaMix-Royal® (Microzone) and forward (5’-gaccatacgatgggttttcc3’) and reverse (5’-
ccgctcccaacttgtataagaa3’) primers.  PCR products were cleaned, and 5-20ng was 
sequenced in a reaction containing 5x Reaction Buffer, BigDye® (Applied Biosystems) 
and the forward primer.  Sequencing reaction products were cleaned, and sequencing 
was performed on a 3730 DNA Analyzer (Applied Biosystems).  Sequence traces were 
analysed using Seqscape software (version 2.7).   
Genotyping  
Controls from the UK 1958 Birth cohort (n=2381) (University of Leicester), were directly 
genotyped for p.R47H using a Taqman minor groove binding probe. 
APOE status for cases of p.R47H variant associated Alzheimer’s disease identified was 
ascertained by minor groove binding probe and fluorescent PCR.   
8.2.3 Clinical phenotyping 
To determine the clinical features of p.R47H Alzheimer’s disease, I carried out a pseudo-
case controls study. I established age at symptom onset (AAO), where available from 
the entire genetic cohort and reviewed medical records for p.R47H Alzheimer’s cases 
(n=14) and a group of nil TREM2 variant cases (n=33), matched for sex and age at 
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symptom onset (Table 8.1) to determine sex, annualised rates of decline on the mini-
mental state examination (MMSE) based on the longest available interval, presenting 
clinical features (visual, language, behavioural/dysexecutive, memory), neurological and 
psychiatric signs and symptoms.   
I extracted the following neuropsychometric data, where available from the clinical 
records: general intellectual function - Wechsler Adult Intelligence Scale-Revised or the 
Wechsler Abbreviated Scale of Intelligence [259, 303];  verbal and visual memory - 
Recognition Memory Test for words and faces respectively [260]; and visuospatial and 
visuoperceptual skills - Visual Object and Spatial Perception battery [266].  Raw scores 
were converted into percentiles for reporting.   
Post mortem data reports for individuals with p.R47H variants held in the Queen Square 
brain bank (University College London) and Institute of Psychiatry brain bank (Kings 
College London) were also reviewed where available   
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 AD p.R47H variant AD nil TREM2 variants P value 
Leading symptom and 
neurological features 
n 12 33 n/a 
M:F 5:7 9:24 0.47 c 
AAO (mean yrs ± SD yrs) 55.2 ± 8.5 56.1 ± 7.2 0.72 a 
Rate MMSE decline n 5 21 n/a 
M:F 2:3 9:12 1.0 c 
AAO (mean yrs ± SD yrs) 53.6 ± 6.5 56.6 ± 7.4 0.42 a 
Volumetric imaging 
analysis 
n 4 22 n/a 
M:F 3:1 7:15 0.26 c 
AAO (mean yrs ± SD  yrs) 53.5 ± 4.8 56.0 ± 7.0 0.45 b 
Disease duration at time of scan  
(mean yrs±SD yrs) 
5.0 ± 3.4 3.5 ± 2.3 0.33 b 
Table 8.1 Demographics of age and sex matched p.R47H and nil TREM2 variant Alzheimer’s disease cases 
a P value calculated using T test for equal variance.  b P values calculated using the Wilcoxon-Mann-Whitney test. c P values calculated using Fisher’s 
exact test.  
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8.2.4 Imaging  
T1 weighted volumetric brain MRI scans were reviewed retrospectively and volumetric 
region of interest comparisons performed for p.R47H variant individuals (3T n=3 and 
1.5T n=1) and 22 AAO and disease duration matched Alzheimer’s disease individuals 
with no TREM2 variants (3T n=17, 1.5T n=5) (Table 8.1). 
T1-weighted volumetric brain MRIs had been acquired using a Magnetization Prepared 
Rapid Gradient Echo sequence: 1.5T GE Signa scanner (General Electric Milwaukee, 
WI, USA) (256×256 matrix; 1.5mm slice thickness) and 3.0T Siemens Trio scanner 
(Siemens, Germany) (256×256 matrix; 1.1mm slice thickness). 
MR images were corrected for intensity inhomogeneity using N3 [304, 305].  Whole brain 
volumes were generated using an automated segmentation technique (brain-MAPS) 
[306].  Hippocampi were delineated using the automated STEPS algorithm [307].  Both 
the brain regions and hippocampal regions were checked by experienced raters.  Total 
intracranial volumes (TIV) were calculated by summing grey matter, white matter and 
cerebrospinal fluid volumes acquired using the new segmentation toolbox within 
Statistical Parametric Mapping – version 8 [308].  
All analyses were performed blind to genetic status.   
8.2.5 Statistics 
The association between TREM2 variants and each neurodegenerative condition was 
examined using odds ratios and Fisher exact test based on allelic frequencies.  
The characteristics of the p.R47H variant and nil TREM2 variant Alzheimer’s disease 
cases were compared using two tailed T-tests or Wilcoxon-Mann-Whitney test where 
appropriate.  Brain and total hippocampal volumes (expressed as ratio of TIV to correct 
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for head size) between p.R47H positive and TREM2 negative Alzheimer’s disease 
subjects were compared using the Wilcoxon-Mann-Whitney test.  
All statistical tests were two-tailed, with significance set at p<0.05 without any correction 
for multiple hypothesis testing.  Statistical analyses were performed using Stata (version 
12).    
8.3 Results 
8.3.1 TREM2 in YOAD cohort 
There were no R47H variants identified in the YOAD cohort.  
8.3.2 TREM2 in DRC genetics cohort 
TREM2 variants identified in exon 2 for Alzheimer’s disease (n=1002) FTD (n=358) and 
UK controls (n=534) are show in Table 8.2. 
There were fifteen non reference alleles causing p.R47H variants (13 heterozygote 
individuals and 1 homozygote) in the Alzheimer’s disease population, and 2 in the FTD 
cohort.  A number of other possible damaging variants were identified, including p.C51Y, 
p.D87N, p.T96K and A105V.  Using the UK control cohort as a reference there were no 
TREM2 variants significantly associated with disease. 
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Sanger Sequencing of Exon2 AD (n=971) FTD (n=358) Controls (n=534) 
Variant SNP Number Position† Reference  Allele 
Minor 
allele 
PolyPhen-2‡  
?damaging 
No. non  
ref alleles MAF 
No. non  
ref alleles MAF 
No. non  
ref alleles MAF 
p.Q33R n/a 41129296 A G Benign (0) 0 0.0000 1 0.0014 0 0.0000 
p.D39E rs200392967 41129275 G C Possibly (0.89) 1 0.0005 0 0.0000 1 0.0009 
p.R47H rs75932628 41129252 C T Probably (1.00) 15 0.0077 2 0.0028 5 0.0047 
p.C51Y n/a 41129264 G A Probably (1.00) 1 0.0005 0 0.0000 0 0.0000 
p.R62H rs143332484 41129207 C T Benign (0.02) 22 0.0113 8 0.0112 9 0.0084 
p.R62C n/a 41129208 G A Possibly (0.99) 1 0.0005 0 0.0000 0 0.0000 
p.D87N rs142232675 41129133 C T Probably (1.00) 0 0.0000 0 0.0000 1 0.0009 
p.T96K rs2234253 41129105 G T Probably (1.00) 8 0.0041 1 0.0014 1 0.0009 
p.R98W rs147564421 41129100 G A Probably (1.00) 1 0.0005 0 0.0000 1 0.0009 
p.R98Q n/a 41129099 C T Benign (0.02) 0 0.0000 0 0.0000 0 0.0000 
p.A105V rs145080901 41129078 G A Probably (1.00) 0 0.0000 0 0.0000 1 0.0009 
Total  49  12  19  
Table 8.2 TREM2 coding variants identified using Sanger sequencing of exon 2 
† Position denotes the location of the variant in base pairs in chromosome 6 (hg19).  ‡ PolyPhen-2 refers to the pathogenicity prediction on 
Polymorphism Phenotyping, version 2.  The numbers in brackets represent prediction scores ranging from 0 (benign) to 1 (damaging).  The 15 non-
reference alleles at 41129252 (R47H variant) in the AD cohort represent 13 heterozygote individuals and 1 homozygote individual.  One further individual 
had two different variants (R62H and T96K).  
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Using a larger control cohort (n=534+2381) to calculate control minor allele frequencies 
there was an odds ratio of increased risk in Alzheimer’s disease verses UK controls of 
2.19 (95%CI=1.04-4.51, P=0.03) (Table 8.3), confirming the significant association 
demonstrated in previous studies [39, 40, 309-311].  There was no significant 
association for p.R47H with FTD. 
 n non reference 
alleles 
MAF 
cases 
MAF 
controls 
OR 95% CI P 
AD 1002 15† 0.0075† 0.0034† 2.19 1.04-4.51 0.03 a 
        
FTD 358 2† 0.0028† 0.0034† 0.81 0.09-3.36 1.00 a 
Table 8.3 p.R47H TREM2 variants in Alzheimer’s disease and frontotemporal 
dementia 
MAF; minor allele frequency, OR; odds ratio, CI; confidence interval.  MAF in cases were 
genotyped by Sanger Sequencing, MAF in controls were genotyped by Sanger 
Sequencing (n=534) or minor groove binding R47H probe (n=2381).a P values were 
calculated using 2 sided Fisher’s exact test.  
8.3.3 TREM2 variants are associated with earlier disease onset in Alzheimer’s disease 
Age at disease onset was not available for all individuals in the genetic cohort, however 
where data was recorded individuals with p.R47H TREM2 variants had significantly 
younger ages at onset than individuals with no TREM2 variants (AAO=55.2±8.5yrs, n=12 
vs. AAO=61.7±13.1yrs, n=551, P=0.024).  10/12 (83%) of these p.R47H variant 
individuals met criteria for YOAD, defined as symptom onset less than 65 years, with 
4/12 (33%) of individuals having an age at onset <50 years, indicating very early onset 
disease.  
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8.3.4 R47H variants in Alzheimer’s disease: clinical features and neuropsychological 
profiles  
Disease duration (age from first reported symptom to death) was known for 6/14 
individuals, for whom the mean was 11.3 years (range 7-15 years).  6/12 (50%) of the 
individuals with detailed clinical information had at least one first or second degree 
relative with a diagnosis of Alzheimer’s disease.  Case 1 (p.R47H homozygote) had a 
mother who developed Alzheimer’s disease in her 70s who died in her 80s, and a brother 
with disease onset at 52 years, who died in his 60s.  Their TREM2 statuses are unknown.   
The majority of p.R47H individuals (10/12, 83%) for whom clinical information was 
available had an amnestic presentation.  This was supported by neuropsychology data, 
available on seven individuals (Table 8.4).  The disease duration at time of testing varied 
from one to seven years.  All cases had impairment (<5th percentile) on at least one 
recognition memory test at the time of testing.  Three also had some evidence of 
visuospatial and/or visuoperceptual disturbance, but for no cases was this 
disproportionate to the degree of amnesia. 
Anecdotally, none of the Alzheimer’s disease p.R47H patients were reported to have 
had bone cysts or pathological fractures, but this was not examined or investigated for 
systematically. 
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Case M/F TREM2 R47H  
Other 
gene  
variants 
APOE  AAO (yrs) 
DD  
(yrs) 
Family 
history 
Leading  
symptom 
Neuropsychology 
years  
since  
onset 
VIQ PIQ RMT-W 
RMT-
F 
Visuo- 
Percept 
(VOSP) 
Visuo-
spatial 
(VOSP) 
1 F  homozygote nil 3 4 64 14 yes frontal - - - - - - - 
2 F heterozygote nil 3 3 44 - no memory  3 86 77 <5 <5 - - 
3 M  heterozygote nil 3 4 49 15 yes memory  3 67 64 <5 <5 10-25 - 
4 M heterozygote nil 3 3 49 - no memory  3 80 65 - - 25-75 25-75 
5 M heterozygote nil 3 3 54 - yes memory  4 55 63 <5 <5 <5 <5 
6 M heterozygote nil 3 3 60 - yes  memory  1 87 72 <5 10-25 <5 25-75 
7 F heterozygote nil 3 4 71 8 yes memory  - - - - - - - 
8 F heterozygote nil 3 3 46 - no memory  - - - - - - - 
9 M  heterozygote nil 4 4 50 - no language - - - - - - - 
10 F heterozygote nil 4 4 51 15 no memory  7 78 83 <5  <5 25-75 25-75 
11 F heterozygote nil 3 3 59 7 yes memory  4 - - <5 - 25-75 10-25 
12 F heterozygote PS1  E318G  3 4 65 9 no memory  5 73 62 <5 25-75 25-75 25-75 
13 F heterozygote nil - unknown - unknown unknown - - - - - - - 
14 F heterozygote nil 3 3 unknown - unknown unknown - - - - - - - 
Table 8.4 Clinical features of Alzheimer’s disease individuals with p.R47H variant 
Positive family history denotes those with at least one secondary case of Alzheimer’s disease diagnosed in a first or second degree relative; VIQ, verbal 
intelligence quotient; PIQ, performance intelligence quotient; RMT-W, Recognition Memory Test for words; RMT-F, Recognition Memory Test for faces; 
VOSP, Visual object and spatial perception battery.  RMT and VOSP scores given as percentiles. ‘-‘ indicates no data available.
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  AD p.R47H variant (n=12) AD nil TREM2 variant (n=33) P value a  
n % n % 
Leading symptom memory 10 83.3 21 63.6 0.29 
language 1 8.3 1 3.0 0.47 
frontal 1 8.3 2 6.1 1.00 
parietal 0 0.0 9 27.3 0.09 
       
Neurological 
signs 
myoclonus 3 25.0 10 30.3 1.00 
seizures 2 16.7 2 6.1 0.29 
cerebellar signs 2 16.7 0 0.0 0.07 
extrapyramidal motor features 2 16.7 3 9.1 0.60 
pyramidal motor features 1 8.3 3 9.1 1.00 
dystonia 1 8.3 0 0.0 0.27 
hallucinations 1 8.3 3 9.1 1.00 
other psychiatric symptoms  1 8.3 12 36.4 0.13 
sleep disturbance 1 8.3 2 6.1 1.00 
dyspraxia 2 16.7 5 15.2 1.00 
Table 8.5 Leading symptoms and neurological signs in AD patients by p.R47H genotype 
a P values calculated using Fisher’s exact test.   
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There was no significant difference in the annual rate of MMSE decline between the 
p.R47H variant (n=5) and nil TREM2 variants (n=21) groups, albeit with small numbers 
(4.3 points/year ± 3.8 vs. 3.2 points/year ± 2.6 respectively, P=0.43). Most individuals in 
both the TREM2 positive and negative variant groups had an amnestic presentation.  No 
TREM2 p.R47H individual presented with cognitive deficits referable to parietal lobe 
dysfunction.  (Table 3).  There were no significant differences in neurological signs 
reported between the p.R47H variant positive (n=12) and nil TREM2 variant (n=33) 
cases (Table 8.5).   
8.3.5 Neuroimaging in p.R47H variants 
MRI in the p.R47H cases (n=4) was typical for Alzheimer’s disease, revealing 
generalised cerebral and symmetrical hippocampal atrophy (Figure 8.1).  Other than 
case 10, who had participated in the AN1792 vaccination trial [312], none of the other 
individuals with neuroimaging had any white matter disease greater than would have 
been expected for age.  No basal ganglia calcification was evident on any of the T1 
sequences.  Quantitative analysis of cross-sectional brain volumes revealed no 
difference in brain volume/TIV (median [IQR] = 0.69 [0.66-0.70] vs. 0.70 [0.66-0.73], 
p=0.40), or total hippocampal volume*1000/TIV (median [IQR] = 3.5 [3.2-3.6] vs. 3.3 
[2.9-3.6], p=0.43), between p.R47H positive (n=4) and nil TREM2 variant (n=22) 
Alzheimer’s disease cases. 
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Case       4 5 6 10 
Age at scan (yrs)      55  58  60  60  
Disease duration (yrs)        6  4  1  9  
Figure 8.1 Coronal MRI images in 4 individuals with Alzheimer’s disease and p.R47H variant 
Disease duration denotes time from first symptom to time of scan. 
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8.3.6 Pathology in p.R47H cases 
Alzheimer’s disease pathology was confirmed in all 4 p.R47H Alzheimer’s disease 
individuals who had post mortem examination, and two had at least moderate cerebral 
amyloid angiopathy.  Pathological slides for case 10, previously published elsewhere 
[39], showed mature diffuse amyloid plaques.  Case 1 (p.R47H homozygote, 
behavioural/dysexecutive presentation) showed marked frontal atrophy 
macroscopically, as is typical in PLOSL cases [313], however the associated typical 
white matter lesions were absent.  There was extensive formation of senile plaques, 
neurofibrillary tangles and neuropil threads throughout the grey matter, but relative 
preservation of the hippocampus histologically. 
8.4 Discussion 
This chapter reports a sequencing and genotyping survey of TREM2 variants in a large 
cohort of individuals with Alzheimer’s disease (including those from the YOAD study) 
and FTD.  There a significant association for p.R47H with Alzheimer’s disease, but not 
FTD.  Several other exon 2 variants predicted to be damaging were identified: including 
p.C51Y, p.D87N, p.T96K and A105V.  None of these were significantly associated with 
either Alzheimer’s disease or FTD using the UK control cohort n=534.  Of other TREM2 
variants only p.Arg62His has since shown genome wide association levels of 
significance independently of the p.R47H association [314].  
Given that the frequency of R47H was around 1:70 it is arguably not surprising that there 
were no carriers of this variant in the YOAD patient cohort.  Possession of a p.R47H 
TREM2 variant in Alzheimer’s disease is associated with a significantly younger age at 
symptom onset than nil TREM2 variant cases, and p.R47H associated Alzheimer’s 
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disease is otherwise usually indistinguishable from typical, amnestic Alzheimer’s disease 
on clinical, imaging, and neuropsychometric grounds.  
It remains unclear whether p.R47H is a risk factor for neurodegeneration in general, or 
is specific to Alzheimer’s disease. This study did not find any evidence that p.R47H 
variants are associated with FTD.  Whilst there were no p.R47H variants identified in 
either French (n=175) [315], or Spanish (n=628) [316] FTD populations, a North 
American cohort (n=609) found a significant association (OR=5.06, P=0.001) [293].  
Data from this UK study was not consistent with an association as large as an OR=5, 
but does not rule out a more modest association between p.R47H and frontotemporal 
dementia (95% CI=0.09-3.36). Whether these differences reflect the underlying 
pathological heterogeneity of patients presenting with behavioural problems or 
population differences in risk remains to be determined and further studies are 
warranted, ideally with post mortem confirmation of the underlying pathology, or using 
other biomarkers (e.g. CSF tau and Aβ1-42, amyloid imaging) to improve the diagnostic 
certainty in life.  
The majority of individuals with p.R47H had young onset Alzheimer’s disease, with 4/12 
of these cases identified having very young age at onset (<50yrs) in the absence of other 
known genetic variants, consistent with results from a French YOAD population showing 
p.R47H is a risk factor for young onset disease [311].  p.R47H has previously been found 
to correspond with earlier age of onset in both Icelandic (3.18 years, P=0.20) and Dutch 
populations (3.65 years, P=0.13) [40].  In this UK YOAD enriched Alzheimer’s disease 
population the mean AAO for p.R47H variant Alzheimer’s disease patients was 
significantly earlier than nil TREM2 variant cases (6.5 years, P=0.024).  In families with 
late onset Alzheimer’s disease, carrying p.R47H did not affect the age of disease onset, 
however the disease duration was significantly shorter in individuals who carried the 
mutation that those who did not [317]. 
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In the majority of cases, heterozygous p.R47H variants were associated with typical 
‘amnestic’ Alzheimer’s disease presentations.  Whereas atypical presentations are more 
commonly seen in YOAD than late onset Alzheimer’s disease, accounting for between 
30-40% of cases [159, 318], these data suggest that, if anything, individuals with TREM2 
variants were less likely to have a non-memory presentation compared with other YOAD 
individuals.  This p.R47H cohort had a mean disease duration fairly typical for sporadic 
Alzheimer’s disease, rates of MMSE decline were within the published range [319, 320] 
and there were no specific neurological features that could reliably be useful in identifying 
p.R47H TREM2 variants.  A Spanish study examining a cohort of individuals with late 
onset Alzheimer’s disease carrying p.R47H variants found more frequent apraxia, 
psychiatric symptoms (personality change, anxiety, paranoia) and parkinsonism than in 
individuals without the p.R47H variant, most notably in the first two years of clinically 
manifest disease [321].  Both of these studies have small numbers of p.R47H cases to 
report, so results must be considered preliminary, but it is possible that p.R47H variants 
modify phenotype differently in early and late onset disease.  
Brain volume analysis revealed no differences between p.R47H carriers and non-
carriers, which may reflect the small numbers in this study.  Interestingly, data from ADNI 
has shown individuals with TREM2 variants lose 1.4 to 3.3% more brain tissue per year 
than non-carriers, and p.R47H is significantly associated with smaller hippocampal 
volumes [322].  The individuals in the Spanish cohort with more apraxia and psychiatric 
symptoms had higher frontobasal grey-matter cortical loss [321]. 
All p.R47H Alzheimer’s disease individuals with post mortem data available had 
Alzheimer’s pathology confirmed, although the topography of atrophy seen in case 1, 
(p.R47H homozygote) was similar to the ‘generalised cerebral gyral atrophy with frontal 
accentuation’ pathologically observed in a case series of eight patients with PLOSL 
[313]. 
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Due to the relative rarity of TREM2 variants the numbers of individuals identified were 
small, and not all had post-mortem diagnostic confirmation.  Statistical analyses were 
not corrected for multiple comparisons, so results should be considered exploratory.  The 
retrospective nature meant clinical information was limited and collected in a non-
standardised manner, hence limiting direct comparisons and inferences with respect to 
the whole cohort.  Whilst very large multicentre prospective studies will be needed to 
establish the true spectrum of clinical features, neuroimaging and pathological 
signatures of TREM2 variants in Alzheimer’s disease, these findings suggest p.R47H 
confers specific risk for typical, amnestic and often very young onset Alzheimer’s 
disease. 
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9 APOE and structural brain imaging: brain and grey matter 
volumes 
9.1 Introduction 
APOE genotype appears to exert regionally specific effects on brain atrophy.  The first 
studies examining ε4 genotype and brain atrophy in late onset Alzheimer’s disease found 
a dose-effect relationship between an increasing number of ε4 alleles and decreasing 
volume of the temporal lobe [200, 323].  They also suggested that possession of ε4 
alleles was associated with increased whole brain volume, and hence that individuals 
with Alzheimer’s disease who do not carry an ε4 allele have more marked generalised 
atrophy, which has been confirmed by several later studies [199, 201, 324]. 
It is possible that the modulating effect of APOE genotype on regional vulnerability varies 
by age at clinical disease onset.  This chapter studies the disease associated grey matter 
atrophy in the YOAD cohort and investigates how APOE ε4 status affects regional brain 
atrophy in YOAD using hippocampal, ventricle and brain volumes, and voxel based 
morphometry.   
9.2 Methods 
9.2.1 Participants 
This analyses in this chapter include the participants recruited into the YOAD study, as 
described in Chapter 5.  All participants underwent MRI scanning and testing on the 
MMSE [108].  The individual with a pathogenic PSEN1 variant was excluded from the 
analyses in this chapter. 
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9.2.2 APOE genotyoing 
As per previous chapters, patient participants gave separate specific consent to donate 
blood for genetic analyses. DNA was extracted and APOE genotype was determined by 
PCR with 3’-minor groove binding probes.  
9.2.3 Imaging acquisition 
All imaging was acquired on a 3T TIM Trio whole-body MRI scanner (Siemens 
Healthcare, Erlangen, Germany) using a 32-channel phased-array head coil.  T1-
weighted volumetric brain images were acquired using a sagittal 3-D magnetization 
prepared rapid gradient echo sequence (repetition time/echo time = 2200/2.9ms, 
dimensions 256x 256x208, voxel size 1.1x1.1x1.1 mm).   
Scans were assessed by experienced raters for quality control purposes, based on 
coverage and movement artefact. 
9.2.4 Data analyses 
9.2.4.1 Volumetric data 
Raw MR images were pre-processed to correct for magnetic field bias (inhomogeneity) 
using a non-parametric non-uniform intensity normalization (N3) algorithm [304, 305].   
Brains were automatically segmented using Multi-Atlas Propagation and Segmentation 
[306], followed by manual editing to give a brain region separated from dura and skill; 
i.e. a whole brain volume.   
Ventricle and hippocampal analysis was carried out on images registered to standard 
space [325] using a rigid (6 degree of freedom, dof) transformation derived from 9dof 
registration.  All region editing and volume measurements were carried out using the 
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Medical Information Display and Analysis (MIDAS) package [326]. Ventricle 
segmentation was performed in a semi-automated method (intensity thresholding, 
morphological operations and editing) using MIDAS.  Hippocampal segmentation was 
performed automatically using STEPS [307] followed by manual editing using MIDAS.  
9.2.4.2 Voxel based morphometry  
Pre-processing of 3D T1 brain MRIs used the New Segment and DARTEL toolboxes 
[327, 328].   Normalisation, segmentation and modulation of grey and white matter 
images were performed using default parameter settings in statistical parametric 
mapping software (SPM12; http://www.fil.ion.ucl.ac.uk/spm) running under MATLAB 
2012a, with a Gaussian smoothing kernel of 6mm full-width-at-half-maximum.   
Total intracranial volume was calculated for each participant by summing grey matter, 
white matter and CSF volumes following segmentation of all three tissue classes and 
used to adjust for differences in participant head size during subsequent analyses.   
The general linear model was applied at the level of each voxel using all images.  Grey 
matter volume was modelled as a function of group and corrected for age, gender and 
total intracranial volume (TIV), included as nuisance covariates in the model.   
Group differences were calculated using one-tailed t-tests (in both directions) between 
group parameter estimates for each group comparison.  A mask was created based on 
the optimal threshold of the group average image, using the automatic mask creation 
strategy in the SPM toolbox [329] 
Random field theory was used to correct for multiple comparisons, controlling the family-
wise error (FWE) rate at a significance level of 0.05, unless otherwise stated. 
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In addition to the thresholded statistical parametric maps, differences in grey matter 
volume between groups that did not reach statistical significance are presented on effect 
maps (the t statistic for each contrast at each voxel is plotted without any threshold being 
applied) to provide more information about the patterns of cerebral atrophy associated 
with each group. 
9.3 Results 
40/44 patients and 21/24 control participants had scans that passed T1 quality control 
and are included in the analyses that follow.  Those that failed were due to severe motion 
artefact, giving a failure rate of 11% for patients and 17% for controls.  This is comparable 
to rates seen in other longitudinal studies running locally.   
9.3.1 Demographics and clinical phenotypes 
The groups included in these analyses, whilst not the full YOAD cohort, remained well 
matched based on sex, age, disease duration and MMSE score (Table 9.1). 
 Controls  YOAD ε4-ve ε4+ve 
n 21 40 16 24 
Sex (M:F, %M) 8:13, 38 15:25, 38 6:10, 38 9:15, 38 
Age (yrs) 60.3 (6.1) 61.9 (5.2) 60.5 (3.9) 62.8, (5.8) 
Disease duration (yrs) - 5.9 (3.0) 5.7 (2.7) 6.1 (3.2) 
Phenotype 
(tAD:PCA:LPA:frontal) 
- 26:12:1:1 9:7:0:0 17:5:1:1 
MMSE (x/30) 29.4 (0.7) 21.4 (4.7) 20.1 (4.5) 22.3 (4.8) 
Table 9.1 Demographics for YOAD study participants included in the grey matter 
atrophy analyses 
Results are shown as mean (standard deviation) unless otherwise indicated. 
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9.3.2 Brain, ventricle and hippocampal volumes 
Volumetric analyses showed that, as expected, there were significant differences 
between the patient and control group when considering brain, ventricle and 
hippocampal volumes, and the brain/total intracranial volume ratio (to correct for head 
size), but not TIV.  However, none of these indices showed differences between APOE 
ε4+ve and ε4-ve groups (Table 9.2). 
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 Control 
n=21 
YOAD 
n=40 
P value APOE  ε4-ve 
n=16 
APOE  ε4+ve 
n=24 
P a 
Brain/TIV, mean (±SD) 0.75 (0.02) 0.69 (0.03) <0.0001 0.68 (0.03) 0.69 (0.03) 0.5 
Ventricles, mls, mean (±SD) 28.0 (13.6) 47.6 (21.5) <0.0001 47.4 (23.7) 47.7 (20.4) 1.0 
L hippocampus, mls, mean (±SD) 2.69 (0.2) 2.44 (0.4) 0.005 2.52 (0.4) 2.39 (0.5) 0.3 
R hippocampus, mls, mean (±SD) 2.77 (0.3) 2.52 (0.4) 0.001 2.61 (0.4) 2.49 (0.4) 0.4 
TIV, mls, mean (±SD) 1491 (141) 1504 (164) 0.73 1480 (135) 1521 (182) 0.4 
Brain, mls, mean (±SD) 1121 (105) 1040 (124) 0.01 1017 (90) 1056 (142) 0.3 
Table 9.2 Volumetric data for 40 YOAD patient participants and 21 controls 
a unpaired T-test 
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9.3.3 Grey matter structural changes: VBM analyses 
When the controls and patient cohorts were compared using VBM, there was a 
significant disease associated atrophy profile in the patient group affecting the 
hippocampi, posterior cingulate and precuneus and temporo-parietal lobes (Figure 9.1). 
Relative to controls, ε4-ve individuals showed greatest atrophy in the right temporo-
parietal junction, and ε4+ve individuals in the left inferior posterior temporal lobe (Figure 
9.2).  Comparing the ε4+ve and ε4-ve cohorts directly did not show any statistically 
significant differences in atrophy at the prescribed threshold. Uncorrected analyses 
confirmed that there was an area in the right parietal lobe where the ε4-ve group showed 
more atrophy that the ε4+ve.  Examining effect maps for atrophy (where the T statistic 
for each contrast at each voxel is plotted without any threshold), ε4+ve patients show 
more atrophy in the medial temporal lobes, and ε4-ve individuals have more atrophy 
throughout the neocortex (Figure 9.3). 
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Figure 9.1 Atrophy in young onset Alzheimer’s disease relative to controls. Top row: unthresholded t-statistic maps are shown on the left, 
statistical parametric maps on the right. Bottom row: additional coronal SPM slices 
SPMs are corrected for multiple comparisons using random field theory to control the family-wise error (FWE) rate at a significance level of p<0.05.  
The crosshairs represent the global maximum difference.  The right cerebral hemisphere is displayed on the right in coronal and axial sections. 
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Figure 9.2 Atrophy in young onset APOE ε4 positive and negative individuals with Alzheimer’s disease relative to controls  
Effect size maps are shown on the left, statistical parametric maps on the right. Additional coronal SPM slices are presented for the whole Alzheimer’s 
disease cohort vs control group comparison.  SPMs are corrected for multiple comparisons using random field theory to control the family-wise error 
(FWE) rate at a significance level of 0.05.  The crosshairs represent the global maximum difference.  The right cerebral hemisphere is displayed on the 
right in coronal and axial sections. 
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Figure 9.3 Atrophy differences between ε4–ve and ε4 +ve individuals  
The top row demonstrates the regions where volume loss in the ε4–ve group was greater 
than in the ε4+ve group. There were no regions where the volume loss in the ε4+ve 
group was greater than in the ε4-ve group.  The bottom row shows effect size maps, with 
regions in blue more atrophied in the ε4+ve group, and regions in red more atrophied in 
the ε4-ve group.  
9.4  Discussion 
This chapter investigates the pattern of grey matter atrophy in YOAD.  As expected, 
individuals with YOAD had significantly smaller brain and hippocampal volumes and 
increased ventricle volumes relative to control participants, and the atrophy profile 
demonstrated in VBM analyses is fairly typical for YOAD with a hippocampal-parietal-
posterior cingulate predominance [172, 180, 330].  
Individuals with an APOE ε4 allele had smaller mean hippocampal volumes than 
individuals without an ε4 allele, but these differences did not reach statistical 
significance.  It is possible that this is due to the YOAD study being relatively small and 
ε4+ve	>	ε4	-ve 
(p<0.001	unc) 
ε4	+ve	vs	ε4	-ve 
L R R 
!"# Page 
 
these analyses being cross-sectional in nature.  Longitudinal analyses of hippocampal 
atrophy rates may show a more marked differential effect of possession of an ε4 allele 
as previous studies have shown greater hippocampal atrophy rates in carriers of an ε4 
allele [331].  The tendency for ε4+ve individuals to have more hippocampal involvement, 
and ε4-ve individuals to have more widespread neo-cortical atrophy was borne out on 
effect map comparisons, consistent with previous studies that have reported greater 
medial temporal lobe atrophy in APOE ε4+ve carriers, and greater fronto-parietal atrophy 
in non-carriers [290, 332].  These patterns of atrophy are congruent with the differences 
in neuropsychological profiles in the presence and absence of an ε4 allele described in 
Chapter 7. 
This association of APOE ε4 status with regional atrophy profiles is also seen in other 
imaging modalities including PIB-PET amyloid burden and FDG-PET hypometabolism 
[203].  Despite primarily thought to be involved in amyloid metabolism, differential tau 
distribution is also seen in the presence of APOE ε4, mirroring the patterns of 
neurodegeneration.  ε4-ve patients have greater 18F-AV-1451 uptake in lateral parietal, 
medial parietal, occipital, and whole brain cortical areas compared with APOE ε4+ve 
patients [333].  The mechanisms why the neocortex, especially the frontal and parietal 
lobes, are more vulnerable to tau pathology and neurodegeneration in patients who 
develop Alzheimer’s disease despite lacking APOE ε4 is unclear. 
These data suggest that APOE ε4 status affects regional susceptibility to molecular 
pathology and modulates the anatomic pattern of neurodegeneration in Alzheimer’s 
disease.  The greater degree of cortical damage in ε4-ve individuals likely results in more 
significant, wide-spread neurologic dysfunction, potentially explaining the observation 
that such individuals have a broader profile of clinically manifest cognitive dysfunction, 
as seen in Chapter 7, and can experience a more rapid clinical decline [334].  This 
'hippocampal effect' of APOE ε4 may also mask the influence of other genetic and 
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epigenetic factors, hence these factors may have a greater role in the absence of ε4; 
their variability in turn explaining the greater heterogeneity of non-ε4 young onset 
Alzheimer’s disease. 
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10 APOE and structural brain imaging: microstructural white 
matter changes 
10.1 Introduction 
The imaging techniques explored thus far in the thesis have focussed on atrophy, i.e. 
neuronal loss, the end stage of neurodegeneration. As discussed in Chapter 2, there is 
considerable interest in exploring genetic influences on other aspects of the pathological 
process, and network breakdown in particular to understand how this relates to clinical 
heterogeneity.   
Chapter 9 explored associations between APOE ε4 status and regional macrostructural 
brain damage.  Patterns of microstructural white matter network damage, as evidenced 
by altered metrics on diffusion weighted imaging, may also affect the cognitive domains 
involved clinically and the severity of impairment, which is the subject of this chapter.  
Diffusion tensor imaging (DTI) is a magnetic resonance (MR) technique for exploring the 
structural integrity of brain networks and white matter in vivo using water diffusion to 
distinguish different microstructural environments.  As outlined in Chapter 3, DTI 
provides voxel-level estimates of fractional anisotropy (FA), axial diffusivity (AxD) and 
radial diffusivity (RD).  Neurite orientation dispersion and density imaging (NODDI) [242] 
is an advanced diffusion MRI technique designed to probe tissue microstructure beyond 
a composite view of each voxel by modelling water diffusion in multiple compartments 
[243]: i.e. diffusion that is restricted in axons and dendrites, hindered in extra-neurite 
space and  isotropic in cerebrospinal fluid.  NODDI derives a neurite density index (NDI), 
orientation dispersion index(ODI) and the fraction of free water (Fiso).  This model allows 
axonal loss in white matter (modelled by NDI) to be distinguished from altered patterns 
of axonal organization (modelled by ODI) on a voxel-by-voxel basis, thereby 
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disentangling two key factors contributing to changes in FA.  A key strength of NODDI, 
compared to alternative multi-compartment techniques, is the use of standard MRI 
acquisition similar to DTI, making it accessible for routine clinical studies.  To date, it is 
the only multi-compartment technique whose utility has been widely demonstrated in a 
broad range of applications, including Parkinson’s disease [244], epilepsy [245], normal 
ageing [246], brain development [247], and neurogenetic disorders [248]. 
In this chapter, DTI and NODDI are employed in a population of patients with YOAD and 
healthy controls to investigate the nature of microstructural damage underpinning 
changes in FA, and test the hypothesis that (i) APOE ε4 status in YOAD modulates 
regional signatures of white matter network breakdown, and (ii) reduction in white matter 
NDI, reflecting neurite loss, influences the clinical phenotype of YOAD. 
10.2 Methods 
10.2.1 Participants 
Forty-five patients meeting consensus criteria for probable Alzheimer’s disease [117] 
with symptom onset <65 years and twenty-four healthy controls matched for mean age 
and gender were recruited in the YOAD study, as described in Chapter 5.  None had a 
known mutation or family history suggestive of autosomal dominant inheritance at time 
of recruitment but dedicated screening for autosomal dominant mutations in genes 
known to cause Alzheimer’s disease had not been performed at the time of analyses in 
this chapter.  The presenting cognitive symptom was recorded for all patients, and 
patients were classified as having a typical [117] or atypical (PCA [165]) Alzheimer’s 
disease phenotype according to published criteria.  
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All participants underwent MRI scanning, testing on the MMSE [108], assessment on the 
Hachinski Ischaemic Score [278] and an extensive neuropsychology battery (see 
Chapter 5 for details).  
10.2.2 APOE genotyping 
As per previous chapters, patient participants gave separate specific consent to donate 
blood for genetic analyses.  DNA was extracted and APOE genotype was determined 
by PCR with 3’-minor groove binding probes.  
10.2.3 Imaging acquisition  
MRI imaging was performed on a Siemens Magnetom Trio (Siemens, Erlangen, 
Germany) 3T MRI scanner using a 32-channel phased array head coil.   
Two identical Diffusion Weighted Imaging (DWI) acquisitions were performed using a 
single-shot, spin-echo echo planar imaging sequence (64 diffusion-weighted directions, 
b=1000 s/mm2; 9 b=0 s/mm2 images (referred to as ‘b0’ images); 55 slices; voxel size 
2.5x2.5x2.5mm3; TR/TE=6900/91ms; total acquisition time for both sequences=16:29 
minutes).   
A three-shell diffusion sequence optimised for NODDI was acquired (64, 32, and 8 
diffusion-weighted directions at b=2000, 700 and 300 s/mm2; 14 b=0 images; 55 slices; 
voxel size 2.5x2.5x2.5mm3; TR/TE=7000/92ms; total acquisition time=16:13 minutes).  
Both single-shell (DTI) and multi-shell (NODDI) diffusion weighted sequences utilise 
twice-refocused spin echo to minimise distortion effects from eddy-currents.   
All scans were visually assessed for quality control purposes by experienced raters 
based on coverage and movement artefact. 
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10.2.4 Data analyses 
10.2.4.1 Demographic and neuropsychology  
Statistical tests comparing clinical characteristics and neuropsychology scores were 
performed in Stata version 12. Patient neuropsychology raw scores (x) were converted 
to z scores using the formula z=(x-μ)/σ (σ - control population standard deviation, μ - 
control population mean).  Mean z scores were calculated for each neuropsychological 
test within participant groups, and across neuropsychological tests (where applicable) to 
generate a composite score for each cognitive domain (Table 10.1).   
10.2.4.2 Diffusion imaging data: DTI and NODDI 
Sixty participants (37 YOAD, 23 controls) had both DTI and NODDI data that passed 
quality control criteria and were included for analysis.  Images were confirmed to have 
minimal eddy-current distortion and were corrected for motion by rigidly registering each 
diffusion-weighted image to the first b0 image using FLIRT [270, 271].  Diffusion tensor 
volumes were spatially normalized with DTI-TK (http://dti-tk.sourceforge.net) which 
bootstraps a population-specific tensor template from the input tensor volumes and 
aligns them to the template in an iterative fashion [272] with a tensor-based registration 
algorithm [273].  This framework has been shown to improve white matter alignment 
compared to conventional FA-based registration [274]. DTI metrics (FA, AxD, RD) were 
estimated using FSL [275]. NODDI metrics (NDI, ODI, Fiso) were estimated using the 
NODDI Matlab toolbox (http://www.nitrc.org/projects/noddi_toolbox).  
The Tract-Based Spatial Statistics [335] pipeline from FSL [336], optimised [337] by 
incorporating a population-specific template [338] with tensor-based registration [273, 
339] was used to detect whole-brain white matter differences between YOAD groups as 
defined by APOE ε4 status relative to controls, including age and gender as covariates 
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(5000 permutations, corrected for multiple comparisons with Threshold-Free Cluster 
Enhancement [340], p<0.05). 
10.2.5 Neurite density index region of interest analyses 
To assess the relationship between microstructural tissue changes and clinical 
phenotype in YOAD patients, correlations between NDI and neuropsychological 
performance (z scores by cognitive domain) were assessed in four manually-defined 
regions of interest corresponding to left and right posterior quadrants (parieto-occipital 
lobe projections) and left and right anterior quadrants (fronto-temporal lobe projections) 
of the mean white matter skeleton.  These ROIs were delineated by dividing the white 
matter skeleton into 4 areas at coordinates (x=112, y=88) in standard template space.  
Mean NODDI metrics (NDI, ODI and Fiso) within each quadrant ROI were calculated for 
each individual, and for patient and control groups.  Age and gender were included as 
covariates and correlations with a p<0.05 were reported. 
10.3 Results 
10.3.1 Demographics and clinical features 
Demographic and clinical data for participant groups included in the analyses are 
summarised in Table 10.1.  Mean age and gender did not differ significantly between 
patients and controls (age, p=0.3; gender, p=0.8), and no individual scored >4 on the 
Hachinski Ischaemic Score.  APOE ε4 status was available for the 37 YOAD patients, of 
whom 22 (59%) were APOE ε4+ve (18 heterozygotes, 4 homozygotes).  Patients who 
had an APOE ε4 allele (ε4+ve) were significantly older than those who did not (ε4-ve) at 
enrolment to the study (p=0.03).  There were no significant differences between ε4+ and 
ε4-ve patients for age at clinical symptom onset, clinical disease duration at enrolment 
to the study, or MMSE.  The majority of ε4+ve patients presented with a ‘typical 
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Alzheimer’s disease’ amnestic phenotype (16/22, 73%) as did 3/4, (75%) of the ε4+ 
homozygotes.  The ε4-ve patient group however contained approximately equal 
numbers of individuals with an amnestic (8/15, 53%) and atypical visual-led posterior 
cortical atrophy presentations (7/15, 47%); or alternatively expressed 67% of the 
amnestic patients carried one or more ε4 alleles while only 46% of the non-amnestic 
patients were ε4+ve. 
10.3.2 Neuropsychological profiles 
Neuropsychological analyses showed that as expected, patients with YOAD had multi-
domain cognitive impairment, performing significantly less well than controls on 
measures of performance IQ; recognition memory for words; literacy and numeracy; 
visuospatial and visuoperceptual performance; speed of information processing and 
executive function (Table 10.1).   
In keeping with Chapter 7, the ε4-ve patients included in this analysis were more 
impaired on tests of literacy and numeracy (p=0.04) and speed of information processing 
and executive function (p=0.01) than ε4+ve patients, despite there being no significant 
difference in the clinical disease durations between the patient groups. 
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Table 10.1 Study Participants’ Demographic, Neuropsychological and Clinical Characteristics 
Neuropsychology scores shown are mean z scores for each cognitive domain (a z score <- 1.96 indicates statistical difference from controls at p<0.05, 
indicated in bold).  Probability values for neuropsychology scores show significance value comparing APOE ε4- and APOE ε4+ patient groups. 
a two sided Fisher’s exact, b two-tailed t-test, c Wilcoxon rank sum 
 Controls n=23 YOAD n=37  APOEε4- n=15 APOEε4+ n=22  
Mean SD Mean SD P Mean SD Mean SD P 
Demographic and Clinical           
Sex, M:F, n 10:13 - 18:19 - 0.8a 7:8 - 11:11 - 1.0a 
Age (years) 60.7 6.0 62.3 4.9 0.3b 60.2 3.8 63.6 5.2 0.03b 
Handedness, L:R, n 3:20 - 1:36 - 0.2a 0:15 - 1:21 - 1.0a 
Years of education 16.7 3.1 14.9 2.8 0.03a 15.5 2.3 14.5 3.0 0.3a 
MMSE ( /30) 29.3 1.0 21.3 4.5 <0.0001c 19.9 4.4 22.3 4.4 0.1c 
Age at onset (years) - - 56.8 4.4 n/a 55.4 4.3 57.8 4.4 0.1b 
Disease Duration (years) - - 5.4 3.2 n/a 4.8 3.0 5.9 3.3 0.3b 
           
Neuropsychology           
General intellect: Verbal IQ (WASI vocabulary), z score - - -1.15 1.9 - -1.56 2.3 -0.88 1.6 0.4c 
General intellect: Performance IQ (WASI matrices), z 
score 
- - -5.80 2.4 - -6.24 2.3 -5.43 2.39 0.4c 
Episodic memory for faces (RMT), z score - - -1.90 1.8 - -1.65 1.3 -2.08 2.1 0.6c 
Episodic memory for words (RMT), z score  - - -4.35 2.6 - -4.38 2.7 -4.33 2.5 0.8c 
Literacy and numeracy (GDST, GDA), z score - - -2.04 1.3 - -2.54 1.0 -1.70 1.4 0.04b 
Visuoperceptual and visuospatial (VOSP), z score  - - -6.81 6.5 - -8.34 5.7 -5.76 7.0 0.09c 
Processing speed and executive function (DKEFS, 
verbal fluency, DSMT), z score 
- - -2.23 0.8 - -2.6 0.7 -1.97 0.7 0.01c 
           
Phenotype n  N   n  n   
Leading symptom, memory / visual / language / 
behavioural 
n/a  24/13/0/0  n/a 8/7/0/0  16/6/0/0  0.3a 
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10.3.3 White matter changes by APOE ε4 genotype: DTI and NODDI 
DTI and NODDI metrics are shown for ε4-ve and ε4+ve patients relative to controls in 
Figure 10.1.   
Both patient groups had decreased FA in white matter tracts projecting from the parieto-
occipital lobes (inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, 
superior longitudinal fasciculus, genu of corpus callosum, posterior thalamic radiation), 
with ε4- patients also having decreased FA in the splenium of the corpus callosum and 
anterior corona radiata.  AxD and RD were increased in both patient groups relative to 
controls in the genu, body and splenium of the corpus callosum, and parieto-occipital 
white matter projections (those listed above and the internal capsules). ε4+ve patients 
additionally had increased RD in the white matter projections from the frontal lobes.  
There were no areas where patients had increased FA or decreased diffusivity relative 
to controls, and no significant differences in any DTI metric when APOE ε4+ve and ε4-
ve groups were compared directly. 
NDI was reduced in the parieto-occipital white matter projections (same as listed above) 
of both ε4-ve and ε4+ve patient groups relative to controls, but was more widespread in 
ε4+ve patients, additionally affecting the body and genu of the corpus callosum, and 
extending further into the frontal and temporal lobe white matter projections.  ε4-ve and 
ε4+ve patient groups had a common signature of decreased ODI in the posterior parts 
of the corpus callosum and internal capsule.  ε4-ve patients also had increased Fiso in 
the corpus callosum, whereas there were no significant differences in Fiso in ε4+ve 
patients relative to controls.   
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Figure 10.1 DTI and NODDI metrics in patients with (A) ε4-ve YOAD (n15) and (B) 
ε4+ve YOAD (n=22) relative to controls (n=23)  
Voxel-wise group differences are shown in red for metrics that are decreased in patients 
and blue for those increased in patients.  Results are overlaid on axial and sagittal 
sections of the group-specific white matter skeleton (shown in green) in neurologic 
convention (the left side appears on the left). 
AxD, axial diffusivity; FA, fractional anisotropy; Fiso, fraction of isotropic water; L, left; 
NDI, neurite density index; ODI, orientation dispersion index; RD, radial diffusivity; R, 
right. 
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Figure 10.2 Added sensitivity and specificity of NODDI over DTI 
 (A) Left posterior white microstructural changes in ε4+ve (n=22) relative to controls (n=23).  Patients with ε4+ve YOAD have lower FA and 
increased RD.  NODDI metrics for this region suggest that the underlying microstructural change is decreased neurite density, rather than 
alteration in neurite orientation, illustrating the additional specificity of NODDI. (B) Right frontal white microstructural changes in ε4+ve 
(n=22) relative to controls (n=23).  There is no significant change in FA.  However, axial diffusivity increases suggesting underlying 
microstructural damage, which is corroborated by NODDI metrics revealing reduction in both NDI and ODI (which would tend to affect FA 
in opposite directions, and hence manifest as no overall change in FA).  Here NODDI metrics are more sensitive than FA by avoiding 
cancelling effects.  
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The tissue specificity afforded by NODDI revealed a landscape of microstructural 
damage in YOAD underpinning these changes in DTI metrics; e.g. identifying areas of 
FA reduction specifically due to decreased NDI rather than changes in ODI (Figure 10.2).  
NODDI metrics could also be more sensitive to change; e.g. identifying regions where 
NDI and ODI reduction occurred in parallel, hence resulting in no overall FA change 
(Figure 10.2). 
There were no significant differences in any NODDI metric when directly comparing ε4-
ve and ε4+ve patient groups at the prescribed statistical threshold; however, plotting the 
NDI t-statistic maps (uncorrected) (Figure 10.3) revealed that ε4-ve patients had greatest 
NDI reduction relative to ε4+ve in the right parietal lobe white matter projections; and 
ε4+ve patients had greatest reduction in NDI relative to ε4-ve in the left temporal lobe 
projections. 
 
Figure 10.3 Coronal (left), sagittal (middle) and axial (right) neurite density index 
t-statistic maps  
Areas where APOE ε4-ve patients have reduced NDI relative to ε4+ve patients are 
shown in warm colours, and where ε4+ve patients have reduced NDI relative to ε4-ve 
patients are shown in cool colours. 
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10.3.4 Region of interest NDI correlation with cognitive function 
Mean values for NODDI metrics in each of the 4 regions of interest are shown in Table 
10.2.  There were borderline significant differences between patients and control NDI 
metrics in the two anterior quadrants, and strong evidence for differences in the posterior 
(particularly left) quadrants.  There were no differences in ODI or FISO for any quadrant. 
 
WM ROIs YOAD Mean ± SD 
Controls 
Mean ± SD P
a 
NDI (mean±SD)  
Left anterior quadrant 0.554±0.022 0.538±0.031 0.043 
Left posterior quadrant 0.559±0.029 0.518±0.031 <0.00002 
Right anterior quadrant 0.555±0.022 0.539±0.036 0.067 
Right posterior quadrant 0.552±0.029 0.511±0.052 0.001 
ODI (mean±SD)  
Left anterior quadrant 0.214±0.015 0.214±0.007 0.95 
Left posterior quadrant 0.202±0.023 0.201±0.007 0.76 
Right anterior quadrant 0.213±0.014 0.211±0.008 0.54 
Right posterior quadrant 0.195±0.013 0.194±0.008 0.68 
FISO (mean±SD)  
Left anterior quadrant 0.105±0.017 0.108±0.016 0.67 
Left posterior quadrant 0.107±0.024 0.111±0.017 0.58 
Right anterior quadrant 0.099±0.017 0.106±0.018 0.22 
Right posterior quadrant 0.101±0.023 0.111±0.034 0.26 
Table 10.2 NODDI metrics in each region of interest 
FISO, fraction of free water; NDI, neurite density index; NODDI, neurite orientation 
dispersion and density imaging; ODI, orientation dispersion index; P, probability; ROI, 
region of interest; SD, standard deviation; WM, white matter; YOAD, young onset 
Alzheimer’s disease.  a two-tailed T-test 
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Having demonstrated regional differences in NDI between patients and controls, I next 
correlated the neuropsychology profiles with the mean NDI values in each quadrant. As 
shown in Figure 10.4, in patients there were significant positive correlations between a 
visually-demanding measure of performance IQ (WASI matrices) and regional NDI in 
white matter projections from the right parieto-occipital lobe (10.4, A) and between 
visuospatial and visuoperceptual tasks and NDI in white matter projections from the 
parieto-occipital lobes bilaterally (Figures. 10.4 B and 10.4 C).  There were no significant 
positive correlations between NDI and performance on other cognitive domains, and no 
significant negative correlations between regional NDI and any cognitive score.    
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Figure 10.4 Significant correlations between regional neurite density index and 
neuropsychological measures in white matter projections from the right (A and B) 
and left (C) parieto-occipital cortices of patients with YOAD (n=37) 
Regions of interest (red) are shown on the group mean white matter skeleton (green) to 
the left of each graph.  L, left; IQ, intelligence quotient; R, right; VOSP, visual object and 
spatial perception battery; WASI, Wechsler Abbreviated Scale of Intelligence. 
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10.4 Discussion 
This chapter uses DTI and NODDI to explore signatures of white matter structural brain 
damage and their biological underpinnings in patients with YOAD on the basis of APOE 
ε4 genotype.  DTI metrics showed regions of altered white matter microarchitecture in 
both ε4+ve and ε4-ve patients relative to controls.  NODDI, a multi-shell diffusion 
technique implemented on standard 3T clinical MR scanners, provided further insights 
into the commonalities and differences in white matter change associated with ε4 
genotype; namely more widespread NDI reduction in ε4+ve individuals and more focal 
posterior reductions in patients without an ε4 allele.   
Despite being the most important risk factor for Alzheimer’s disease, the effects of APOE 
ε4 on clinical phenotype white matter damage are incompletely understood.  The 
relatively few previous DTI studies in YOAD have shown decreased white matter FA and 
increased diffusivity, but have focussed on describing regional variation between 
phenotypes [239, 240, 341] or in YOAD relative to late onset Alzheimer’s disease [238] 
rather than investigating potential differential effects of APOE ε4.  Studies in late onset 
Alzheimer’s disease have shown contradictory findings: APOE ε4 allele status was 
associated with an increase in parahippocampal white matter mean diffusivity [342], yet 
Kljajevic et al. found ε4 status affected mean diffusivity in controls, but not in participants 
with clinically-manifest Alzheimer’s disease [343].  The observation here that axial and 
radial diffusivity changes are more prominent than FA in both the presence and absence 
of an ε4 allele is consistent with previous observations that these directional diffusivity 
metrics can be a more sensitive marker of structural change than FA [344].  The areas 
of increased RD and AxD, and FA reduction in bilateral parietal lobes, genu of the corpus 
callosum, frontal white matter lobe projections shown here are broadly in keeping with 
changes in DTI metrics reported in YOAD patients (ε4 status unspecified) previously 
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[238], and an additional possible modulating effect of ε4 status is shown: less anterior 
FA reduction in the presence of an ε4 allele.   
The NODDI results allow more specific inferences about the nature of the underlying 
microstructural damage. Thus, as illustrated in Figure 10.2. NODDI metrics can explain 
different mechanisms underlying changes in FA; or indeed detect the effects of 
concomitant pathological processes that would individually affect FA in opposing ways 
and hence cancel one another out, resulting in no observable FA change.  
White matter NDI reduction was more extensive anteriorly in ε4+ve than ε4-ve YOAD 
patients (Figure 10.1).  Although differences did not survive the statistical threshold for 
multiple comparisons when comparing the patient groups directly, T-statistic maps 
(uncorrected) reveal potential subtle differences in regional NDI values between the ε4-
ve and ε4+ve groups (Figure 10.3).  The former appears to have more NDI loss in right 
parietal lobe white matter connections, in keeping with a trend for worse performance on 
visual tasks.  Conversely the ε4+ve group tends to more NDI reduction in left temporal 
lobe connections.  The similarities and differences could suggest there being a “generic” 
signature of network breakdown in Alzheimer’s disease, with relatively subtle ε4 
modulation of network dysfunction, perhaps influencing phenotype through differential 
propagation of pathology. 
Histological evidence supports a relationship between MRI estimates of axonal density 
reduction and actual axon loss.  Ex vivo studies in animals have demonstrated that 
diffusion MRI estimates of axon density, using a related diffusion model, show a high 
degree of correlation with optical staining intensity of myelin and stereological estimates 
of axonal volume fraction in white matter [345].  If reduced NODDI NDI truly reflects axon 
loss in YOAD, then it follows that even partial disconnection of brain regions should lead 
to functional consequences that manifest in the phenotype.   
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Whilst DTI metrics do not correspond to compartment-specific microstructural changes, 
previous studies have shown correlation with global measures of cognition.  In patients 
with LOAD, fractional anisotropy in the corpus callosum has been shown to correlate 
with performance on the MMSE [238], and more specifically, radial diffusivity and 
fractional anisotropy in the splenium correlate with dementia severity on the ACE-R 
[346].  In YOAD, global cognitive performance on the Clinical Dementia Rating Sum of 
Boxes has been found to correlate with mean diffusivity in several brain regions including 
the corpus callosum, posterior cingulate, frontal and parietal parts of the superior 
longitudinal fasciculus bilaterally, and left temporal regions [238]. However, no 
correlation has been demonstrated between diffusion MRI metrics and performance on 
focal cognitive test scores sensitive to regional brain dysfunction.  
In the analyses presented in the chapter, NDI in white matter projections from both left 
and right parieto-occipital lobes correlated with visuospatial and visuoperceptive 
cognitive performance, a sensitive marker of non-dominant parietal cortex function; 
bilateral correlations are likely to reflect that the parietal lobes are structurally closely 
inter-connected.  Right parieto-occipital white matter NDI also correlated with a measure 
of performance (non-verbal) intelligence, reflecting right hemisphere dysfunction.   
These correlations suggest that regional reductions in NDI can provide in vivo measures 
of cell loss and network breakdown, which in turn shape clinical phenotype.  The lack of 
correlation of NDI with other neuropsychological scores may reflect these cognitive 
functions being underpinned by a more distributed white matter network, or relate to the 
dispersion of results on psychology testing - the tests that showed correlation were those 
with the largest range of patient performance.  
NODDI has since been applied to studying cortical diffusion in grey matter where 
microstructural damage modelled by regional changes in NODDI metrics may be 
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expected to show closer correlation with performance on specific neuropsychological 
tests.  Lower NDI was associated with lower MMSE scores, with the strongest 
associations seen in the precuneus, inferior temporal and middle temporal gyri [347], but 
regional correlation with focal cognitive scores has not been investigated.  
Orientation dispersion is thought to relate to axonal organisation [348] and white matter 
orientation dispersion index has been shown to correlate with altered neurite morphology 
histologically [349].  White matter ODI has been reported to increase in normal aging 
[246].  The data presented here show ODI was reduced (i.e. the tracts were more 
coherent) in the corpus callosum and internal capsule of individuals in both ε4-ve and 
ε4+ve YOAD patients relative to controls, notably even in some regions unaffected by 
significant NDI change. The anatomical dissociation may suggest alterations in NDI and 
ODI reflect different pathophysiological phenomena in neurodegeneration. One possible 
histological explanation is that reduced orientation dispersion reflects loss of secondary 
crossing fibres to leave more aligned neurons in the primary tracts, perhaps mediated 
by selective axonal degeneration. Longitudinal NODDI studies will be needed to 
understand the temporal sequence of change, but it may be that reduction in orientation 
dispersion precedes reduction in neurite density.   
The work presented in this chapter has a number of limitations.  As with all biophysical 
models, and specifically multi-compartment diffusion models, NODDI requires a number 
of assumptions:  modelling axon orientation does not account for crossing fibres, the 
value of intrinsic diffusivity is fixed over the whole brain, and intra-neurite diffusion is 
modelled as being completely restricted within a collection of impermeable sticks.  It is 
conceivable that this does not fully characterise all pathological processes involved in 
neurodegenerative diseases (e.g. Alzheimer’s disease) such as possible regional 
variation in intrinsic diffusivity, alterations in neurite membrane permeability or damage 
to intra-neurite architecture.  Jesperson et al. have used a related multi-compartment 
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diffusion model [350] to examine the relationship between neurite density and orientation 
dispersion with histological measures in animal brains [345].  There is however, currently 
limited histopathological evidence to specifically validate NODDI model metrics in the 
human brain;  however an ex vivo study of human spinal cord in multiple sclerosis 
showed NODDI replicated the trends of histological indices and could detect specific 
features of tissue pathology [351].   
The potential presence of white matter hyperintensities is not accounted for.  These have 
been shown to result in lower FA and higher MD relative to normal appearing white 
matter [352]. In Alzheimer’s disease, white matter hyperintensities may be related to 
coexistent vascular burden, or be part of Alzheimer’s disease pathogenesis. One of the 
advantages of studying patients with YOAD is that they are less likely to have significant 
coexistent vascular disease than individuals with late onset disease. All participants in 
this study scored 4 or less on the Hachinski ischaemic score indicating that on clinical 
grounds there was not a significant vascular component to their syndrome; and as shown 
in Chapter 6, no differences in blood pressure were seen between patients and controls 
in the wider YOAD study from which these participants were drawn. There may be more 
amyloid angiopathy observed in patients with ε4+ve disease than those who do not carry 
an ε4 allele [353] which could both explain some of the differences observed. It is 
unknown how the presence of white matter hyperintensities affect NODDI metrics – and 
indeed future studies with post-mortem verification are needed to see if NODDI may be 
a useful imaging technique to understand the microstructural changes underpinning 
these white matter alterations.  If quantifiable, WMH lesions loads could be included as 
a covariate in the modelling. 
The participant groups reported are relatively small, yet indicative of the relative rarity of 
YOAD, and may explain why direct comparisons of ε4+ve and ε4-ve groups were not 
sufficiently powered to reach statistical significance.  The individual with a PSEN1 variant 
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had also been included as his autosomal dominant genetic status was not known at the 
time of these analyses.  Ideally in studying the differential effect of APOE ε4, individuals 
with autosomal dominant disease would be excluded to try to remove a potential 
confounder for any differences found between groups being attributed to APOE ε4 
status.  It is possible, but unlikely that the presence of a single individual with an 
autosomal dominant mutation will have significantly changed the results. 
Alzheimer disease is a complex genetic disease and any modulation of network 
breakdown due to APOE ε4 here observed likely occurs in the context of attenuation by 
a host of other genetic and environmental factors.  
NODDI metrics in the healthy aging brain show good short interval reproducibility [354] 
but longitudinal studies, ideally with post mortem histological evaluation, are required to 
establish if NODDI metrics are robust, reproducible and capable of tracking Alzheimer’s 
disease progression, characteristics that may give the technique utility in clinical trials.  
Given the interest in testing potential therapeutic agents at earlier stages of disease it is 
important to assess if, as predicted, NODDI metrics can detect white matter 
microstructural changes in people with very mild or pre-symptomatic stages of disease.   
A large longitudinal cohort study of healthy older adults is now underway investigating 
whether NODDI can detect microstructural changes in people with pre-symptomatic 
disease [355]. 
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11 Investigating the functional basis of memory impairment in 
Alzheimer’s disease 
11.1 Introduction 
Data presented in this thesis thus far have concentrated on the genetic, volumetric and 
diffusion imaging characteristics of YOAD, and presented indirect evidence for links 
between regional structural network breakdown and cognitive performance in individuals 
with different APOE ε4 genotypes.  Activation fMRI can be used to study functional, 
rather than structural, connections between brain regions, and identify areas of both 
decreased activity, and disease mediated aberrant and compensatory increases in 
activity.  This chapter describes a series of experiments using activation fMRI to 
investigate differences in aspects of memory processing and their functional 
neuroanatomical bases in patients with different phenotypes of Alzheimer’s disease, 
using music as a stimulus.  
As outlined in Chapter 2, substantial evidence has implicated a core neural network as 
the key target of pathogenic protein spread in Alzheimer’s disease [177, 222, 356, 357].  
This ‘default mode’ network links medial temporal lobe structures to lateral temporo-
parietal and medial prefrontal regions via a ‘hub’ zone in postero-medial cortex (posterior 
cingulate and precuneus).  Differential Involvement of this network is thought to underpin 
the variable clinical deficits seen in the major Alzheimer’s disease variant phenotypes: 
typical memory led Alzheimer’s disease (tAD) and posterior cortical atrophy (PCA) [101, 
165, 222, 358-360].   
Music is a very salient stimulus for studying default mode network function.  In addition 
to mediating stimulus-independent thought [217] the DMN plays an active role in 
coordinating brain activity during other cognitive operations including the analysis of 
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auditory scenes and patterns [361, 362].  Components of the default mode network are 
also implicated in the processing of several aspects of musical memory processing. 
Impaired processing of complex auditory stimuli has been linked specifically to 
dysfunction and atrophy of the postero-medial hub region, and reported in both tAD and 
PCA [101, 222, 358-360, 363].   
As a research stimulus, music also enables multiple fundamental aspects of information 
encoding and processing to be experimentally altered and studied.  Musical processing 
involves appreciation of temporal information (regularity and irregularity in rhythms), 
pitch and timbre perception, spatial encoding of where a sound is coming from, emotional 
aspects (whether music sounds ‘sad’ or ‘happy’, depending on the key) and several 
aspects of memory processing.  Music engages separable cognitive systems mediating 
procedural memory (playing an instrument), semantic memory (recognition of musical 
objects, such as familiar tunes) and episodic memory (encoding and recollection of 
specific musical events) [364, 365].  These musical memory systems are likely to be 
differentially vulnerable to the effects of Alzheimer’s disease [364-367] with the balance 
of evidence suggesting that episodic memory for music becomes impaired early in the 
course of Alzheimer’s disease, while effects on musical semantic and procedural 
memory are more variable and may become more evident only with advancing disease 
[366, 368-370] mirroring the variable susceptibility of memory functions in non-musical 
domains [222].  People with advanced dementia may still remember the tunes of their 
favourite songs from earlier in life and familiar music appears to be able to ‘unlock’ 
autobiographical memories and other cognitive capacities in Alzheimer’s disease [371].  
Functional neuroanatomical work in the healthy brain has identified separable, 
distributed, bi-hemispheric cerebral networks that support these different musical 
memory systems. Musical semantic memory has been shown to engage anterior 
temporal, inferior and supero-medial prefrontal cortices [367, 372-375] while musical 
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episodic memory engages precuneus, posterior cingulate, hippocampus and other 
medial temporal lobe structures [372, 376, 377]. The processing of unfamiliarity (novelty) 
in music and other sensory stimuli engages a distributed network of brain areas 
overlapping those implicated in musical semantic and episodic memory, including medial 
temporal lobes and temporo-parietal, inferior frontal, insula and anterior cingulate 
cortices [378-380].  
Despite considerable interest however, the neural mechanisms underlying musical 
memory in Alzheimer’s disease remain contentious.  It has been proposed that 
preservation of musical memory (in particular, musical semantic memory) in Alzheimer’s 
disease might be attributable to relative sparing of the medial prefrontal cortices 
implicated in mediating musical familiarity in healthy listeners [367].  However, changes 
in musical memory processing in Alzheimer’s disease have not been studied directly in 
patients.  It remains unclear if Alzheimer’s disease affects processing in core musical 
memory systems differentially, and how this manifests in patients with variant AD 
syndromes who have DMNs with regionally different patterns of structural damage. 
In this chapter I start to address these issues using activation fMRI in a cohort of patients 
representing the canonical syndromes of tAD and PCA, relative to healthy age-matched 
individuals. The neuropsychological and regional atrophy profiles of the YOAD cohort 
based on phenotype are described.  Then a simple paradigm is used to capture disease-
associated changes in the core semantic (familiarity) and episodic (tune repetition) 
dimensions of musical memory that might be relevant to any listener, including those 
without specific musical training.  In everyday music listening, we are generally not called 
upon to analyse melodies explicitly but the sense that a tune is familiar, that musical 
motifs are repeating or that new material is being presented are common experiences 
that contribute importantly to the appreciation of music even among musically naïve 
listeners.  These listening experiences are in turn likely to depend on semantic and 
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episodic musical memory systems: prior familiarity with a melody engages musical 
semantic memory while the incidental detection of repeating motifs engages (incidental) 
episodic memory for music.  In the fMRI paradigm used these factors of prior familiarity 
and repetition are presented orthogonally in a stimulus set comprising short musical 
melodies.   
Although familiarity decisions on melodies have been used as a model for musical 
semantic memory in previous studies [364], familiarity does not, of course, equate to 
detailed semantic knowledge of a musical piece; nor does incidental memory for music 
equate to explicit episodic recall.  The objective was not to delineate fully the brain 
systems that mediate musical semantic and episodic memory, but rather to probe these 
systems using a paradigm relevant to listeners potentially varying widely in musical 
expertise and in particular, without the requirement for an overt task during scanning. 
Task effects are particularly problematic in fMRI studies of cognitively impaired 
individuals due to confounds from e.g. remembering what button to press, and when to 
do so.  Therefore, in order to provide a behavioural reference for the neuroanatomical 
changes observed, all participants also completed tasks assessing aspects of musical 
semantic and episodic memory following the scanning session.     
Based on behavioural and neuroanatomical evidence from previous studies [222, 364-
367, 370, 372, 374-377], I hypothesized that Alzheimer’s disease and PCA would be 
associated with a similar profile of abnormal activation of postero-medial cortices during 
incidental episodic processing of repeated melodies relative to healthy individuals, 
whereas these syndromes would show divergent activation profiles during semantic 
processing of prior melody familiarity, due to sparing of more anterior cortical regions in 
PCA relative to tAD [381].   
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11.2 Methods 
11.2.1 Participants 
A subset of thirty-four patients (mean age 60.9 years; 20 female) fulfilling consensus 
criteria for Alzheimer’s disease [117] and 19 age-matched healthy individuals (60.5 
years, 10 female) from the YOAD cohort participated in the experiments described in 
this chapter.  Twenty-four of these patients presented with an amnestic clinical syndrome 
of tAD [116] and 10 patients presented with a syndrome meeting research criteria for 
PCA [165].  The clinical syndromic diagnosis was corroborated by neuropsychological 
assessment (for details of the neuropsychological battery, see Chapter 5).  Patients had 
a compatible profile of regional atrophy and no significant associated burden of 
cerebrovascular disease on volumetric structural T1 brain MRI.  No participant had a 
history of hearing loss or congenital amusia.    
No participants had a known mutation or family history suggestive of autosomal 
dominant inheritance at time of recruitment but dedicated screening for autosomal 
dominant mutations in genes known to cause Alzheimer’s disease had not been 
performed at the time of analyses in this chapter, hence the tAD participant harbouring 
a pathogenic PSEN1 variant is included. 
CSF examination was undertaken in 30 of these patients (23/24 with tAD, 7/10 with 
PCA), all of whom had a profile of neurodegeneration protein markers (tau and Aβ1-42) 
consistent with likely underlying Alzheimer’s disease pathology [382].   
At the time of participation, 32 patients were receiving symptomatic treatment with an 
acetylcholinesterase inhibitor (two were also taking memantine), one patient was taking 
memantine without a cholinesterase inhibitor and the remaining patient was taking no 
symptomatic treatment.   
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Demographic, clinical and neuropsychological details for all participant groups are 
summarised in Table 11.1.   
11.2.2 Assessment of musical background and peripheral hearing function  
All participants completed a questionnaire detailing their prior musical training and 
current music listening [383]. In order to assess peripheral hearing function, all 
participants had pure-tone audiometry using a procedure adapted from a commercial 
screening audiometry software package (http://www.digital-
recordings.com/audiocd/audio.html). The test was administered via headphones from a 
laptop in a quiet room.  Five frequency levels (500, 1000, 2000, 3000, 4000Hz) were 
assessed: at each frequency participants were presented with an intermittent tone that 
slowly and linearly increased in intensity.  Participants were instructed to indicate as 
soon as they were sure they could detect the tone; this response time was measured 
and stored for offline analysis.    
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Characteristic Healthy controls 
n=19 
tAD  n=24 PCA n=10 
General    
Gender (M:F) 9:10 12:12 2:8 
Age (years) 60.5 (6.0) 60.3 (4.4) 62.1 (5.6) 
Handedness (L:R) 3:16 1:23 1:9 
Education (years) 17.1 (3.1) 15.5 (2.9)   15.0 (2.9) 
Musical training (years) 2.7 (5.2) 3.8 (5.3) 1.2 (2.1) 
Music listening (hours/week 9.4 (10.5) 6.8 (7.4) 5.9 (8.1) 
MMSE ( /30) 29.5 (0.7) 19.7* (3.7) 22.9* (4.3) 
Age at onset (years) NA 55.2 (3.9) 55.8 (4.3) 
Symptom duration (years) NA 5.1 (2.6) 6.3 (3.3) 
CSF examination NA 23§ 7§ 
Neuropsychological 
assessment 
   
Episodic memory    
RMT words (short, /25) 24.5 (0.8) 16.8†* (2.5) 20.0†* (4.0) 
RMT faces (short, /25) 24.5 (1.0) 20.0† (4.6) 18.3† (4.7) 
Executive skills    
WASI matrices ( /35) 26.9 (2.3) 9.0 †*(6.6) 3.6 †*(3.8) 
WMS-R digit span forward ( /12) 8.9 (1.8) 5.8† (2.1) 6.2† (3.0) 
WMS-R digit span backwards (/12) 7.8 (1.6) 3.7† (1.6) 3.9† (2.7) 
DSMT ( /93) 54.6 (9.1) 13.4 † (11.9) 5.8 † (8.7) 
A cancellation 20.7 (5.1) 50.2†* (20.5) 74.5†* (18.0) 
Verbal skills    
NART ( /50) 40.3 (5.1) 30.6† (10.3) 28.4† (12.4) 
WASI vocabulary ( / 80) 69.7 (7.5) 53.0† (17.4) 55.5† (21.7) 
GNT ( /30) 25.7 (2.7) 14.1† (9.3) 17.6† (7.1) 
Literacy and numeracy skills    
GDST ( /30) 27.4 (3.0) 16.1† (8.6) 13.5† (8.1) 
GDA ( /24) 13.7 (6.7) 1.8 † (2.8) 1.5† (2.0) 
Visuoperceptual skills    
VOSP object decision ( /20) 18.2 (1.5) 15.6†* (3.0) 10.4†* (4.5) 
VOSP shape detection ( /20) 19.4 (0.8) 18.3†* (1.4) 16.2†* (2.4) 
VOSP fragmented letters ( /20) 19.4 (0.7) 12.3†* (7.1) 5.3†* (5.6) 
VOSP dot counting ( /10) 9.9 (0.3) 8.1†* (2.8) 4.9†* (3.0) 
Post-scan musical tasks    
Melody familiarity judgement (d’) 2.8 (0.7) 2.8 (0.8) 2.7 (0.8) 
Melody episodic memory# (d’) 1.6 (0.8) 0.8 (0.7) 0.9 (0.6) 
Table 11.1 Demographic, clinical and behavioural characteristics of participants 
Mean (standard deviation) values are presented unless otherwise indicated. Raw data 
are shown for neuropsychological tests (maximum scores in parentheses). Bold 
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indicates patient performance was significantly impaired (<5th percentile) relative to age 
matched published norms; †significant difference between patient group and healthy 
controls (p<0.05), *significant difference between patient syndromic groups (p<0.05); 
#18 controls, 14 tAD, eight PCA patients completed this test; §profile of 
neurodegeneration markers consistent with Alzheimer’s disease pathology in all cases; 
CSF, cerebrospinal fluid; DSMT, Digit Symbol Modalities Test [268]; F, female; GDA, 
Graded Difficulty Arithmetic [264]; GDST, Graded Difficulty Spelling Test [265]; GNT, 
Graded naming test [263]; IQ, intelligence quotient; M, male; MMSE, Mini Mental State 
Examination [108]; n, number; NA, not applicable; NART, National Adult Reading Test 
[384]; P, probability; PCA, patient group with posterior cortical atrophy; RMT, 
Recognition Memory Test [260]; SD, standard deviation; verbal fluency [385]; tAD, 
patient group with typical amnestic presentation of Alzheimer’s disease; VOSP, Visual 
Object and Spatial Perception battery [266]; WASI, Wechsler Abbreviated Scale of 
Intelligence [259]; WMS-R, Wechsler Memory Scale Revised [262]. 
11.2.3 Experimental stimuli and protocol 
Two musical stimulus subsets were created, based respectively on previously familiar 
melodies (widely-known tunes that would be recognised based on long-term, general 
musical experience rather than specific autobiographical recall) and previously 
unfamiliar melodies (melodies created de novo for the experiment). During scanning, 
particular melodies from each set were either presented once only or twice, to vary the 
frequency of particular musical episodes over the experimental session. This yielded 
four stimulus conditions:  familiar melodies, each presented once; unfamiliar melodies, 
each presented once; familiar melodies, each presented twice; unfamiliar melodies, 
each presented twice.   
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This experimental design allowed construction of key contrasts to assess musical 
semantic memory (previously familiar > unfamiliar melodies), musical novelty (the 
‘reverse’ contrast, previously unfamiliar > familiar melodies), musical episodic memory 
(repeat [second] > first presentation of repeated melodies) and musical encoding (the 
‘reverse’ contrast, first > repeat presentation of repeated melodies). 
Musical stimuli were synthesised in MatlabR2012a® as digital wave files (sampling rate 
44.1kHz) and comprised sequences of harmonic complexes (notes) with defined 
fundamental pitch and fixed inter-note gap (6ms). The total length of each stimulus 
sequence was fixed at eight seconds and mean sound intensity was fixed across stimuli.  
Familiar melodies comprised excerpts from popular classical instrumental tunes widely 
known among older British individuals (details in Table 11.2), selected based on a pilot 
survey; the tune excerpts selected were classified as familiar (versus unfamiliar) by ≥ 
80% of healthy older British participants (n=5, all >50 years), none of whom participated 
subsequently in the fMRI study.  Non-vocal tunes were used to minimise implicit 
processing of verbal (song lyric) associations.  Unfamiliar melodies were created by re-
distributing the notes from each familiar melody to create a novel musical sequence with 
equivalent temporal and pitch interval structure.  Repeated melodies (half familiar, half 
unfamiliar) were distributed such that repeats were separated by two intervening 
melodies (stimulus trials) which (in the ‘sparse’ (long TR) acquisition protocol used here) 
corresponded to an interval of approximately 33 seconds between repetitions of a given 
note sequence.  This design was intended to maximise any effect from melody repetition 
while minimising musical short-term sensory trace memory or working memory 
processing.  A silent ‘rest’ condition was also included to provide a low-level baseline for 
assessing the effect of auditory stimulation.  
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The complete stimulus set (144 trials) comprised 96 unique melodies (48 familiar, 48 
unfamiliar) plus 48 repeat-presentation trials (24 familiar melodies, 24 unfamiliar 
melodies). The stimuli were delivered binaurally from a laptop using electrodynamic 
headphones (MR Confon GmbH, Magdeburg) at a comfortable listening level 
(approximately 70 dB).  The presentation order of familiar and unfamiliar melody trials 
was randomised. In-house routines in Python (http://www.python.org) were used to 
integrate stimulus delivery with the scanner controls. Participants were instructed to 
listen to the sound stimuli; there was no output task and no participant responses were 
collected during the scanning session.   
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Composer Musical piece Notes 
(no.) 
Pitch range 
(notes) 
Pitch 
change 
(semitones) 
Bach Fugue in D minor 32 A0 - A1 7.07 
Bach Jesu Joy of Man’s Desiring 32 D1 - G2 2.87 
Bach Minuet in G: excerpt 1 32 A1 - E2 1.67 
Bach Minuet in G: excerpt 2 32 F1# - G2 3.91 
Bach Toccata in D minor 32 F1 - A2# 2.58 
Barber Adagio for Strings 16 A1 - D2# 1.84 
Beethoven Fur Elise: excerpt 1 32 E0 - E3 8.44 
Beethoven Fur Elise: excerpt 2 32 E0 - E2 6.74 
Beethoven Moonlight Sonata 32 G0# -F1# 5.93 
Beethoven Ode to Joy  32 D1 - E2 3.67 
Bizet Toreador’s Song (Carmen) 18 C1 - D2 3.18 
Bizet Habanera (Carmen): excerpt 1 35 D1 - C2# 2.40 
Bizet Habanera (Carmen): excerpt 2 29 D1 - D2 2.23 
Boccherini Minuet (String Quintet in E) 30 D1 - A2 4.12 
Brahms Hungarian Dance No 5 19 F1# - A2 3.27 
Charpentier Prelude (Te Deum) 21 G1 - G2 2.87 
Delibes Mazurka (Coppelia) 21 G1 - C3 4.61 
Delibes Flower Duet (Lakme) 32 G1 - D2# 1.74 
Dvorak Humoreske: excerpt 1 21 G1 - B2 3.35 
Dvorak Humoreske: excerpt 2 28 C1 - A2 2.70 
Dvorak New World Symphony, Adagio 16 F1 - C2 2.42 
Grieg Morning Mood (Peer Gynt): excerpt 1 32 F1 - D2 2.95 
Grieg Morning Mood (Peer Gynt): excerpt 2 32 E1 - C2# 3.43 
Grieg Hall of the Mountain King (Peer Gynt) 
excerpt 1 
32 C1# - A1 3.03 
Grieg Hall of the Mountain King (Peer Gynt) 
excerpt 2 
32 B0 - B1 3.60 
Handel Hornpipe (Water Music) 28 C1 - G1 2.87 
Handel Arrival of Queen of Sheba: excerpt 1) 32 B0 - E2 2.35 
Handel Arrival of Queen of Sheba: excerpt 2 32 G1 - G2 3.79 
Joplin  The Entertainer: excerpt 1 36 D1 - E2 5.14 
Joplin  The Entertainer: excerpt 2 48 D1 - E2 2.6 
Mozart Eine Kleine Nachtmusik 18 D1 - D2 4.25 
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Mozart Piano Concerto No 21, Mov 2 26 C2 - D3 4.68 
Mozart Symphony No 40, Mov 1: excerpt 1 40 C1 - A1# 2.86 
Mozart Symphony No 40, Mov 1: excerpt 2 31 C2# - C3 2.96 
Mozart Turkish Rondo (Piano Sonata No 11) 43 G1# - C3 2.35 
Offenbach  Infernal Gallop (Orpheus): excerpt 1 32 A1 - D3 3.94 
Offenbach  Infernal Gallop (Orpheus): excerpt 2 32 G1 - G2 3.20 
Prokofiev Peter’s theme (Peter and the Wolf) 25 G1 - C3 4.28 
Puccini Nessum Dorma 16 B1 - G2 2.52 
Quilter Upon St Paul’s 16 D1 - D2 4.72 
Ravel Bolero 33 C1 - D2 1.99 
Saint-Saens Danse Macabre 32 D1 - A1# 2.26 
Strauss Radetsky March 43 C1 - B1 3.34 
Strauss Tritsch Tratsch Polka 38 B0 - E2 5.10 
Tchaikovsky Waltz of the Flowers (Nutcracker) 27 F1 - F2 4.17 
Tchaikovsky Dance of the Little Swans (Swan Lake) 32 F0# -F2# 4.84 
Vivaldi Spring (The Four Seasons) 32 B1 - B2 3.03 
Wagner Ride of the Valkyries 18 F0# - A1 5.02 
Mean:  29.4  3.6 
Table 11.2 Familiar melodies presented in the fMRI experiment 
The 48 familiar melodies used are indicated, with relevant stimulus parameters; all 
stimuli were edited to duration 8 seconds and presented using a pleasant synthetic 
timbre with fixed overall (root-mean-square) intensity. Familiar melodies comprised 48 
excerpts from tunes widely known among older British people. *standard deviation for 
inter-tone pitch variation across the 8 second excerpt.  
11.2.4 Brain imaging acquisition  
MRI data were acquired on a 3T TIM Trio whole-body MRI scanner (Siemens 
Healthcare, Erlangen, Germany). 92 gradient-echo echo-planar image (GE-EPI) 
volumes were acquired in each run using a 12-channel RF receive head and body 
transmit coil in sparse (TR 11.3 seconds) acquisition mode (to reduce any interaction 
between scanner acoustic noise and auditory stimulus presentations). Each EPI volume 
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comprised 48 oblique transverse slices with slice thickness 2mm, inter-slice gap 1mm 
and 2x2mm in-plane resolution (TR/TE=11340/30ms; echo spacing=0.69ms; matrix 
size=96x96 pixels; FoV=192x192mm, GRAPPA factor 2 in anterior-posterior phase 
encoding direction). The initial two brain volumes were discarded to allow for equilibrium 
of longitudinal T1 magnetization. B0 field-maps were acquired using two gradient echo 
sequences (TR=688ms; TE1/TE2=4.92/7.38ms, 3x3x3mm resolution, no inter-slice gap; 
matrix size=80x80pixels; FoV=192x192mm; phase encoding anterior-posterior) to allow 
correction of field inhomogeneity.   
Volumetric structural brain MR images were also obtained in each participant. A sagittal 
3-D magnetization prepared rapid gradient echo T1-weighted volumetric MRI 
(TR/TE=2200/2.9ms, dimensions 256x 256x208, voxel size 1.1x1.1x1.1 mm) was 
acquired on the same 3.0T Siemens scanner using a 32-channel phased-array head 
coil.  
All structural and functional MR scans were visually assessed for quality control 
purposes by an experienced rater, based on coverage and movement artefact. 
11.2.5 Post scan behavioural testing  
Immediately after the scanning session two behavioural tests based on the fMRI 
conditions were administered, in order to assess each participant’s ability to process 
relevant dimensions of musical memory.  
To assess musical semantic memory, 24 (12 familiar, 12 unfamiliar) melodies from the 
set used during scanning were presented in randomised order and the task on each trial 
was to decide whether the tune was familiar or unfamiliar. The second test was designed 
to assess musical episodic recognition memory using novel musical stimuli. The 
participant was first asked to assess the pleasantness of three probe melodies (not 
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previously presented during scanning) and then, after a delay of 60 seconds, to identify 
these melodies among nine foil melodies (the task on each trial was to decide whether 
or not the melody had been presented earlier); this same procedure was repeated for a 
second set of probes and foils.  
Participant responses were given verbally and recorded by the researcher.  No feedback 
was given during either test and no time limits were imposed. Participant responses were 
recorded for off-line analysis.  
11.2.6 Data analyses 
11.2.6.1 Demographic and behavioural data 
All statistical analyses were conducted using Stata version 12. Demographic 
characteristics and musical experience were compared between the control and patient 
groups using two sample t-tests and Wilcoxon rank sum; gender differences were 
assessed using a Pearson’s chi-square test. Neuropsychological data were compared 
between study groups using Wilcoxon rank sum tests. Tone detection thresholds on 
audiometry screening and musical familiarity and repetition judgement results were 
analysed using linear regression models with clustered, robust standard error.   
Performance data for the post-scan musical memory tasks were analysed using signal 
detection theory. Hit rate and false alarm rates were calculated and combined to create 
sensitivity measure d-prime (Z(Hit rate)–Z(False alarm rate). Two sample t-tests were 
used to compare d-prime values between participant groups on each task.   
A threshold p<0.05 was accepted as the criterion of statistical significance for all tests. 
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11.2.6.2 Voxel-based morphometry data.   
Structural brain MR images were compared between patient and control groups in a 
VBM analysis. Normalisation, segmentation and modulation of grey and white matter 
images were performed using default parameter settings in statistical parametric 
mapping software (SPM8; http://www.fil.ion.ucl.ac.uk/spm), with a Gaussian smoothing 
kernel of 6mm full-width-at-half-maximum.  To help protect against voxel drop-out 
because of potentially marked local regional atrophy in particular scans, a customised 
explicit brain mask was derived by maximising the correlation between the binary mask 
and the average of the images to be analysed [329].  Regional grey matter volume was 
compared between patient and control groups and between syndromic groups using 
voxel-wise two sample t-tests, including covariates of age, gender and total intracranial 
volume.  Statistical parametric maps of grey matter atrophy were thresholded at peak 
voxel level p<0.05 after family-wise-error (FWE) correction for multiple comparisons over 
the whole brain volume. 
11.2.6.3 Functional MRI data.  
Data from the fMRI experiment were pre-processed using SPM8.  Scans for each 
participant were realigned using the first image as a reference, and unwarped 
incorporating field-map distortion information.  DARTEL processing was used to spatially 
normalise individual scans to a group mean template image in MNI space.  Normalised 
images were smoothed using a Gaussian smoothing kernel 6mm full-width at half-
maximum.  
Pre-processed images were entered into a first-level design matrix modelling each 
experimental condition as a separate regressor with boxcars of one-TR duration 
convolved with the canonical haemodynamic response function and six head movement 
regressors derived from the realignment process.  First-level contrast images were 
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generated for effects of musical semantic memory (familiar > unfamiliar melody 
conditions), musical novelty (unfamiliar > familiar melody conditions), incidental musical 
episodic memory (repeat > first presentation of repeated melodies) and musical 
encoding (first > repeat presentation of repeated melodies).  Contrast images for each 
participant were entered into a second-level random-effects analysis using T-tests to 
examine within- and between-group effects.  
Contrasts were assessed at peak voxel level within small anatomical volumes of interest, 
as specified by our prior hypotheses based on previous functional neuroanatomical work 
in the healthy brain [367, 372-379, 386]. Relevant small volumes were derived from the 
Oxford Harvard Brain Atlas [387] in FSL view [275](Figure 11.1). These regions 
comprised an anterior peri-Sylvian region (combining inferior frontal gyrus, frontal 
operculum and anterior temporal cortex) and supplementary motor cortex, for the 
contrast assessing musical semantic memory; regions comprising posterior cingulate 
cortex, precuneus and hippocampi, for the contrasts assessing musical episodic memory 
and encoding; and the combination of these regions for the contrast assessing musical 
novelty (unfamiliarity) processing. A statistical threshold p<0.05 after family-wise error 
(FWE) correction for multiple comparisons (pFWE<0.05) over the pre-specified region of 
interest was used in assessing all contrasts. For each contrast of interest showing a 
significant difference between patients and healthy controls, the voxel peak effect size 
(beta estimate value) was extracted for correlation with post-scan behavioural test 
performance.  
&%) Page 
 
 
Figure 11.1 Anatomical small volumes used in analysis of fMRI data 
Representative coronal (left) and sagittal (right) sections of the anatomically-defined 
small volumes used in the fMRI analysis are shown, projected on the study-specific 
group mean T1-weighted structural MR brain image. Anatomical regions were derived 
from the Oxford Harvard Brain Atlas [35] and created in FSL view [275], as follows: A, 
inferior frontal gyrus, frontal operculum and anterior temporal cortex (cyan); B, 
supplementary motor cortex (green); C, posterior cingulate cortex (magenta) and 
precuneus (blue); D,  hippocampi (yellow). Volumes shown in A and B were used in 
analysis of the contrast assessing musical semantic memory; volumes shown in C and 
D were used in analysis of contrasts assessing musical episodic memory; and both 
regions were used in analysis of the contrast assessing musical novelty processing (see 
text).
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11.3 Results 
11.3.1 General characteristics of participant groups  
Demographic, clinical and neuropsychological data for participant groups are 
summarised in Table 11.1.  Patients and controls did not differ in age, gender, years of 
education, years of musical training or current musical listening.  The patient groups did 
not differ significantly in symptom duration, but the tAD group had lower mean Mini-
Mental State Examination score than the PCA group (p=0.04).   
In keeping with the results presented previously, the syndromic groups showed the 
anticipated profiles of multi-domain cognitive impairment: relative to published norms, 
patients with tAD had deficits of verbal episodic memory, naming, arithmetic, visual 
processing and executive function while patients with PCA had markedly impaired 
visuoperceptual and visuospatial skills but relatively preserved episodic memory and 
verbal skills; comparing syndromic groups, the tAD group had significantly worse verbal 
episodic memory performance than the PCA group, and the PCA group had significantly 
worse visuoperceptual skills than the tAD group.  
There were no significant effects of group membership on tone detection thresholds 
across frequencies (F(2,53)=0.59, p=0.56). 
11.3.2 Post scan behavioural data 
Group performance data for the post scan behavioural tests are summarised in Table 
11.1. Both patient groups performed significantly worse than the control group on the 
musical episodic memory task (tAD p=0.005, PCA p=0.03) but had unimpaired musical 
semantic memory (tAD p=0.7, PCA p=0.8).  There were no significant performance 
differences between the patient groups.  Performance on the musical episodic memory 
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test was correlated with performance on the musical semantic memory test (r=0.5, 
p=0.04) across the patient cohort.  There were no significant correlations between any 
musical memory task and standard neuropsychological measures of memory 
(Recognition Memory Test for Words and Faces [260], all p>0.05). 
11.3.3 Structural neuroanatomical data 
The tAD and PCA groups showed the anticipated profiles of grey matter atrophy relative 
to the healthy control group (Figure 11.2). The tAD group showed widespread atrophy 
involving the hippocampi, temporo-parietal and postero-medial cortices, also extending 
to involve prefrontal cortices; while the PCA group showed relatively selective posterior 
atrophy preferentially affecting the parietal and occipital lobes.  
There were no significant differences in grey matter atrophy profiles when the syndromic 
groups were directly compared (not shown).  
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Figure 11.2 Regional grey matter atrophy profiles in the patient groups 
Results of the voxel-based morphometry analysis showing statistical parametric maps 
(SPMs) of regional grey matter atrophy in the patient group with a memory-led syndrome 
of Alzheimer’s disease (panels a, b, c) and the patient group with a syndrome of posterior 
cortical atrophy (panels d, e, f) relative to the healthy control group. SPMs are rendered 
on representative coronal (a,d), axial (b,e) and sagittal (c,f) sections of the group mean 
T1-weighted MR brain image in MNI space, thresholded at p<0.05 after family-wise-error 
correction for multiple voxel-wise comparisons over the whole brain volume.  The colour 
bar codes voxel-wise t-scores of grey matter change across the patient cohort. Planes 
of sections have the following MNI coordinates (mm): a, y=-31; b, z=39; c, x=0; d, y=-
49; e, z=-14; f, x=3. The right cerebral hemisphere is displayed on the right in coronal 
and axial sections. 
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11.3.4 Functional neuroanatomical data 
Regional activation profiles for the musical contrasts of interest are summarised in Table 
11.3.  Statistical parametric maps are presented in Figure 11.3 (within participant groups) 
and Figure 11.4 (comparing patients and healthy controls).  All contrasts were 
thresholded at p<0.05FWE after correction for multiple voxel-wise comparisons within the 
pre-specified anatomical small volume of interest. 
Musical semantic processing (familiar > unfamiliar melody conditions) was associated in 
the healthy control group with significant activation of bilateral supplementary motor and 
anterior superior temporal cortices and right inferior frontal gyrus; and in the tAD group, 
with significant activation of bilateral supplementary motor cortex and left anterior 
superior temporal cortex.  No significant activation for musical semantic processing was 
identified in the PCA group.  
Musical novelty processing (unfamiliar > familiar melody conditions) was associated in 
the healthy control group with activation of right precuneus.  There were no significant 
activations within either patient group for this contrast.  
Comparing participant groups on the musical semantic memory contrasts revealed a 
significant activation difference (Figure 11.4) between the healthy control group and the 
tAD group in right inferior frontal gyrus.  From inspection of plots of effect size (Figure 
11.4), this interaction was driven chiefly by reduced activation to familiar melodies in the 
tAD group. There were no other significant activation differences between participant 
groups at the prescribed threshold. 
Incidental musical episodic memory (repeat > first presentation of repeated melodies) 
and musical encoding (first > repeat presentation of repeated melodies) revealed no 
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significant activations within any participant group at p<0.05FWE within the pre-specified 
anatomical small volume of interest.  
However, comparing groups revealed significant differences between the healthy control 
group and each of the patient groups for musical episodic memory processing: for the 
comparison between healthy control and tAD groups, this activation difference occurred 
in left precuneus while for the comparison between healthy control and PCA groups the 
activation difference occurred in right posterior cingulate cortex (Figure 11.4).  From 
inspection of plots of effect size, the interaction versus healthy controls was driven for 
the tAD group chiefly by abnormal activation of precuneus (relative to baseline) during 
melody encoding; and for the PCA group, by abnormal activation of posterior cingulate 
cortex by repeated melodies. There were no significant activation differences between 
patient groups at the prescribed threshold. 
In a regression analysis of out-of-scanner behavioural performance (d-prime) against 
peak effect size in the relevant anatomical regions, no significant correlations with output 
behaviour were found for the patient cohort for either the musical semantic memory or 
musical episodic memory contrasts (all p>0.05).   
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Table 11.3 Summary of fMRI data within and between participant groups 
Cerebral activations significant at peak voxel threshold p<0.05FWE after correction for multiple voxel-wise comparisons within the pre-specified 
anatomical volume of interest are shown, for clusters >10 voxels; coordinates of local maxima are in MNI space.  Significant within-group contrasts are 
presented above and significant between-group comparisons below (the contrasts between familiar [widely-known] and unfamiliar [newly-created] 
melody conditions refer to familiarity prior to scanning, i.e., musical semantic memory or musical novelty; the contrasts between repeat [second] and 
first presentations refer to melodies heard [musical events] during scanning, i.e., musical episodic memory).  
Group Contrast Region Side Cluster 
(voxels) 
Peak 
(mm) 
t-value P 
x y z     
Healthy Controls   Familiar > unfamiliar Supplementary motor R 85 6 2 66 8.83 <0.001 
Supplementary motor  L 30 0 8 63 4.42 0.05 
Anterior superior temporal 
cortex 
L 312 -54 14 6 6.78 0.003 
Anterior superior temporal 
cortex 
R 90 58 
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-9 6.44 0.004 
 
Inferior frontal gyrus R 55 58 26 18 6.28 0.006 
Unfamiliar > familiar Precuneus  R 95 14 -58 18 7.43 0.006 
tAD Familiar > unfamiliar Supplementary motor L 49 -6 6 63 5.03 0.006 
Supplementary motor R 25 8 6 63 4.89 0.008 
Anterior superior temporal 
cortex 
L 38 -52 10 -12 4.91  0.033 
Control > tAD Familiar > unfamiliar Inferior frontal gyrus R 13 60 24 15 4.46 0.032 
 Repeat > 1st presentation Precuneus  L 13 -4 -56 42 4.21 0.049 
PCA > Control Repeat > 1st presentation Posterior cingulate cortex R 20 6 -22 33 5.73 0.002 
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Figure 11.3 Functional neuroanatomy of musical memory: within-group correlates 
for patients and healthy controls 
Statistical parametric maps (SPMs) show all significant regional brain activations for 
musical memory contrasts within participant groups; significant activations were 
demonstrated in the patient group with memory-led Alzheimer’s disease (panel a) and 
in the healthy control group (panels b,c). Contrasts forming SPMs were as follows: a,b 
previously familiar [widely-known] > unfamiliar [newly-created] melody conditions 
(musical semantic memory); c, unfamiliar > previously familiar melody conditions 
(musical novelty). SPMs are rendered on coronal (a,b) and axial (c) sections of the group 
mean T1-weighted structural MR brain image, thresholded for display purposes at 
p<0.001 uncorrected over the whole brain volume; sections have been selected to show 
activations significant at p<0.05 after family-wise-error correction for multiple voxel-wise 
comparisons within the pre-specified small anatomical volumes of interest (see Table 3).  
Colour bars alongside panels a and c code voxel-wise activation t-scores in the AD group 
and the healthy control group. Planes of sections have the following MNI coordinates 
(mm): a, y=6; b, y=16; c, z=22. The right cerebral hemisphere is displayed on the right 
in all panels.  
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Figure 11.4 Functional neuroanatomy of musical memory: patients compared with 
healthy controls 
Panels a and b compare the tAD and healthy control groups in the musical semantic 
memory contrast (previously familiar > unfamiliar melody conditions); panels c and d 
compare the tAD and healthy control groups in the musical episodic memory contrast 
(repeat > first melody presentations); panels e and f compare the PCA and healthy 
control groups in the musical episodic memory contrast (see also text and Table 11.3). 
Statistical parametric maps (SPMs) of significant differences in regional brain activation 
between groups are presented in panels a, c, e; plots of peak voxel condition effect size 
(mean beta parameter estimate ± standard error, with MNI coordinates of corresponding 
local maxima) are presented in panels b, d, and f.  SPMs are rendered on sagittal 
sections of the group mean T1-weighted structural MR brain image, thresholded for 
display purposes at p<0.001 uncorrected over the whole brain volume; activations shown 
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were significant at p<0.05 after family-wise-error correction for multiple voxel-wise 
comparisons over the anatomical small volume of interest.  Colour bars alongside panels 
a, c and e code voxel-wise activation t-values for each comparison.  Control, healthy 
control group; fam, previously familiar melodies condition; first, first presentation of 
repeated melodies; PCA, patient group with a syndrome of posterior cortical atrophy; 
repeat, second presentation of repeated melodies; tAD, patient group with a syndrome 
of memory-led Alzheimer’s disease; unfam, unfamiliar melodies condition. 
 
11.4 Discussion 
This chapter describes a functional neuroanatomical basis for alterations of musical 
memory in tAD and its major ‘visual’ variant syndrome, PCA. Both tAD and PCA groups 
showed neuropsychological profiles and regional atrophy patterns in line with previous 
studies [101, 381].  
As per the prior experimental predictions, relative to the healthy control group both 
syndromic groups showed altered activation of postero-medial cortical regions during 
episodic processing of repeated melodies and the tAD group additionally showed altered 
activation of inferior frontal cortex during semantic processing of familiar (relative to 
unfamiliar) melodies.  
Out-of-scanner behavioural testing demonstrated the anticipated neuropsychological 
profiles of impaired musical episodic memory but retained musical semantic memory in 
both patient groups: however, behavioural performance in the patient groups did not 
correlate with brain activation profiles, suggesting these profiles may represent true 
disease signatures rather than simply compensatory effects.  
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During processing of familiar melodies, both the control and tAD groups showed 
activation of a predominantly anterior fronto-temporal cortical network previously 
implicated in musical semantic memory in healthy brain [367, 372-375] (Figure 11.3).  
Involvement of anterior temporal cortex is consistent this region integrating domains of 
semantic knowledge and previous evidence that anterior temporal degeneration is 
associated with impaired recognition of familiar music [388, 389]. Inferior and dorso-
medial prefrontal regions may be engaged in anticipating syntactical structure in familiar 
music and implicitly preparing motor responses [390, 391].  The healthy control group 
showed activation of right precuneus by previously unfamiliar melodies: this response 
was lost in the patient groups, consistent with Alzheimer’s disease pathology affecting 
the hippocampus and linked temporo-parietal circuits that decode musical novelty [380, 
390, 392]. 
The lack of a significant difference between patient and control groups on the musical 
novelty contrast may simply reflect the relatively small cohort size here; alternatively, it 
may imply that the neuroanatomical substrates of novelty processing within the 
distributed functional network vary widely between individuals, which could plausibly 
reflect the complex behavioural and experiential influences that modulate the novelty 
value of particular stimuli (i.e., musical novelty is not simply the cognitive ‘mirror image’ 
of familiarity [392]).  Although inferior frontal cortex is not a classical site of pathological 
involvement in Alzheimer’s disease and did not emerge as a site of significant disease-
related atrophy in the present Alzheimer’s disease cohort (Figure 11.2), reduced 
activation of this region by familiar melodies in the tAD group relative to the healthy 
control group here might reflect an abnormal interaction of fronto-temporo-parietal brain 
networks that decode novelty and familiarity [392]. In contrast, dorsal medial prefrontal 
cortex did not emerge as a functional locus of altered musical semantic processing in 
either Alzheimer’s disease syndromic group: as proposed by Jacobsen and colleagues 
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[367]. This region may be relatively resistant to the effects of Alzheimer’s disease 
pathology and may therefore provide a substrate for relative preservation of musical 
semantic memory in Alzheimer’s disease. 
No within-group functional neuroanatomical correlates of incidental episodic melody 
processing were identified at the prescribed threshold. This is in line with previous work 
employing a similar paradigm in the healthy brain [367]; melody repetition is likely to be 
less salient than prior familiarity, particularly where, (as here) there is deliberately no 
task demanding active recall or recognition during scanning. Nevertheless, incidental 
processing of repeated melodies left its traces in the comparison between patients and 
healthy controls (Figure 12.4). The tAD group failed to deactivate precuneus normally 
on first presentation of melodies (implicit melody encoding) while the PCA group showed 
abnormally increased activation of posterior cingulate cortex on second presentation of 
melodies (implicit melody recollection). Postero-medial cortex constitutes a principal 
projection zone of the hippocampal outflow [393] and a core target of Alzheimer’s 
disease pathology, here as in previous studies [177] (Figure 11.2).  However, the over-
activation of this region in patients relative to healthy controls argues against this being 
simply signal attenuation due to atrophy.  While information for melodies remains limited, 
these findings fit with previous fMRI evidence for the processing of other kinds of memory 
by postero-medial cortex.  Task-induced deactivation of postero-medial cortex has been 
shown to predict successful memory formation in both younger and healthy older cohorts 
[394, 395], whereas memory impairment in Alzheimer’s disease has been linked to 
impaired deactivation and paradoxical activation of postero-medial cortex [219, 396, 
397],. 
The precise functions of the subregions composing postero-medial cortex and the impact 
of different Alzheimer’s disease phenotypes on these subregions contine to be defined.  
However, the syndromic profiles for incidental musical episodic memory observed here 
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are consistent with findings from studies examining other cognitive domains. 
Behaviourally, tAD is associated with impaired memory encoding while PCA has been 
found to be particularly associated with impaired memory retrieval [398]; this would 
predict relatively greater disruption of melody encoding (first presentation of melodies) 
in tAD and relatively greater disruption of melody retrieval (second presentation of 
melodies) in PCA, as indexed by condition-specific activation profiles here (Figure 11.4). 
In tAD, dysfunction of the precuneus might impair the preparation of responses to 
external sensory events and encoding of those events into memory [395]; while in PCA, 
dysfunction of posterior cingulate cortex might underpin impaired attentional shifts 
across internal states (for example, during re-awakening of memories) as well as the 
external sensory environment [361, 399].  The correlation between musical semantic 
and episodic memory performance seen here argues for at least some functional inter-
dependence of these two musical memory systems.  The overall balance of effects 
observed may depend on the particular musical memory paradigm employed.  
These findings substantiate previous evidence that musical memory in Alzheimer’s 
disease is not one process.  In the patient cohort in this study, behaviourally observed 
deficits of incidental musical episodic memory led deficits of musical semantic memory 
both in tAD and PCA. This differential vulnerability of musical memory is underpinned by 
separable functional neuroanatomical substrates: the core region for altered musical 
episodic processing in both Alzheimer’s disease and PCA lies within the postero-medial 
cortical ‘hub’ zone of the core ‘default-mode’ network targeted by Alzheimer’s disease 
pathology.  The key functional neural substrate of musical semantic memory however lie 
in prefrontal cortex and the impact of different Alzheimer’s disease phenotypes on this 
anterior substrate appears to be more variable.  Taken together, these findings suggest 
that heteorogentity of musical memory deficits exist both in different memory systems 
and between individual patients with Alzheimer’s disease [364-367, 369-371]. The 
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neuroanatomical profiles identified here and the complexity of functional alterations (in 
particular, abnormal increased activations) produced by Alzheimer’s disease relative to 
the healthy brain underline the potential of music to capture dynamic disease-associated 
effects in vulnerable neural networks.  The present findings add to a growing body of 
evidence suggesting that disordered analysis of complex auditory environments may be 
a robust and relevant functional marker of Alzheimer’s disease pathology. 
This study has several limations and raises important issues for future work.  Most 
fundamentally, the deliberately simple, task-free fMRI paradigm deliberately does not 
model much of the complexity of musical semantic and episodic memory. These memory 
systems are likely to involve multiple components and levels to encoding and retrieval, 
for example, explicit melody recognition and recall of musical episodes often entails the 
activation of associated knowledge about musical objects and associated detail about 
musical events.  Future studies should begin to disentangle this complexity and also 
address the effects of explicit memory tasks and dimensions such as musical emotion 
that are likely to have potent modulatory effects.   
The PCA group here was relatively small; the findings described here should be further 
corroborated in larger cohorts, covering the full phenotypic spectrum of Alzheimer’s 
disease, and ultimately with histopathological correlation.  It will be important to assess 
the wider population of Alzheimer’s disease and in particular the more frequent scenario 
of older age onset.  It remains unclear how musical memory evolves over the clinical 
course of Alzheimer’s disease: this will only be established by longitudinal study of 
episodic and semantic musical memory in Alzheimer’s disease, ideally including 
presymptomatic carriers of pathogenic mutations.   
It is also likely that profiles of musical memory (including the relative prominence of 
episodic and semantic deficits) differ between Alzheimer’s disease and other 
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neurodegenerative proteinopathies [364, 369]. Therefore behavioural and 
neuroanatomical correlates of musical memory in these diseases should be compared 
directly and assessed in relation to other components of music cognition [364, 369, 400].  
The roles played by particular components of the musical memory networks implicated 
here will only be fully elucidated by paradigms that incorporate techniques with high 
temporal resolution (such as magnetoencephalography) that can track dynamic 
connectivity shifts between memory phases and among brain regions.  
Taking these limitations into account, musical memory may be a flexible, clinically 
relevant tool to define behavioural and functional neuroanatomical signatures of 
Alzheimer’s disease that reflect the autobiographical and emotional resonance of music 
in everyday life. Improved understanding of musical memory in Alzheimer’s disease may 
in turn inform rational music-based therapies.  Music already provides a welcome source 
of comfort for patients and their caregivers.  However, music-based therapies may have 
cognitive benefits beyond enjoyment and improved quality of life [401].  Work such as 
this has the potential to guide the development of such therapies, by suggesting relevant 
targets within the domain of music cognition and providing surrogate therapeutic markers 
of altered brain function.   
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12 General discussion 
12.1 Summary of findings 
This thesis has recruited a cohort of 45 individuals with YOAD across the phenotypic 
spectrum of Alzheimer’s disease and 24 matched healthy controls to investigate clinical 
heterogeneity, evidence for selective vulnerability, and potential genetic factors 
underpinning this.  The clinical, neuropsychological and regional grey matter atrophy 
profiles of individuals with YOAD are described by both APOE ε4 status (Chapters 7 and 
9) and phenotype (Chapter 11).  The effect of APOE ε4 status on microstructural white 
matter changes, and how alterations in white matter microstructure relate to clinically 
observed neuropsychological deficits is explored in Chapter 10.  The effect of a rare 
TREM2 variant, p.R47H, on phenotype is investigated in Chapter 8.  Mechanisms 
underpinning aspects of memory processing in different YOAD phenotypes are explored 
in Chapter 11 using musical stimuli and activation fMRI to study functional brain network 
changes.   
Setting up and recruitment to the YOAD study 
The YOAD study (methods described in Chapter 5, participant recruitment and clinical 
features described in Chapter 6) was set up to be a representative sample of patients 
with sporadic YOAD with evidence for Alzheimer’s disease pathology where possible, in 
the absence of significant vascular disease, and to include a representative range of 
phenotypes including amnestic, posterior cortical atrophy, logopenic aphasia and frontal 
Alzheimer’s disease.  Participants were assessed using a range of clinical measures and 
neuropsychological batteries, and underwent multimodal MRI and genetic testing.  This 
body of work paved the way for the investigation of phenotypic diversity in subsequent 
chapters.   
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Genetic heterogeneity in the YOAD study 
In Chapter 7 I examined for the presence of any autosomal dominant mutations in genes 
known to cause dementia using next generation sequencing on a customised ‘dementia 
panel’.  Despite patient participants only being recruited in the absence of a family history 
suggestive of autosomal dominant disease, one individual was found to be harbouring a 
pathogenic PSEN1 variant that has previously been described in families in the UK and 
Mexico.  He was excluded from analyses of psychology, brain volumes and grey matter 
VBM, but had already been included in the analyses of Chapters 10 and 11.   
The APOE ε4 allele, a low frequency variant with intermediate effect was over 
represented in the YOAD cohort relative to population data.  However, individuals 
homozygous for ε4 did not have the youngest age of clinical disease onset, hence the 
common tenet that APOE ε4 reduces age at onset does not apply to patients with young 
onset disease. 
Variant AD presentations were more common in the ε4-ve cohort, and these individuals 
were more impaired in non-memory cognitive domains than those who did carry an ε4 
allele.  Hence APOE ε4 contributes to, but does not fully explain heterogeneity in YOAD 
– there must be other factors yet to be determined.  Importantly, I show that there is no 
clear relationship between the canonical AD syndromes – and PCA in particular – with 
APOE genotype. 
Other rare genetic variants – TREM2 
TREM2, a rare but significant risk factor for Alzheimer’s disease may be one such other 
genetic factor, but provisional analyses presented in this thesis suggest it drives age at 
onset more than phenotype.  
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Chapter 8 uses sanger sequencing and p.R47H genotyping in cohorts of individuals with 
Alzheimer’ disease, frontotemporal dementia and healthy controls to investigate 
whether this TREM2 variant is a risk factor or phenotypic modifier in patients for 
Alzheimer’s disease alone, or a more general risk factor for neurodegeneration with other 
pathologies.  I found it to be confirmed as a risk factor for Alzheimer’s disease, but not 
for frontotemporal dementia.  The individuals with p.R47H associated Alzheimer’s 
disease had significantly earlier symptom onset than individuals with no TREM2 variants. 
Heterozygous p.R47H AD appeared to be memory led and otherwise indistinguishable 
from "typical" sporadic AD. 
The role of APOE E4: brain volumes and grey matter atrophy 
In Chapter 9 I investigated regionally specific effects of APOE genotype on brain atrophy 
using brain, hippocampal and ventricle volumes, and grey matter VBM analyses.  ε4+ve 
patients tended towards having more atrophy in the medial temporal lobes, and ε4-ve 
individuals having more atrophy throughout the neocortex, broadly aligning with 
neuropsychological profiles described in Chapter 7.  Whilst APOE ε4 status is associated 
with regional vulnerability to neurodegeneration the reasons why the neocortex, 
especially the frontal and parietal lobes, are more vulnerable to tau pathology and 
neurodegeneration in patients who develop Alzheimer’s disease despite lacking 
APOE ε4 is unclear and warrants further study.  Other genetic risk factors may have an 
unmasked disproportionate effect in the absence of ε4, with their variability explaining 
the greater heterogeneity in ε4-ve YOAD.   
The role of APOE and microstructural WM changes 
Chapter 10 looked at whether considering Alzheimer’s disease as a network disease 
and examining at microstructural white matter track damage may provide further insights 
to clinical heterogeneity.  DTI and NODDI with tract-based spatial statistics were used to 
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investigate APOE ε4 modulation of white-matter damage in a subset of 37 patients with 
YOAD and 23 age-matched controls.  
In contrast to the grey matter VBM analyses in Chapter 9, microscopic white-matter 
disruption tended towards being more widespread in ε4+ individuals and more focal 
(posterior predominant) in the absence of an ε4 allele, however there were no significant 
differences between groups when compared directly.  NDI effect maps showed ε4-ve 
patients had greatest NDI reduction relative to ε4+ve in the right parietal lobe white 
matter projections; and ε4+ve patients had greatest reduction in NDI relative to ε4-ve in 
the left temporal lobe projections which was more consistent with grey matter analyses 
showing ε4+ve as a more hippocampal disease. 
NODDI metrics also indicated that observed changes in fractional anisotropy are 
underpinned by combinations of axonal loss and morphological change.  Regional NDI 
correlated with some measures of focal neuropsychological deficit, giving indirect 
evidence that the model of neurite density loss reflects disconnection and loss of 
function. 
Investigating the functional basis of memory impairment in Alzheimer’s disease variants 
In Chapter 11 I set out to explore how phenotype in the YOAD cohort relates to changes 
in brain function using activation fMRI.  Both the atrophy profile and neuropsychological 
profiles by phenotype were consistent with current formulations of typical memory led 
Alzheimer’s disease and PCA.  Music was used to study brain function with activation 
fMRI as characteristics of music can be augmented to study different aspects of 
information processing.  The paradigm used explored memory processing, for melodies 
that are ‘familiar’ well-known tunes to model semantic memory for music, and motifs that 
were repeated during the scanning session to model ‘episodic memory’ processing.  
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Both typical memory led Alzheimer’s disease and PCA groups showed significant 
functional neuroanatomical alterations relative to the control group.  For musical 
semantic memory, disease-associated activation group differences were localised to 
right inferior frontal cortex (reduced activation in the group with memory-led Alzheimer’s 
disease); while for incidental musical episodic memory, disease-associated activation 
group differences were localised to precuneus and posterior cingulate cortex 
(abnormally enhanced activation in the syndromic groups).  In post-scan behavioural 
testing, both patient groups had a deficit of musical episodic memory relative to healthy 
controls whereas musical semantic memory was unimpaired 
This demonstrates functional neuroanatomical substrates for the differential involvement 
of musical semantic and incidental episodic memory in major phenotypes of Alzheimer’s 
disease and suggests that musical memory is a useful paradigm to probe neural network 
function in Alzheimer’s disease.  Different activation profiles in the hub of the default 
mode network in typical Alzheimer’s disease and posterior cortical atrophy suggests  
there is differential vulnerability within a common ‘faulty’ network, that is consequently 
(mis)behaving in different ways, and manifests as different clinical phenotypes.   
12.2 Limitations 
Cohorts 
The YOAD study cohort recruited for this thesis was relatively small, reflecting the rarity 
of young onset Alzheimer’s disease.  This may account for the lack of significant 
differences when comparing imaging metrics between patient groups directly.  
Logopenic and frontal Alzheimer’s disease phenotypes were also relatively under-
represented, as patients with these phenotypes were often recruited for other studies 
running concurrently at the Dementia Research Centre.  
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Given the increasing emphasis on biomarker evidence of Alzheimer’s disease in 
research criteria, it would have been ideal for all patient participants in the study to have 
supporting molecular biomarker evidence, but some individuals did not wish to have a 
lumbar puncture and there was no access to amyloid PET imaging at the time of 
recruitment.   
The genetic cohort used in Chapter 8 to investigate the frequency of TREM2 variants in 
Alzheimer’s disease and frontotemporal dementia was acquired over two decades and 
so comprehensive use of research diagnostic criteria could not be confirmed.  Age of 
clinical disease onset for individuals was also not universally recorded.  Some samples 
were classified based on clinical diagnoses only, and hence it is possible that clinical 
diagnoses did not reflect the underlying pathology (for example, an individual with frontal 
presentation of Alzheimer’s disease could easily have been clinically (mis)diagnosed 
with frontotemporal dementia).  This may account for the differences observed in 
strength of association between p.R47H and frontotemporal dementia observed across 
other studies.  Further studies are warranted, ideally with post mortem confirmation of 
the underlying pathology, or using other biomarkers (e.g. CSF tau and Aβ1-42 or amyloid 
imaging) to corroborate clinical diagnoses.  The clinical information reviewed 
retrospectively for individuals found to have p.R47H variants in Alzheimer’s disease was 
also limited and had been collected and recorded in a non-standardised manner, making 
my conclusions preliminary and in need of corroboration from large multicentre 
prospective studies to establish the true spectrum of clinical features, neuroimaging and 
pathological signatures of TREM2 variants in Alzheimer’s disease.  
Sample size calculations 
As outlined in the previous section, this study was small and exploratory.  Formal sample 
size calculations were not performed.  There is empirical evidence in activation fMRI 
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[402], voxel based morphometry [403] and theoretical data [404] to suggest a sample 
size of as few as ~10-20 subjects is sufficient to detect group differences in key primary 
neuroimaging outcome measures (p<0.05 corrected for multiple comparisons over the 
entire brain).  However, these sample sizes are for detecting differences between patient 
and control groups, the sample size for detecting differences with a disease group will 
be much higher.  
Given the number of techniques used in this thesis it would potentially require many 
sample size calculations for each chapter: e.g. in Chapter 10 calculations could be done 
for each of the DTI indices between the groups.   
For novel techniques the expected measured effect size attributable to disease (or 
specific genetic risk factor within two disease groups), is unknown and would also need 
to be estimated.   
The lack of power calculations used in this body of work means that a negative statistical 
result when comparing two groups does not differentiate between (i) there being no true 
effect and (ii) there being an effect that is present but not detected due to the study being 
underpowered.  In taking this work forward I would consider using an approach similar 
to that employed in Mahoney et al., 2015 [405] whereby longitudinal data is collected 
and sample sizes required for future clinical trials calculated using annualised change 
scores in potential outcome measures (e.g. NDI in a region of interest).      
Genetics 
Genetic analyses for autosomal dominant causes of Alzheimer’s disease were not 
available until after the diffusion MRI and activation fMRI analyses had been completed.  
Whilst no individual included had a family history supportive of an autosomal dominant 
cause, the lack of genetic screening at entry to the study resulted in the one individual 
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with a PSEN1 variant being included in Chapters 10 and 11.  He presented with a 
memory led phenotype and was an ε4 heterozygote. It is possible, but unlikely, that the 
inclusion of a single individual with an autosomal dominant mutation in a subgroup of 22 
patients with an ε4 allele significantly changed the results presented in Chapter 10. 
Ideally in studying the differential effect of APOE ε4, individuals with autosomal dominant 
disease would be excluded to try to remove a potential confounder for any differences 
found between groups being attributed to APOE ε4 status.  The activation fMRI 
experiment described in Chapter 11 set out to investigate how phenotype related to 
regional brain activation changes, so arguably the effect of this individual (with a typical 
memory-led phenotype) being included in this chapter is less marked than in Chapter 
10, as differences were not being associated with a genotype.  
Finally, Alzheimer’s disease is a complex genetic disease, and any associations of 
APOE ε4 with clinical features or neuropsychological profile (Chapter 7) and changes in 
brain structure (Chapters 9 and 10) observed here are likely an oversimplification and 
occur in the context of attenuation by a milieu of other genetic and environmental factors, 
the contribution of which has not been studied.   
Imaging techniques and models 
The MRI techniques used in this thesis each have a number of limitations.  Individuals 
with severe claustrophobia or other physical restrictions (e.g. morbidly obese, severe 
kyphoscoliosis) are unable to tolerate the physical restriction of MRI scanning.  During 
YOAD cohort recruitment this resulted in one control and one participant not entering the 
study (in both cases due to claustrophobia), however this was a small number overall.  
Furthermore, a small number of both controls and patient participants moved during 
certain MRI sequence acquisitions, resulting in movement artefact precluding use of the 
scans for some analyses.       
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As with all biophysical models, the structural and functional imaging techniques used in 
this thesis all require a number of assumptions.  The imaging metrics may not perfectly 
reflect the underlying pathological changes in Alzheimer’s disease, but can give insight 
and estimates of atrophy, changes in brain microstructure, and brain activation.  Voxel 
based morphometry includes a number of pre-processing steps, namely tissue 
classification, spatial normalisation and spatial smoothing (required due to not being able 
to perfectly warp one brain so that it matches another), followed by statistical analysis.  
Whilst a model, it has become a widely used and accepted method.  DTI models each 
voxel as a single compartment to give an estimate of the fraction of anisotropic water 
from which inferences about brain microstructure are made.  DTI cannot model crossing 
fibres.  NODDI modelling is arguably more reflective of underlying brain microstructure 
as it models three different diffusion compartments.  However, it’s model of axon 
orientation still cannot account for crossing fibres, the value of intrinsic diffusivity is fixed 
over the whole brain, and intra-neurite diffusion is modelled as being completely 
restricted within a collection of impermeable sticks.  It is likely that this also does not fully 
characterise all pathological processes involved in neurodegenerative diseases (e.g. 
Alzheimer’s disease) but starts to explain some of the factors underpinning changes in 
fractional anisotropy seen on DTI.  White matter hyperintensities are also not accounted 
for in either of the diffusion models used in this thesis.  Future work should look at 
whether white matter lesion loads can be quantified and included as a covariate in the 
analyses.  Activation fMRI cannot measure the magnetic fields associated with neural 
activity directly as they are too small to be localised using MRI. The MRI signal 
associated with the vascular response to the neural activity (the BOLD signal) depends 
on the blood’s velocity, volume fraction and oxygenation, and is only qualitative rather 
than quantitative.  Activation fMRI is also vulnerable to the presence of physiological 
noise and physiological data was not separately accquired during scanning, instead 
relying on processing to remove this from the model.  The application of task based fMRI 
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to patients with cognitive impairment can be challenging, so the paradigm I used was 
kept deliberately simple and task-free to make it accesbile to people with cognitive 
impairment.  Whilst the music paradigm employed does not model all of the complexity 
of musical semantic and episodic memory, within these limitations it appears to be useful 
for investigating aspects of memory processing in individuals with Alzheimer’s disease. 
12.3 Why clinical heterogeneity matters: Future Directions 
As outlined in Chapter 2, diagnostic criteria developed for both clinical and research 
purposes have attempted to include and define atypical presentations of Alzheimer’s 
disease.  However, in view of the challenges posed by defining clinical heterogeneity, 
the most recent NIA-AA 2018 Research Framework acknowledge the difficulty of 
defining disease based on clinical features and have moved to a purely biological 
construct using biomarkers of Aβ1-42 deposition, pathologic tau, and neurodegeneration 
[169].  Whilst defining disease based on biomarkers is important, recognising, 
characterising and understanding rarer Alzheimer’s disease variants is also important 
and should not be overlooked.  Studying common and discordant genetic (and 
environmental) risk factors for typical and atypical Alzheimer's disease, combined with 
neuroimaging, cerebrospinal fluid and other biomarkers, may provide fundamental 
insights into Alzheimer's disease pathogenesis.  It is entirely plausible that different risk 
factors modulate the rate, timing and site of amyloid deposition; whether or when amyloid 
deposition leads to neurodegeneration; and which neuronal networks bear the brunt of 
the disease.  This in turn may influence how pathology spreads through the brain, and 
what symptoms predominate.   
Cohorts 
Findings from this thesis should be further corroborated in larger cohorts, covering the 
full phenotypic spectrum of Alzheimer’s disease, ideally with biomarker evidence of 
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underlying Alzheimer’s disease pathology and ultimately, with histopathological 
correlation.  It will be important to also assess how applicable my findings are to the more 
frequent scenario of Alzheimer’s disease occurring with late age of onset.   
Longitudinal studies 
Whilst the YOAD study set up as part of this thesis included a one year follow up visit 
with repeat clinical, neuropsychological assessments, and neuroimaging, only cross-
sectional analyses are presented here.  Longitudinal analyses are required to assess 
how heterogeneity evolves over time, whether the MRI techniques employed here are 
reproducible and capable of detecting interval change, and over what periods of time 
this change can be detected.  For example, if NODDI can reliably detect microstructural 
brain changes over shorter intervals than volumetric MRI can track macrostructural brain 
atrophy, this could enable clinical trials to be conducted over shorted time periods.  
Equally, it is important to understand whether these imaging techniques can be useful in 
the pre-symptomatic period of Alzheimer’s disease, and help define the optimal point in 
the disease course for a disease modifying therapy to be given. 
Polygenic risk scores 
The genetic architecture of Alzheimer’s disease likely includes many common variants 
with small effect that are likely to reflect a large number of susceptibility genes and a 
complex set of biological pathways related to disease.  The effect of these have not been 
studied or accounted for in the APOE and TREM2 analyses in this thesis.  A way forward 
may be to look at ‘polygenic’ risk scores and consider how they are associated with 
clinical heterogeneity.    
In addition to identifying susceptibility alleles for complex diseases, GWAS can identify 
common single nucleotide polymorphisms that show disease association but do not 
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meet genome wide significance.  Considering these weak effect loci significantly 
increases the estimated heritability detected in AD [406].  Polygenic risk scores are 
estimated using both the genome-wide-significant polymorphisms and other nominally 
associated variants (typically thousands) at a lower significance threshold.  Their use 
can increase the accuracy of Alzheimer’s disease prediction models [407], so may in the 
future prove useful for calculating the genetic risk profile of an individual for developing 
Alzheimer’s disease.  Measures of polygenic disease burden in Alzheimer’s disease 
could also help clinical trial design, and lead to better understanding of how gene-
environment interactions affect the development of AD.  
Neuroimaging  
Advances in neuroimaging techniques, MRI physics and image analysis techniques 
including machine learning will all aid our study of clinical heterogeneity in Alzheimer’s 
disease in the future.   
The development of ultra-high field 7T MRI offers superior signal-to-noise and spatial 
resolution relative to the 3T MRI used in this thesis.  Whilst not currently widely available, 
the increase in image resolution afforded by 7T MRI gives the potential for brain 
microstructure, such as cortical layers, hippocampal subfields, and potentially even 
amyloid plaques, to be imaged in vivo [408].   
Amyloid and tau molecular PET imaging is also transforming neuroimaging in 
Alzheimer’s disease research by making it possible to assess the regional distribution of 
proteinopathy and how it changes over time in vivo during life [409].  It will be possible 
to better understand how amyloid and tau pathology relate to each other, and to the 
associated phenotype and underlying genotype.   
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Multimodal imaging, including techniques to combining PET and MRI [410]. and large 
multicentre studies using multimodal imaging protocols, such as the Human 
Connectome Project [411], are studying how molecular and metabolic changes relate to 
the anatomy and function of the brain and clinical presentation. 
New therapeutic targets in Alzheimer’s disease 
Identifying TREM2 variants as risk factors for AD has led to research into the 
pathobiological mechanisms this microglial receptor mediates.  p.R47H variants cause 
partial loss of function of TREM2 in in vitro studies [412].  This is thought to impair the 
response of microglia to amyloid pathology by preventing a switch from a homeostatic 
to neuroprotective disease-associated phenotype, and/or interfering with tonic TREM2 
signalling required to support microglial metabolism and the ability to respond to 
stressors.  As more is understood about the pathways involved, therapeutic targets to 
augment this inflammatory response may be identified.    
Towards a unifying model for understanding heterogeneity in YOAD 
Whilst each individual technique used in this thesis offers insights into heterogeneity, 
methods to combine modalities are described [413] but not well established.  These 
multimodal techniques need to be further refined in order to study how genetic variation 
interplays with structural and functional brain networks, and clinical manifestation.   
Nexopathies [207] and the network paradigm of neurodegenerative disease [357] as 
outlined in Chapter 2 offer hypotheses that can potentially be tested to better understand 
the basis clinical heterogeneity.  For example, the molecular nexopathy paradigm makes 
specific predictions about the sequence of regional involvement with particular 
proteinopathies.  The ‘problem’ of heterogenetiy may be resolved in part by mapping 
disease evolution using neuroimaging longitudinally.  This is where fMRI and diffusion 
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weighted imaging techniques, such as DTI and NODDI, could be used to examine for 
convergent structural and/or functional changes across the brain over time   Specifically, 
in variant forms of Alzheimer’s disease, differential involvement of cortico-cortical 
projection zones that are part of a core Alzheimer’s disease vulnerable network may 
explain the atypical phenotypes that characterise posterior cortical atrophy and 
logopenic aphasia.   
We will also need to understand how genetic differences not only relate to these 
structural and functional imaging metrics, but the mechanisms by which they do so, and 
how this is augmented by environmental factors.  Innoculation studies and tracer studies 
in animal and stem cell models, will continue to further our understanding of how proteins 
can spread through a brain network.  The basis of the interaction between proteins and 
specific brain networks, or parts of a network, can be studied by developing model neural 
circuits in vitro [414] to examine effects on cellular transport, morphology and cell-cell 
interactions, and computational modelling of artificial neural networks.   
Implications for clinical trials 
The diversity of Alzheimer’s disease may in part account for the failure to date to develop 
effective disease modifying therapies.  Better understanding of syndromic 
inhomogeneity may disentangle its confounding effects in clinical trials.  We may also 
use heterogeneity to our advantage by using it to enrich study populations for specific 
interventions, or selecting individuals with certain genotypes or phenotypes to allow 
clinical trials to be powered using smaller cohorts.  Improved understanding of the 
determinants and natural history of network disintegration would enable more accurate 
tracking of disease evolution and potentially enable prediction of clinical course. 
Furthermore, understanding the factors that influence the initiation, spread and 
differential vulnerability seen in atypical Alzheimer’s disease variants may lead to new 
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targets for therapy and allow for better tailoring of existing therapies to individuals.  Just 
as treatments in other fields of medicine have moved towards a more personalised 
approach, such as Herceptin for individuals with breast cancer overexpressing the HER2 
gene [415], a similar approach is likely to be possible, and perhaps necessary, in 
Alzheimer’s disease therapy.  There are already examples of how APOE ε4 status 
affects response to potential new therapeutic agents in clinical trials, such as the 
increased risk of intracerebral vasogenic oedema and haemorrhage seen in relation to 
APOE genotype in a trial of bapineuzamab, a monoclonal antibody against amyloid 
[139].  This is hypothesized to be related to the presence of more cerebral amyloid 
angiopathy in ε4 carriers.   Equally, genetic differences between familial Alzheimer’s 
disease and apparent sporadic disease are likely to be important.  For example, in vitro 
studies suggest that some presenilin variants are associated with resistance to inhibitors 
of γ-secretase inhibitors [416].  Hence, if a clinical trial did not show efficacy using a 
familial Alzheimer’s disease cohort, it does not necessarily follow that the agent would 
also be ineffective for individuals with sporadic Alzheimer’s disease.  Clinical trial 
participant selection on genetic basis is also being used in studies of individuals ‘at risk’ 
for Alzheimer’s disease, offering an opportunity to intervene before Alzheimer’s 
pathological changes become clinically manifest disease, with certain studies recruiting 
individuals with autosomal dominant familial Alzheimer’ disease [132, 133], APOE ε4 
homozygotes [133] and Downs Syndrome [417]. 
Implications for clinical practice 
As a clinician faced with a patient, it is important to recognise that Alzheimer’s disease 
can present with non-memory symptoms and signs, and that these other cognitive 
domains can also be affected in individuals with a more typical amnestic presentation, 
as the disease progresses.  Early and more accurate diagnosis will become ever more 
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important should a disease modifying therapy become available, and tailored support 
and guidance is important for symptomatic management regardless. 
12.4 Conclusions 
This thesis has explored the clinical heterogeneity in young onset Alzheimer’s disease 
and investigated some of the genetic factors underpinning this.  APOE ε4 genotype 
contributes to, but does not fully explain clinical heterogeneity, with the youngest ages 
of onset and most atypical presentations seen in ε4-ve individuals.  Heterozygosity of 
the rare p.R47H TREM2 genetic variant for late-onset Alzheimer’s disease is shown to 
confer risk for young onset Alzheimer’s disease but drives younger age of onset rather 
than clinical phenotype. Regional brain atrophy profiles in APOE ε4 genotypes are 
shown to broadly align with the associated neuropsychological deficits.  Microstructural 
damage studied using Diffusion Tensor Imaging, and Neurite Orientation Dispersion and 
Density Imaging provides a fine-grained profile of white matter network breakdown, 
revealing regional differences based on APOE ε4 genotype, and correlations with focal 
neuropsychological deficits.  Finally, activation fMRI using a music paradigm to probe 
relationships between cognitive performance and brain function shows different patterns 
of brain activation during memory tasks in different Alzheimer’s disease phenotypes. 
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Appendix 1: YOAD cohort characteristics and participation by imaging modality 
subject 
ID 
phenotype sex 
Years 
education 
handedness age 
age at symptom 
onset 
MMSE 
Ε4 
status 
Volumes VBM NODDI / DTI act FMRI 
01-001 control F 17 R 51  29  √ √ √ √ 
01-002 tAD M 15 R 63 56 24 4 4 √ √ √ √ 
01-003 tAD F 16 R 63 61 20 3 4 √ √ √ √ 
01-004 PCA F 12 R 65 61 27 3 4 √ √ √ √ 
01-005 tAD F 12 R 64 60 26 3 4 √ √ √ √ 
01-006 control F 16 R 64  30  √ √ √ √ 
01-007 control M 17 L 68  30  √ √ √ √ 
01-008 tAD F 18 R 53 50 24 3 4 √ √ √ √ 
01-009 tAD M 17 R 65 57 16 3 3 √ √ √ √ 
01-010 tAD F 18 R 62 53 17 3 3 √ √ √ √ 
01-011 control M 22 R 63  30  √ √ √ √ 
01-012 tAD M 18 R 61 58 24 2 3 √ √ √ √ 
01-013 control F 12 R 62  28  √ √ √ √ 
01-014 PCA F 12 R 67 59 21 2 4 √ √ √ √ 
01-015 control M 20 R 66  29    √ √ 
01-016 control M 16 R 66  30  √ √ √  
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01-017 tAD F 10 R 73 62 27 3 4 √ √ √  
01-018 tAD M 10 R 64 57 13 3 4 √ √ √ √ 
01-019 tAD M 12 R 62 56 25 2 4 √ √ √ √ 
01-020 control F 12 R 65  30  √ √ √ √ 
01-021 tAD M 18 R 59 54 20 3 3 √ √ √ √ 
01-022 tAD F 14 R 58 57 15 3 3 √ √ √ √ 
01-023 control M 17 R 60  30  √ √ √ √ 
01-024 control M 15 R 59  30    √ √ 
01-025 tAD F 12 R 58 55 18 2 4 √ √ √ √ 
01-026 control M 17 R 58  30  √ √ √  
01-027 PCA F 13 R 57 54 21 3 3 √ √ √ √ 
01-028 control M 17 R 60  30     √ 
01-029 tAD F 12 R 60 50 20 3 3 √ √ √ √ 
01-030 control M 15 R 63  30  √ √ √ √ 
01-031 frontal M 14 R 53 42 15 3 4 √ √   
01-032 tAD F 16 R 66 63 16 3 4 √ √ √ √ 
01-033 control M 18 R 52  29  √ √ √ √ 
01-034 tAD F 17 R 51 47 19 3 4 √ √  √ 
01-035 PCA F 17 R 57 49 22 3 3 √ √ √ √ 
01-036 control M 20 R 59  28  √ √ √ √ 
01-037 tAD M 20 R 55 52 22 3 4   √ √ 
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01-038 control F 21 R 51  30  √ √ √ √ 
01-039 control F 19 L 48  29  √ √ √ √ 
01-040 control F 20 R 67  30  √ √ √ √ 
01-041 control F 18 R 63  29  √ √ √ √ 
01-042 PCA F 20 L 65 60 27 3 3 √ √  √ 
01-043 PCA F 12 R 60 56 25 3 3   √ √ 
01-044 tAD M 17 R 55 53 16 3 3 √ √ √ √ 
01-045 tAD F 12 R 64 58 17 3 3 √ √ √ √ 
01-046 control F 12 R 66  28  √ √ √  
01-047 PCA F 14 R 70 56 22 3 4 √ √ √ √ 
01-048 PCA F 15 R 58 53 24 3 4   √ √ 
01-049 tAD F 17 R 57 53 15 4 4 √ √  √ 
01-050 PCA M 18 R 67 60 27 3 3 √ √ √ √ 
01-051 control F 11 L 62  30 . √ √ √ √ 
01-052 tAD M 17 R 52 49 23 3 4 √ √ √  
01-053 tAD F 17 R 59 55 22 3 3 √ √  √ 
01-054 LPA M 20 R 65 62 23 3 4     
01-055 tAD M 11 L 67 60 23 2 4 √ √ √ √ 
01-056 control F 17 R 60  29 . √ √ √ √ 
01-057 tAD M 19 R 59 57 16 3 4   √ √ 
01-058 tAD M 17 R 64 54 22 4 4 √ √ √ √ 
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01-059 PCA M 17 R 53 50 13 3 3 √ √ √ √ 
01-060 PCA M 15 R 65 62 29 3 4 √ √ √  
01-061 tAD F 10 R 59 55 25 3 4 √ √   
01-062 control F 13 R 58  29 . √ √ √  
01-063 PCA F 15 R 59 55 18 2 3 √ √ √  
01-064 control F 18 R 51  30 . √ √ √  
01-065 PCA M 14 R 57 55 27 3 3 √ √ √  
01-066 PCA M 12 R 64 61 16 4 4 √ √ √  
01-067 tAD F 17 R 64 63 27 3 4 √ √ √  
01-068 LPA F 14 R 62 56 29 4 4 √ √   
01-069 tAD M 18 R 68 64 28 4 4 √ √ √  
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Appendix 2: Items used in the musical experience questionnaire 
The questionnaire items used in Chapter 11 are taken from Hailstone et al., (2009).  
 
1. Have you ever had any musical training (music lessons at school, lessons on an 
instrument, etc)? (yes/no) 
1a. If yes, what kind and for how long? 
  
2. Have you ever played a musical instrument?  (yes/no – if no, skip to question 6) 
 
3. If yes, which instrument(s)? 
3a. How did you play it (them) for? 
3b. What standard did you reach (grade, etc)? 
 
4. Do you still play an instrument regularly?  (yes/no – if no, skip to question 6.) 
If yes, which instrument? 
 
5a. Approximately how many hours per week do you play? 
5b. Where do you play (at home, band, orchestra etc.)? 
 
6. Do you listen to music regularly?  (yes/no) 
If yes, approximately how many hours per week do you listen to music? 
 
7. What kind of music do you mainly listen to (pop, easy listening, jazz, classical etc.)? 
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Appendix 3: YOAD study – participant folder 
 
Patient	details	and	research	schedule	
	
Participant	Name		
	
	
Hospital	Number	
	
	
DOB	 	
YOAD	_	_		
	
Participant	Code	_	_	_	_	_	_	
Address	
	
	
	
	
	
Telephone	number	
	
	
Support		/	carer	
	
	
Address	(if	different)	
	
	
	
	
	
	
	
	
Telephone	number	(if	different)	
	
	
GP	name	and	address	
	
	
	
	
	
	
	
	
	
	
	
	
	 Date	 Transport	
Visit	1	Day	1	
	
	 	
Visit	1	Day	2	
	
	 	
Visit	2	
	
	 	
Visit	3	Day	1	
	
	 	
Visit	3	Day	2	
	
	 	
Post	LP	telephone	call	
	
	 	
Annual	telephone	call	F/U	
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Drug	History	
Aspirin	
0						never	taken		
1						currently	taking	
2						previously	taking	
	
Clopidogrel	
0						never	taken		
1						currently	taking	
2						previously	taking	
	
Warfarin	
0						never	taken		
1						currently	taking	
2						previously	taking	
	
HRT	
0						never	taken		
1						currently	taking	
2						previously	taking	
	
AChE	inhibitor	
0						never	taken		
1						currently	taking	
2						previously	taking	
If	yes,	name	and	dose:	
Memantine	
0						never	taken		
1						currently	taking	
2						previously	taking	
	
Neuroleptics	
0						never	taken		
1						currently	taking	
2						previously	taking	
If	yes,	name	and	dose:	
Antidepressants	
0						never	taken		
1						currently	taking	
2						previously	taking	
If	yes,	name	and	dose:	
Other	
	
If	yes,	name	and	dose:	
	
	
	
	
	
	
	
	
	
Personal	and	Social	History	
Smoking	history	
0						Never	
1						Current	
2						Previous	
If		1	or	2,	Pack	years:	
Alcohol	history	
1						nil	
2						<14	units	per	week	
3						14	to	21	units	per	week	
4						>21	units	per	week	
	
	
Employment		
1						Employed	
2						Unemployed		
3						Retired	(including	
medically)	
	
Occupation	
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Family	History	
Did	any	of	the	following				
members	of	the	subject’s	family	
have	dementia?	
1	AD,	2	VaD,	3	bv	FTD,	
4	PPA,	5	CBS,	6	DLB,	7	
PD,	8	PSP,	9	HD,	
10	Dementia	NOS,	
11	Other,	12	Unknown	
Age	of	onset	
00	unknown	
01	for	N/A		
	
Age	of	death	
00	unknown	
01	for	N/A		
	
Father	 No	0				Yes		1						 	
	
	
	 	
Mother	 No	0				Yes		1						 	
	
	
	 	
Maternal	
Grandfather	
No	0				Yes		1						 	
	
	
	 	
Maternal	
Grandmother	
No	0				Yes		1						 	
	
	
	 	
Paternal	
Grandfather	
No	0				Yes		1						 	
	
	
	 	
Paternal	
Grandmother	
No	0				Yes		1						 	
	
	
	 	
How	many	siblings	does	the	subject	have?	
	
Do	any	have	dementia?		If	yes,	please	specify.	 						No													0							Yes												1	
No.	in	pedigree	 Diagnosis		 Age	of	onset	 Age	of	death	
	 	 	 	
	 	 	 	
	 	 	 	
	
Draw	pedigree	
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Predominant	first	symptom	
notes:	code	symptoms	as	below	
e.g.	A1	-	memory	impairment		
	
Age	of	first	symptom	onset	 _	_	years	
	
A. Cognitive		
1. Memory	impairment	
"forgets	conversations	and/or	dates;	repeats	
questions	and/or	statements;	forgets	names	of	
people	etc."	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
2. Language	impairment	
"difficulty	naming,	long	pauses,	poor	grammar,	
impaired	comprehension,	impaired	reading	or	
writing	etc."	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
3. Visuoperceptual	/	visuospatial	
"difficulty	interpreting	visual	stimuli,	finding	way	
round,	judging	distances	etc."	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
4. Dyspraxia	
"difficulty	in	using	hands	to	manipulate	objects,	
hands	do	not	seem	to	follow	commands"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
5. Executive:	impaired	judgement	and	
problem	solving	
"trouble	handling	money,	paying	bills,	shopping,	
preparing	meals	etc."	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
6. Impaired	attention	/	concentration	
"short	attention	span,	difficulty	concentrating,	
easily	distracted	etc"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
	
B. Behavioural	Symptoms	
1. Disinhibition	
"socially	inappropriate	behaviour;	loss	of	
manners;	impulse,	rash	or	careless	actions"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
2. Apathy	
"loss	of	interest,	drive	and	motivation"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
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1. Loss	of	sympathy	/	empathy	
"diminished	response	to	other	people's	needs	or	
feelings,	diminished	social	interest	or	personal	
warmth"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
2. Ritualistic	/	compulsive	behaviour	
"simple	repetitive	movements	or	complex	
compulsive	or	ritualistic	behaviours"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
3. Hyperorality	/	appetite	changes	
"altered	food	preferences,	binge	eating,	
increased	consumption	of	cigarettes	and	
alcohol"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
	
A. Neuropsychiatric	symptoms	
1. Visual	hallucinations	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
2. Auditory	hallucinations	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
3. Tactile	hallucinations	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
4. Delusions	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
5. Depression	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
6. Anxiety	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
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A. Motor	Symptoms		
1. Dysarthria	
"problems	with	articulation"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
1 Severe	
	
2. Tremor	
"rhythmic	shaking,	especially	in	hands,	arms,	legs	
or	head"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
3. Slowness	
"noticeably	slowed	down	in	walking	or	moving	or	
writing,	other	than	due	to	acute	illness	or	injury"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
4. Weakness	
"weakness	of	arms	or	legs"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
5. Gait	disorder	
"has	the	participant’s	walking	changed,	not	
specifically	due	to	arthritis	or	injury?		Are	they	
unsteady,	or	shuffle	when	walking,	or	drag	a	
foot?"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
6. Falls	
"does	the	subject	fall	more	than	usual?"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
7. Alien	Limb	
"does	either	limb	seem	to	have	a	mind	of	it’s	
own,	or	grab	onto	things	unexpectedly	without	
the	person	intending	to?"	
0					Absent	
0.5	Questionable	/	very	mild	
1					Mild	
2					Moderate	
3					Severe	
	
Cranial	Nerve	Examination		
Visual	fields	on	
confrontation	
0	normal	
1	abnormal	
if	abnormal	-	details:	
Optic	ataxia	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
	
	
Visual	inattention	
0	No	
1	Yes	-	L	
2	Yes	-	R	
3	Yes	-	bilaterally	
	
Eye	movements	
	0	normal	
1	abnormal	
if	abnormal	-	details:	
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Limb	Examination	
	
Myoclonus	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Spasticity	-	upper	
limbs	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
	
Rest	tremor	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Spasticity	-	lower	
limbs	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Postural	tremor	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Hyperreflexia	-	upper	
limbs	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Bradykinesia	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Hyperreflexia	-	lower	
limbs	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Ataxia	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	
Plantars	
0	Normal	
1	Abnormal	-	L	extensor	
2	Abnormal	-	R	extensor	
3	Abnormal	-	bilateral	extensor	
Dystonia	
0	No	
1	Yes	-	L>R	
2	Yes	-	R>L	
3	Yes	-	no	major	asymmetry	 Gait			
0	Normal	
1	Slight	alteration	in	speed	or	
fluidity	of	gait	
2	Walks	with	difficulty	but	requires	
no	assistance	
3	Severe	gait	disturbance	
4	Cannot	walk	
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Limb	Apraxia	
	
5:		an	accurate,	prompt,	complete	and	readable	gesture	
4:	an	ambiguous	or	incorrect	gesture,	but	self	corrects	to	an	accurate	response	
3:	the	gesture	is	basically	correct,	but	crude	and	defective	in	amplitude,	speed	or	accuracy.	
	
If	the	subject	makes	no	response	for	10	seconds,	or	attempts	a	response	but	is	unsuccessful,	demonstrate	the	
gesture.	Then:	
2:		performs	correctly	after	demonstration	
1:	gesture,	after	demonstration,	is	basically	correct,	but	crude	and	defective	in	amplitude,	speed	or	accuracy	
0:	even	after	demonstration,	unable	to	perform	the	correct	gesture		
Score	using	the	scale	above:	
Make	a	fist	 R	score	_													L	score	_		
Wave	goodbye	 R	score	_													L	score	_	
Snap	your	fingers	 R	score	_													L	score	_	
Throw	a	ball		 R	score	_													L	score	_	
Hide	your	eyes	 R	score	_													L	score	_	
Make	a	hitch-hiking	sign	 R	score	_													L	score	_	
Make	a	pointing	sign	 R	score	_													L	score	_	
Salute	 R	score	_													L	score	_	
Play	the	piano	 R	score	_													L	score	_	
Scratch	 R	score	_													L	score	_	
Orofacial	Apraxia				Score	using	the	scale	above:	
	
Stick	out	your	tongue	 _	
Whistle	 _	
Puff	out	your	cheeks	 _	
Pretend	to	kiss	 _	
Clear	your	throat	 _	
Bite	your	lower	lip	 _	
Show	me	your	teeth	 _	
Take	a	deep	breath	in	and	hold	it	 _	
Lick	your	lips	 _	
Open	your	mouth	 _	
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General	Examination		
	
Supine	Blood	Pressure	
	
___/___mmHg	
Standing	Blood	Pressure	 	___/___mmHg	
Resting	Heart	Rate	
	
_	_beats	per	minute	
Height	
	
	
_	_	m	
Weight	
	
	
_	_kg	
BMI	
	
	
_	_	
	
Hachinski	Score	circle	number	as	appropriate		
	Abrupt	onset	 						0						No							2						Yes	
	Stepwise	deterioration	 						0						No							1						Yes	
	Fluctuating	course	 						0						No							2						Yes	
	Nocturnal	confusion	
						0						No	
						1						Yes	
Relative	preservation	of	personality	
	
						0						No	
						1						Yes	
Depression	
						0						No	
						1						Yes	
Somatic	complaints	
						0						No	
						1						Yes	
Emotional	incontinence	
						0						No	
						1					Yes	
History	or	presence	of	hypertension	
					0						No	
					1						Yes	
History	of	strokes	
					0						No	
					2						Yes	
Evidence	of	atherosclerosis	
					0						No	
					1						Yes	
Focal	neurological	symptoms	
						0						No	
						2						Yes	
Focal	neurological	signs	
						0						No	
						2						Yes	
Total	Score		
	
						__/18		
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Mini	Mental	State	Examination	
	
“I	would	like	to	go	through	a	few	questions	with	you.	These	questions	are	a	brief	assessment	of	memory	
and	concentration.”		
	
	
	
ORIENTATION	 Correct?	
1	What	is	the	year?	 Yes					1	 No					0	
2	What	is	the	season?	 Yes					1	 No					0	
3	What	is	the	date?	 Yes					1	 No					0	
4	What	is	the	day	of	the	week?	 Yes					1	 No					0	
5	What	is	the	month?	 Yes					1	 No					0	
6	Can	you	tell	me	where	you	are	now?	For	instance	what	country	are	we	in?	 Yes					1	 No					0	
7	What	is	the	name	of	this	city?	 Yes					1	 No					0	
8	What	are	the	names	of	two	main	streets	nearby	(or	near	your	home)?		
Are	both	streets	correct	(or	plausibly	correct?)	 Yes					1	 No					0	
9	What	floor	of	the	building	are	we	on?	 Yes					1	 No					0	
10	What	is	the	name	of	this	place?	 Yes					1	 No					0	
REGISTRATION	 	
11.	 I	am	now	going	to	name	three	objects.	The	three	objects	are:		 	
Bus,	Door,	Rose.	Please	repeat	the	name	of	these	three	objects	back	to	me.	
Record	the	FIRST	responses	(order	of	object	recall	does	NOT	matter):		
	
First	object	named?	……………………………………………..	 Yes					1	 No					0	
Second	object	named?	………………………………………...	 Yes					1	 No					0	
Third	object	named?		…………………………………………..	 Yes					1	 No					0	
If	all	three	objects	are	repeated	correctly	(in	any	order)	go	to	Q12.	
If	the	participant	does	not	repeat	all	three	words	exactly	then	allow	them	two	
further	attempts	but	DO	NOT	change	their	first	responses	or	scores.	
Attempt	2:	I’m	going	to	repeat	once	more	the	three	objects,	APPLE,	TABLE,	
PENNY.		Please	say	them	back	to	me.	
Attempt	3:	Can	we	try	one	more	time?		The	names	are,	APPLE,	TABLE,	PENNY.		
Please	say	them	back	to	me.	
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ATTENTION	AND	CALCULATION	
	
	
	
	
	
12a.	Please	take	seven	away	from	one	hundred		(Answer:	93)	
Answer	1	 	 	 YES					1	 No					0	
Now	I’m	going	to	ask	you	to	take	seven	away	from	what	you	have	left	over,	and	
then	keep	taking	seven	away	until	I	stop	you.		(Answers:	86,	79,	72	and	65.		If	the	
participant	gets	an	answer	wrong	but	then	takes	seven	away	correctly	from	that	
answer	you	should	score	as	correct).	
	
	
	
	
	
	
	
TOTAL	score	for	1	to	5	of	12a	
If	the	participant	scores	5/5	then	go	to	Q13.	
If	the	participant	scores	less	than	5/5	for	12a	then	complete	question	12b.	
12b.	Please	spell	“WORLD”	backwards		(Answer:	D	L	R	O	W)	
	
TOTAL	number	of	letters	in	correct	order	for	12b	
Answer	2	 	 	 Yes						1	 No					0	
Answer	3	 	 	 Yes						1	 No						0	
Answer	4	 	 	 Yes						1	 No			0	
Answer	5	 	 	 Yes						1	 No					0	
Highest	score	for	12a	or	12b	 	 	
RECALL	 Correct?	
13.	Please	name	the	three	objects	that	I	mentioned	to	you	earlier?	 	
First	object	named?	…………………..…………..	 Yes						1	 No						0	
Second	object	named?........................................	 Yes						1	 No						0	
Third	object	named?............................................	 Yes						1	 No						0	
NAMING	 	
14.	What	is	this	called?	(show	watch)………………………………………	
15.	What	is	this	called?	(show	pen)	…………………………………………	
Yes						1	 No						0	
Yes						1	 No						0	
REPETITION	 	
						/5 
	 	
	
	 		
						/5 
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THREE	STAGE	COMMAND	 Correct?	
17.	Please	take	this	paper	with	your	right	hand,	fold	it	in	half	and	put	it	on	your	
lap.	
Do	not	repeat	the	sentence.		If	necessary	say:	I’m	sorry,	I’m	only	allowed	to	read	
that	out	once.	
Did	the	participant	take	the	paper	in	their	right	hand?	
	
	
	
	
Yes						1	
	
	
	
	
No						0	
Did	the	participant	fold	the	paper	in	half	or	quarter	(both	allowed)?	 Yes						1	 No						0	
Did	the	participant	put	the	paper	on	their	lap?	 Yes						1	 No						0	
READING	 	
18.	Now	give	the	sheet	called	“MMSE	CLOSE	YOUR	EYES”	to	the	participant	and	
say:	Please	read	the	sentence	at	the	top	of	this	sheet	and	do	what	it	says.	
Did	the	participant	close	their	eyes?	
Yes						1	 No						0	
WRITING	 	
19.	Please	write	a	sentence	in	the	space	here.	Indicate	the	space	under	
	 “Write	a	sentence”.	
Did	the	participant	write	a	sentence?	
	
	
Yes						1	
	
	
No					0		
20.	Please	copy	this	drawing.	Indicate	the	space	to	the	right	of	the	design.	
Did	the	participant	copy	the	drawing	correctly?		
	
Yes						1	
	
No						0	
	
Score		
	
/30	
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Genetics	and	biomarker	Sample	Collection		
	
	
Urine	Sample	–	Prion	ethics	form	
	
Hand	the	urine	sample,	and	the	corresponding	tracking	form,	to	the	lab	staff.	
Please	initial	the	box	to	confirm	you	have	done	this.	
	
	
	
Blood	Samples	
	
Complete	Dementia	Genetics	consent	form	(03/N049)	and	DRC	research	sample	record	form.	
	
Collect	blood	in	the	following	tubes:	
	
	
	
	
	
Hand	the	blood	sample,	and	the	corresponding	tracking	form,	to	the	lab	staff.	
Please	initial	the	box	to	confirm	you	have	done	this.	
	
	
	
Scan	the	consent	form	and	save	in	U:\CONSENT	FORMS\03N049_Dementia	Genetics	
	
Give	original	consent	forms	to	Suzie	Barker.	
	
Complete	and	send	out	GP	letter	with	a	copy	of	Dementia	Genetics	03N049	information	sheet.	
	
	
	20mls	EDTA	
	
15	mls	citrate	
	
5	mls	serum	(white)	
	
1x	PAX	gene	tube	
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Imaging	Protocol:	ICELAND	1	(32	channel	head	coil)	
	
• Localiser		
• 3D	T1-volumetric	
• 3D	T2-volumetric		
• Field	map	
• Resting	state	fMRI	(32	channel)	
• DTIx2	
• ASL	
	
Comments:	e.g.	incomplete	acquisition,	excess	participant	movement	etc	
	
	
	
	
	
	
	
	
Please	ask	radiographers	to	send	scan	to	the	“DRC	DICOM	server”	
	
																																																																																																																																													Initial	when	done	
	
	
	
Check	details	updated	on	Research	Scans	Requested	spreadsheet	
	
																																																																																																																																													Initial	when	done	
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Imaging	Protocol:	ICELAND	2	(32	channel	head	coil)	
	
• Localiser  
• Field map  
• Resting state fMRI  
• MPM  
• NODDI  
	
Comments:	e.g.	incomplete	acquisition,	excess	participant	movement	etc	
	
	
	
	
	
	
	
	
Please	ask	radiographers	to	send	scan	to	the	“DRC	DICOM	server”	
	
																																																																																																																																													Initial	when	done	
	
	
	
Check	details	updated	on	Research	Scans	Requested	spreadsheet	
	
																																																																																																																																													Initial	when	done	
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Imaging	Protocol:	ICELAND	3	(12	channel	head	coil)	
	
o Localiser  
o Field map  
o Activation fMRI  
o T2*-weighted  
	
Comments:	e.g.	incomplete	acquisition,	excess	participant	movement	etc	
	
	
	
	
	
	
	
	
Please	ask	radiographers	to	send	scan	to	the	“DRC	DICOM	server”	
	
																																																																																																																																													Initial	when	done	
	
	
	
Check	details	updated	on	Research	Scans	Requested	spreadsheet	
	
																																																																																																																																													Initial	when	done	
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